



US 20240051998A1

(19) **United States**

(12) **Patent Application Publication**
McCoy et al.

(10) **Pub. No.: US 2024/0051998 A1**

(43) **Pub. Date: Feb. 15, 2024**

(54) **ANTIBODY-EVADING VIRUS VECTORS**

Publication Classification

(71) Applicant: **Ginkgo Bioworks, Inc.**, Boston, MA (US)

(51) **Int. Cl.**

C07K 14/005 (2006.01)

A61P 1/16 (2006.01)

A61K 31/7088 (2006.01)

A61K 38/46 (2006.01)

C12N 7/00 (2006.01)

C12N 15/86 (2006.01)

(72) Inventors: **Daniel McCoy**, Durham, NC (US);
Garrett E. Berry, Durham, NC (US)

(21) Appl. No.: **18/372,833**

(52) **U.S. Cl.**

CPC *C07K 14/005* (2013.01); *A61P 1/16*

(2018.01); *A61K 31/7088* (2013.01); *A61K*

38/465 (2013.01); *C12N 7/00* (2013.01);

C12N 15/86 (2013.01); *A61K 48/00* (2013.01)

(22) Filed: **Sep. 26, 2023**

Related U.S. Application Data

(57)

ABSTRACT

(63) Continuation of application No. 17/045,091, filed on Oct. 2, 2020, filed as application No. PCT/US19/25617 on Apr. 3, 2019.

The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and vims capsids of the disclosure to a cell or to a subject in vivo.

(60) Provisional application No. 62/819,388, filed on Mar. 15, 2019, provisional application No. 62/776,814, filed on Dec. 7, 2018, provisional application No. 62/652,111, filed on Apr. 3, 2018.

Specification includes a Sequence Listing.




Fig. 1B





Fig. 1A

Round 2 Input



Round 1 Input





Fig. 2B

Round 3 Output



Round 3 Input




Fig. 2A

Fig. 2C

Fig. 2D




Fig. 3




Fig. 4






Fig. 5






Fig. 7




Fig. 8

ANTIBODY-EVADING VIRUS VECTORS**CROSS REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims priority to U.S. Provisional Application Ser. No. 62/819,388, filed Mar. 15, 2019, U.S. Provisional Application Ser. No. 62/776,814, filed Dec. 7, 2018, U.S. Provisional Application Ser. No. 62/652,111, filed Apr. 3, 2018, each of which is incorporated by reference herein in its entirety for all purposes.

FIELD OF THE DISCLOSURE

[0002] The present disclosure relates to modified capsid proteins from adeno-associated virus (AAV) and virus capsids and virus vectors comprising the same. In particular, the disclosure relates to modified AAV capsid proteins and capsids comprising the same that can be incorporated into virus vectors to confer a phenotype of evasion of neutralizing antibodies without decreased transduction efficiency.

SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 3, 2019, is named STRD_006_03WO_SeqList_ST25.bd and is ~2 MB in size.

BACKGROUND

[0004] Host-derived pre-existing antibodies generated upon natural encounter of AAV or recombinant AAV vectors prevent first time as well as repeat administration of AAV vectors as vaccines and/or for gene therapy. Serological studies reveal a high prevalence of antibodies in the human population worldwide with about 67% of people having antibodies against AAV1, 72% against AAV2, and about 40% against AAV5 through AAV9.

[0005] Furthermore, in gene therapy, certain clinical scenarios involving gene silencing or tissue degeneration may require multiple AAV vector administrations to sustain long term expression of the transgene. To circumvent these issues, recombinant AAV vectors which evade antibody recognition (AAVe) are required. Such vectors will help a) expand the eligible cohort of patients suitable for AAV-based gene therapy and b) allow multiple, repeat administrations of AAV-based gene therapy vectors.

[0006] The present disclosure provides methods and compositions comprising an adeno-associated virus (AAV) capsid protein, comprising one or more amino acid substitutions, wherein the substitutions introduce into an AAV vector comprising these modified capsid proteins the ability to evade host antibodies.

BRIEF SUMMARY

[0007] The present disclosure provides an adeno-associated virus (AAV) capsid proteins, comprising one or more amino acid modifications, wherein the one or more amino acid modifications modify one or more antigenic sites on the AAV capsid protein. In some embodiments wherein the AAV capsid proteins are incorporated into AAV vectors, the modification of the one or more antigenic sites results in evasion of neutralizing antibodies.

[0008] In some embodiments, the disclosure provides a recombinant adeno-associated virus (AAV) capsid protein, wherein the capsid protein comprises a substitution in an antigenic site of the AAV capsid protein, wherein the substitution has a sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, or 411-421. In some embodiments, the AAV capsid protein is of an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, Avian AAV or Bovine AAV. In some embodiments, the AAV capsid protein is chimeric.

[0009] In some embodiments, the disclosure provides a recombinant AAV capsid protein, wherein the AAV capsid protein comprises an amino acid sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, with any one of SEQ ID NOs: 18-80, 300-612, or 783-785.

[0010] The present disclosure also provides a nucleotide sequence, or an expression vector comprising the same, that encodes one or more of the AAV capsid proteins of the disclosure. The present disclosure also provides a cell that comprises one or more nucleotide sequences or expression vectors of the disclosure.

[0011] The present disclosure also provides an AAV capsid comprising the AAV capsid protein of this disclosure. Further provided herein is a viral vector comprising the AAV capsid of this disclosure as well as a composition comprising the AAV capsid protein, AAV capsid and/or viral vector of this disclosure in a pharmaceutically acceptable carrier.

[0012] The present disclosure additionally provides a method of introducing a nucleic acid into a cell in the presence of antibodies against the AAV capsid, comprising contacting the cell with the viral vector of this disclosure. The cell can be in a subject and in some embodiments, the subject can be a human subject.

[0013] In some embodiments, a method of treating a patient in need thereof is provided, the method comprising administering to the patient a therapeutically effective amount of an AAV viral vector of the disclosure.

[0014] These and other aspects are addressed in more detail in the detailed description set forth below.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1A and FIG. 1B. Bubble plots showing analysis of library diversity, directed evolution and enrichment of novel antigenic footprints. Parental (FIG. 1A) and evolved (FIG. 1B) AAV libraries were subjected to high-throughput sequencing using the Illumina MiSeq platform. Following analysis with a custom Perl script, enriched amino acid sequences were plotted. Each bubble represents a distinct capsid amino acid sequence with the radius of the bubble proportional to the number of reads for that variant in the respective library. The y-axis represents the absolute number of reads, transformed to log base 2. Data are spread along the x-axis for ease of visualization. The percent reduction in unique clones (93.4%) demonstrates that numerous “un-fit” sequences were removed after a first round of evolution.

[0016] FIG. 2A, FIG. 2B, FIG. 2C, and FIG. 2D. FIG. 2A is a bubble plot showing the parental (input) library for the first round of evolution. FIG. 2B is a bubble plot showing the output library for the first round of evolution, which was used as the input library for the second round of evolution. FIG. 2C is a bubble blot showing the output library for the

second round of evolution, which was used as the input library for the third round of evolution. FIG. 2D is a bubble plot showing the output library for the third round of evolution, which represents a 97.3% overall reduction in unique clones compared to the parental library shown in FIG. 2A. Notably, FIG. 2A and 2B show the same data as in FIG. 1A and FIG. 1B, respectively, but the data has been normalized to percent total reads, allowing for longitudinal comparison across subsequent rounds of evolution.

[0017] FIG. 3. Luciferase expression in human hepatocytes (HepG2, Huh7) after infection by recombinant AAVs (AAV-SB1, AAV-SB2, AAV-SB3, AAV-SB4, AAV-SB5) at a dose of 10,000 vg/cell.

[0018] FIG. 4. Neutralization of recombinant AAVs (AAV-SB1, AAV-SB2, AAV-SB3, AAV-SB4, AAV-SB5) by human intravenous immunoglobulin (IVIG) compared to neutralization of parental AAV8. Data are presented as transduction after IVIG treatment as a percentage of transduction without IVIG treatment.

[0019] FIG. 5. Curve showing percent transduction (i.e. extent of neutralization) of parental AAV8 and AAV-SB1 after treatment with various doses of IVIG (0-4 mg/mL).

[0020] FIG. 6A. Percentage of donor samples (100 samples total) that were neutralizing and non-neutralizing to the indicated capsids. FIG. 6B. Breakdown of seropositive donor samples by age groups.

[0021] FIG. 7. Representative immunohistochemistry (IHC) images of liver from normal mice after infection with either parental AAV8 or AAV-SB1 at a 3×10^{12} vg/mL dose.

[0022] FIG. 8. Representative fluorescent microscopy images of U87 cells 48 hours after transduction with parental AAV8, AAV-SB1 or AAV-SB6 vectors packaging GFP at an MOI of 40,000. A representative light microscopy image is also shown for reference.

DETAILED DESCRIPTION

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the detailed description herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0024] All publications, patent applications, patents, GenBank or other accession numbers and other references mentioned herein are incorporated by reference herein in their entirety.

[0025] The designation of all amino acid positions in the AAV capsid proteins in the disclosure and the appended claims is with respect to VP1 capsid subunit numbering. It will be understood by those skilled in the art that the modifications described herein if inserted into the AAV cap gene may result in modifications in the VP1, VP2 and/or VP3 capsid subunits. Alternatively, the capsid subunits can be expressed independently to achieve modification in only one or two of the capsid subunits (VP1, VP2, VP3, VP1+VP2, VP1+VP3, or VP2+VP3).

Definitions

[0026] The following terms are used in the description herein and the appended claims:

[0027] The singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0028] Furthermore, the term “about” as used herein when referring to a measurable value such as an amount of the length of a polynucleotide or polypeptide sequence, dose, time, temperature, and the like, is meant to encompass variations of $\pm 20\%$, $\pm 10\%$, $\pm 5\%$, $\pm 1\%$, $\pm 0.5\%$, or even $\pm 0.1\%$ of the specified amount.

[0029] Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).

[0030] Unless the context indicates otherwise, it is specifically intended that the various features described herein can be used in any combination.

[0031] Moreover, the present disclosure also contemplates that in some embodiments, any feature or combination of features set forth herein can be excluded or omitted. To illustrate further, if, for example, the specification indicates that a particular amino acid can be selected from A, G, I, L and/or V, this language also indicates that the amino acid can be selected from any subset of these amino acid(s) for example A, G, I or L; A, G, I or V; A or G; only L; etc., as if each such subcombination is expressly set forth herein. Moreover, such language also indicates that one or more of the specified amino acids can be disclaimed. For example, in particular embodiments the amino acid is not A, G or I; is not A; is not G or V; etc., as if each such possible disclaimer is expressly set forth herein.

[0032] As used herein, the terms “reduce,” “reduces,” “reduction” and similar terms mean a decrease of at least about 10%, about 15%, about 20%, about 25%, about 35%, about 50%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97% or more.

[0033] As used herein, the terms “enhance,” “enhances,” “enhancement” and similar terms indicate an increase of at least about 10%, about 15%, about 20%, about 25%, about 50%, about 75%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500% or more.

[0034] The term “parvovirus” as used herein encompasses the family Parvoviridae, including autonomously replicating parvoviruses and dependoviruses. The autonomous parvoviruses include members of the genera Protoparvovirus, Erythroparvovirus, Bocaparvovirus, and Densovirus subfamily. Exemplary autonomous parvoviruses include, but are not limited to, minute virus of mouse, bovine parvovirus, canine parvovirus, chicken parvovirus, feline panleukopenia virus, feline parvovirus, goose parvovirus, H1 parvovirus, muscovy duck parvovirus, B19 virus, and any other autonomous parvovirus now known or later discovered. Other autonomous parvoviruses are known to those skilled in the art. See, e.g., BERNARD N. FIELDS et al, VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers; Cotmore et al. Archives of Virology DOI 10.1007/s00705-013-1914-1).

[0035] As used herein, the term “adeno-associated virus” (AAV), includes but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, AAV type rh32.33, AAV type rh8, AAV type rh10, AAV type rh74, AAV type hu.68, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, snake AAV, bearded dragon AAV, AAV2i8, AAV2g9, AAV-LK03, AAV7m8, AAV Anc80, AAV PHP.B, and any other AAV now known or later discovered. See, e.g., BERNARD N. FIELDS et al.,

VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers). A number of AAV serotypes and clades have been identified (see, e.g., Gao et al, (2004) J. Virology 78:6381-6388; Moris et al, (2004) Virology 33--:375-383; and Table 2).

[0036] As used herein, the term “chimeric AAV” refers to an AAV comprising a capsid protein with regions, domains, individual amino acids that are derived from two or more different serotypes of AAV. In some embodiments, a chimeric AAV comprises a capsid protein comprised of a first region that is derived from a first AAV serotype and a second region that is derived from a second AAV serotype. In some embodiments, a chimeric AAV comprises a capsid protein comprised of a first region that is derived from a first AAV serotype, a second region that is derived from a second AAV serotype, and a third region that is derived from a third AAV serotype. In some embodiments, the chimeric AAV may comprise regions, domains, individual amino acids derived from two or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and/or AAV12. For example, the chimeric AAV may include regions, domains, and/or individual amino acids from a first and a second AAV serotype as shown below (Table 1), wherein AAVX+Y indicates a chimeric AAV including sequences derived from AAVX and AAVY.

sequences of the native terminal repeats (TRs), Rep proteins, and capsid subunits are known in the art. Such sequences may be found in the literature or in public databases such as GenBank. See, e.g., GenBank Accession Numbers NC_002077, NC_001401, NC_001729, NC_001863, NC_001829, NC_001862, NC_000883, NC_001701, NC_001510, NC_006152, NC_006261, AF063497, U89790, AF043303, AF028705, AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC_001358, NC_001540, AF513851, AF513852, AY530579; the disclosures of which are incorporated by reference herein for teaching parvovirus and AAV nucleic acid and amino acid sequences. See also, e.g., Srivistava et al., (1983) J. Virology 45:555; Chiorini et al, (1998) J Virology 71:6823; Chiorini et al., (1999) J. Virology 73: 1309; Bantel-Schaal et al., (1999) J Virology 73:939; Xiao et al, (1999) J Virology 73:3994; Muramatsu et al., (1996) Virology 221:208; Shade et al, (1986) J. Virol. 58:921; Gao et al, (2002) Proc. Nat. Acad. Sci. USA 99:11854; Moris et al, (2004) Virology 33:375-383; international patent publications WO 00/28061, WO 99/61601, WO 98/11244; and U.S. Pat. No. 6,156,303; the disclosures of which are incorporated by reference herein for teaching parvovirus and AAV nucleic acid and amino acid sequences. See also Table 2. The capsid structures of autonomous

TABLE 1

Chimeric AAVs							
		Second AAV Serotype					
		AAV1	AAV2	AAV3	AAV4	AAV5	AAV6
First AAV Serotype	AAV1	x	AAV1 + 2	AAV1 + 3	AAV1 + 4	AAV1 + 5	AAV1 + 6
	AAV2	AAV2 + 1	x	AAV2 + 3	AAV2 + 4	AAV2 + 5	AAV2 + 6
	AAV3	AAV3 + 1	AAV3 + 2	x	AAV3 + 4	AAV3 + 5	AAV3 + 6
	AAV4	AAV4 + 1	AAV4 + 2	AAV4 + 3	x	AAV4 + 5	AAV4 + 6
	AAV5	AAV5 + 1	AAV5 + 2	AAV5 + 3	AAV5 + 4	x	AAV5 + 6
	AAV6	AAV6 + 1	AAV6 + 2	AAV6 + 3	AAV6 + 4	AAV6 + 5	x
	AAV7	AAV7 + 1	AAV7 + 2	AAV7 + 3	AAV7 + 4	AAV7 + 5	AAV7 + 6
	AAV8	AAV8 + 1	AAV8 + 2	AAV8 + 3	AAV8 + 4	AAV8 + 5	AAV8 + 6
	AAV9	AAV9 + 1	AAV9 + 2	AAV9 + 3	AAV9 + 4	AAV9 + 5	AAV9 + 6
	AAV10	AAV10 + 1	AAV10 + 2	AAV10 + 3	AAV10 + 4	AAV10 + 5	AAV10 + 6
	AAV11	AAV11 + 1	AAV11 + 2	AAV11 + 3	AAV11 + 4	AAV11 + 5	AAV11 + 6
	AAV12	AAV12 + 1	AAV12 + 2	AAV12 + 3	AAV12 + 4	AAV12 + 5	AAV12 + 6

		Second AAV Serotype					
		AAV7	AAV8	AAV9	AAV10	AAV11	AAV12
First AAV Serotype	AAV1	AAV1 + 7	AAV1 + 8	AAV1 + 9	AAV1 + 10	AAV1 + 11	AAV1 + 12
	AAV2	AAV2 + 7	AAV2 + 8	AAV2 + 9	AAV2 + 10	AAV2 + 11	AAV2 + 12
	AAV3	AAV3 + 7	AAV3 + 8	AAV3 + 9	AAV3 + 10	AAV3 + 11	AAV3 + 12
	AAV4	AAV4 + 7	AAV4 + 8	AAV4 + 9	AAV4 + 10	AAV4 + 11	AAV4 + 12
	AAV5	AAV5 + 7	AAV5 + 8	AAV5 + 9	AAV5 + 10	AAV5 + 11	AAV5 + 12
	AAV6	AAV6 + 7	AAV6 + 8	AAV6 + 9	AAV6 + 10	AAV6 + 11	AAV6 + 12
	AAV7	x	AAV7 + 8	AAV7 + 9	AAV7 + 10	AAV7 + 11	AAV7 + 12
	AAV8	AAV8 + 7	x	AAV8 + 9	AAV8 + 10	AAV8 + 11	AAV8 + 12
	AAV9	AAV9 + 7	AAV9 + 8	x	AAV9 + 10	AAV9 + 11	AAV9 + 12
	AAV10	AAV10 + 7	AAV10 + 8	AAV10 + 9	x	AAV10 + 11	AAV10 + 12
	AAV11	AAV11 + 7	AAV11 + 8	AAV11 + 9	AAV11 + 10	x	AAV11 + 12
	AAV12	AAV12 + 7	AAV12 + 8	AAV12 + 9	AAV12 + 10	AAV12 + 11	x

[0037] By including individual amino acids or regions from multiple AAV serotypes in one capsid protein, capsid proteins that have multiple desired properties that are separately derived from the multiple AAV serotypes may be obtained.

[0038] The genomic sequences of various serotypes of AAV and the autonomous parvoviruses, as well as the

parvoviruses and AAV are described in more detail in BERNARD N. FIELDS et al., VIROLOGY, volume 2, chapters 69 & 70 (4th ed., Lippincott-Raven Publishers). See also, description of the crystal structure of AAV2 (Xie et al., (2002) Proc. Nat. Acad. Sci. 99: 10405-10), AAV9 (DiMattia et al., (2012) J. Virol. 86:6947-6958), AAV8 (Nam et al, (2007) J. Virol. 81:12260-12271), AAV6 (Ng et

al., (2010) *J. Virol.* 84:12945-12957), AAV5 (Govindasamy et al. (2013) *J. Virol.* 87, 11187-11199), AAV4 (Govindasamy et al. (2006) *J. Virol.* 80:11556-11570), AAV3B (Lerch et al., (2010) *Virology* 403:26-36), BPV (Kailasan et al., (2015) *J. Virol.* 89:2603-2614) and CPV (Xie et al, (1996) *J. Mol. Biol.* 6:497-520 and Tsao et al, (1991) *Science* 251:1456-64).

TABLE 2

	GenBank Accession Number
Complete Genomes	
Adeno-associated virus 1	NC_002077, AF063497
Adeno-associated virus 2	NC_001401
Adeno-associated virus 3	NC_001729
Adeno-associated virus 3B	NC_001863
Adeno-associated virus 4	NC_001829
Adeno-associated virus 5	Y18065, AF085716
Adeno-associated virus 6	NC_001862
Avian AAV ATCC VR-865	AY186198, AY629583, NC_004828
Avian AAV strain DA-1	NC_006263, AY629583
Bovine AAV	NC_005889, AY388617, AAR26465
AAV11	AAT46339, AY631966
AAV12	ABI16639, DQ813647
Clade A	
AAV1	NC_002077, AF063497
AAV6	NC_001862
Hu.48	AY530611
Hu 43	AY530606
Hu 44	AY530607
Hu 46	AY530609
Clade B	
Hu. 19	AY530584
Hu. 20	AY530586
Hu 23	AY530589
Hu22	AY530588
Hu24	AY530590
Hu21	AY530587
Hu27	AY530592
Hu28	AY530593
Hu 29	AY530594
Hu63	AY530624
Hu64	AY530625
Hu13	AY530578
Hu56	AY530618
Hu57	AY530619
Hu49	AY530612
Hu58	AY530620
Hu34	AY530598
Hu35	AY530599
AAV2	NC_001401
Hu45	AY530608
Hu47	AY530610
Hu51	AY530613
Hu52	AY530614

TABLE 2-continued

	GenBank Accession Number
Hu T41	AY695378
Hu S17	AY695376
Hu T88	AY695375
Hu T71	AY695374
Hu T70	AY695373
Hu T40	AY695372
Hu T32	AY695371
Hu T17	AY695370
Hu LG15	AY695377
Clade C	
Hu9	AY530629
Hu10	AY530576
Hu11	AY530577
Hu53	AY530615
Hu55	AY530617
Hu54	AY530616
Hu7	AY530628
Hu18	AY530583
Hu15	AY530580
Hu16	AY530581
Hu25	AY530591
Hu60	AY530622
Ch5	AY243021
Hu3	AY530595
Hu1	AY530575
Hu4	AY530602
Hu2	AY530585
Hu61	AY530623
Clade D	
Rh62	AY530573
Rh48	AY530561
Rh54	AY530567
Rh55	AY530568
Cy2	AY243020
AAV7	AF513851
Rh35	AY243000
Rh37	AY242998
Rh36	AY242999
Cy6	AY243016
Cy4	AY243018
Cy3	AY243019
Cy5	AY243017
Rh13	AY243013
Clade E	
Rh38	AY530558
Hu66	AY530626
Hu42	AY530605
Hu67	AY530627
Hu40	AY530603
Hu41	AY530604
Hu37	AY530600
Rh40	AY530559
Rh2	AY243007
Bb1	AY243023
Bb2	AY243022
Rh10	AY243015
Hu17	AY530582
Hu6	AY530621
Rh25	AY530557
Pi2	AY530554
Pi1	AY530553
Pi3	AY530555
Rh57	AY530569
Rh50	AY530563
Rh49	AY530562
Hu39	AY530601
Rh58	AY530570
Rh61	AY530572
Rh52	AY530565
Rh53	AY530566

TABLE 2-continued

	GenBank Accession Number
Rh51	AY530564
Rh64	AY530574
Rh43	AY530560
AAV8	AF513852
Rh8	AY242997
Rh1	AY530556
Clade F	
Hu14 (AAV9)	AY530579
Hu31	AY530596
Hu32	AY530597
HSC1	MI332400.1
HSC2	MI332401.1
HSC3	MI332402.1
HSC4	MI332403.1
HSC5	MI332405.1
HSC6	MI332404.1
HSC7	MI332407.1
HSC8	MI332408.1
HSC9	MI332409.1
HSC11	MI332406.1
HSC12	MI332410.1
HSC13	MI332411.1
HSC14	MI332412.1
HSC15	MI332413.1
HSC16	MI332414.1
HSC17	MI332415.1
Hu68 Clonal Isolate	
AAV5	Y18065, AF085716
AAV 3	NC_001729
AAV 3B	NC_001863
AAV4	NC_001829
Rh34	AY243001
Rh33	AY243002
Rh32	AY243003
Others Rh74 Bearded Dragon AAV	
Snake AAV	NC_006148.1

[0039] The term “tropism” as used herein refers to preferential entry of the virus into certain cells or tissues, optionally followed by expression (e.g., transcription and, optionally, translation) of a sequence(s) carried by the viral genome in the cell, e.g., for a recombinant virus, expression of a heterologous nucleic acid(s) of interest.

[0040] Those skilled in the art will appreciate that transcription of a heterologous nucleic acid sequence from the viral genome may not be initiated in the absence of transacting factors, e.g., for an inducible promoter or otherwise regulated nucleic acid sequence. In the case of a rAAV genome, gene expression from the viral genome may be from a stably integrated provirus, from a non-integrated episome, as well as any other form in which the virus may take within the cell.

[0041] As used here, “systemic tropism” and “systemic transduction” (and equivalent terms) indicate that the virus capsid or virus vector of the disclosure exhibits tropism for or transduces, respectively, tissues throughout the body

(e.g., brain, lung, skeletal muscle, heart, liver, kidney and/or pancreas). In embodiments, systemic transduction of muscle tissues (e.g., skeletal muscle, diaphragm and cardiac muscle) is observed. In other embodiments, systemic transduction of skeletal muscle tissues achieved. For example, in particular embodiments, essentially all skeletal muscles throughout the body are transduced (although the efficiency of transduction may vary by muscle type). In particular embodiments, systemic transduction of limb muscles, cardiac muscle and diaphragm muscle is achieved. Optionally, the virus capsid or virus vector is administered via a systemic route (e.g., systemic route such as intravenously, intra-articularly or intra-lymphatically).

[0042] Alternatively, in other embodiments, the capsid or virus vector is delivered locally (e.g., to the footpad, intra-muscularly, intradermally, subcutaneously, topically).

[0043] Unless indicated otherwise, “efficient transduction” or “efficient tropism,” or similar terms, can be determined by reference to a suitable control (e.g., at least about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 95% or more of the transduction or tropism, respectively, of the control). In particular embodiments, the virus vector efficiently transduces or has efficient tropism for skeletal muscle, cardiac muscle, diaphragm muscle, pancreas (including p-islet cells), spleen, the gastrointestinal tract (e.g., epithelium and/or smooth muscle), cells of the central nervous system, lung, joint cells, and/or kidney. Suitable controls will depend on a variety of factors including the desired tropism profile. For example, AAV8 and AAV9 are highly efficient in transducing skeletal muscle, cardiac muscle and diaphragm muscle, but have the disadvantage of also transducing liver with high efficiency. Thus, viral vectors can be identified that demonstrate the efficient transduction of skeletal, cardiac and/or diaphragm muscle of AAV8 or AAV9, but with a much lower transduction efficiency for liver. Further, because the tropism profile of interest may reflect tropism toward multiple target tissues, it will be appreciated that a suitable vector may represent some tradeoffs. To illustrate, a virus vector of the disclosure may be less efficient than AAV8 or AAV9 in transducing skeletal muscle, cardiac muscle and/or diaphragm muscle, but because of low level transduction of liver, may nonetheless be very desirable.

[0044] Similarly, it can be determined if a virus “does not efficiently transduce” or “does not have efficient tropism” for a target tissue, or similar terms, by reference to a suitable control. In particular embodiments, the virus vector does not efficiently transduce (i.e., has does not have efficient tropism) for liver, kidney, gonads and/or germ cells. In particular embodiments, undesirable transduction of tissue(s) (e.g., liver) is about 20% or less, about 10% or less, about 5% or less, about 1% or less, about 0.1% or less of the level of transduction of the desired target tissue(s) (e.g., skeletal muscle, diaphragm muscle, cardiac muscle and/or cells of the central nervous system).

[0045] As used herein, the term “polypeptide” encompasses both peptides and proteins, unless indicated otherwise.

[0046] A “polynucleotide” is a sequence of nucleotide bases, and may be RNA, DNA or DNA-RNA hybrid sequences (including both naturally occurring and non-naturally occurring nucleotide), but in representative embodiments are either single or double stranded DNA sequences.

[0047] As used herein, an “isolated” polynucleotide (e.g., an “isolated DNA” or an “isolated RNA”) means a polynucleotide at least partially separated from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polynucleotide. In representative embodiments an “isolated” nucleotide is enriched by at least about 10-fold, about 100-fold, about 1000-fold, about 10,000-fold or more as compared with the starting material.

[0048] Likewise, an “isolated” polypeptide means a polypeptide that is at least partially separated from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polypeptide. In representative embodiments an “isolated” polypeptide is enriched by at least about 10-fold, about 100-fold, about 1000-fold, about 10,000-fold or more as compared with the starting material.

[0049] As used herein, by “isolate” or “purify” (or grammatical equivalents) a virus vector, it is meant that the virus vector is at least partially separated from at least some of the other components in the starting material. In representative embodiments an “isolated” or “purified” virus vector is enriched by at least about 10-fold, about 100-fold, about 1000-fold, about 10,000-fold or more as compared with the starting material.

[0050] A “therapeutic polypeptide” is a polypeptide that can alleviate, reduce, prevent, delay and/or stabilize symptoms that result from an absence or defect in a protein in a cell or subject and/or is a polypeptide that otherwise confers a benefit to a subject, e.g., anti-cancer effects or improvement in transplant survivability.

[0051] By the terms “treat,” “treating” or “treatment of” (and grammatical variations thereof) it is meant that the severity of the subject’s condition is reduced, at least partially improved or stabilized and/or that some alleviation, mitigation, decrease or stabilization in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder.

[0052] The terms “prevent,” “preventing” and “prevention” (and grammatical variations thereof) refer to prevention and/or delay of the onset of a disease, disorder and/or a clinical symptom(s) in a subject and/or a reduction in the severity of the onset of the disease, disorder and/or clinical symptom(s) relative to what would occur in the absence of the methods of the disclosure. The prevention can be complete, e.g., the total absence of the disease, disorder and/or clinical symptom(s). The prevention can also be partial, such that the occurrence of the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset is less than what would occur in the absence of the present disclosure.

[0053] “Therapeutically effective amount” as used herein refers to an amount that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease, is sufficient to affect such treatment of the disease or symptom thereof. The “therapeutically effective amount” may vary depending, for example, on the disease and/or symptoms of the disease, severity of the disease and/or symptoms of the disease or disorder, the age, weight, and/or health of the patient to be treated, and the judgment of the prescribing physician. An appropriate amount in any given

instance may be ascertained by those skilled in the art or capable of determination by routine experimentation.

[0054] As used herein, the terms “virus vector,” “vector” or “gene delivery vector” refer to a virus (e.g., AAV) particle that functions as a nucleic acid delivery vehicle, and which comprises the vector genome (e.g., viral DNA [vDNA]) packaged within a virion. Alternatively, in some contexts, the term “vector” may be used to refer to the vector genome/vDNA alone.

[0055] A “rAAV vector genome” or “rAAV genome” is an AAV genome (i.e., vDNA) that comprises one or more heterologous nucleic acid sequences. rAAV vectors generally require only the terminal repeat(s) (TR(s)) in cis to generate virus. All other viral sequences are dispensable and may be supplied in trans (Muzyczka, (1992) *Curr. Topics Microbiol. Immunol.* 158:97). Typically, the rAAV vector genome will only retain the one or more TR sequence so as to maximize the size of the transgene that can be efficiently packaged by the vector. The structural and non-structural protein coding sequences may be provided in trans (e.g., from a vector, such as a plasmid, or by stably integrating the sequences into a packaging cell). In embodiments, the rAAV vector genome comprises at least one TR sequence (e.g., AAV TR sequence), optionally two TRs (e.g., two AAV TRs), which typically will be at the 5' and 3' ends of the vector genome and flank the heterologous nucleic acid, but need not be contiguous thereto. The TRs can be the same or different from each other.

[0056] The term “terminal repeat” or “TR” includes any viral terminal repeat or synthetic sequence that forms a hairpin structure and functions as an inverted terminal repeat (i.e., mediates the desired functions such as replication, virus packaging, integration and/or provirus rescue, and the like). The TR can be an AAV TR or a non-AAV TR. For example, a non-AAV TR sequence such as those of other parvoviruses (e.g., canine parvovirus (CPV), mouse parvovirus (MVM), human parvovirus B-19) or any other suitable virus sequence (e.g., the SV40 hairpin that serves as the origin of SV40 replication) can be used as a TR, which can further be modified by truncation, substitution, deletion, insertion and/or addition. Further, the TR can be partially or completely synthetic, such as the “double-D sequence” as described in U.S. Pat. No. 5,478,745 to Samulski et al.

[0057] An “AAV terminal repeat” or “AAV TR” may be from any AAV, including but not limited to serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or any other AAV now known or later discovered (see, e.g., Table 2). An AAV terminal repeat need not have the native terminal repeat sequence (e.g., a native AAV TR sequence may be altered by insertion, deletion, truncation and/or missense mutations), as long as the terminal repeat mediates the desired functions, e.g., replication, virus packaging, integration, and/or provirus rescue, and the like.

[0058] The virus vectors of the disclosure can further be “targeted” virus vectors (e.g., having a directed tropism) and/or a “hybrid” parvovirus (i.e., in which the viral TRs and viral capsid are from different parvoviruses) as described in international patent publication WO00/28004 and Chao et al. (2000) *Molecular Therapy* 2:619.

[0059] The virus vectors of the disclosure can further be duplexed parvovirus particles as described in international patent publication WO 01/92551 (the disclosure of which is incorporated herein by reference in its entirety). Thus, in some embodiments, double stranded (duplex) genomes can

be packaged into the virus capsids of the disclosure. Further, the viral capsid or genomic elements can contain other modifications, including insertions, deletions and/or substitutions.

[0060] As used herein, the term “amino acid” encompasses any naturally occurring amino acid, modified forms thereof, and synthetic amino acids. Naturally occurring, levorotatory (L-) amino acids are shown in Table 3.

TABLE 3

Amino acid residues and abbreviations.		
Amino Acid Residue	Abbreviation	
	Three-Letter Code	One-Letter Code
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid (Aspartate)	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid (Glutamate)	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

[0061] Alternatively, the amino acid can be a modified amino acid residue (nonlimiting examples are shown in Table 4) and/or can be an amino acid that is modified by post-translation modification (e.g., acetylation, amidation, formylation, hydroxylation, methylation, phosphorylation or sulfatation).

TABLE 4

Modified Amino Acid Residues	
Modified Amino Acid Residue	Abbreviation
Amino Acid Residue Derivatives	
2-Amino adipic acid	Aad
3-Amino adipic acid	bAad
beta-Alanine, beta-Aminopropionic acid	bAla
2-Aminobutyric acid	Abu
4-Aminobutyric acid, Piperidinic acid	4Abu
6-Aminocaproic acid	Acp
2-Aminoheptanoic acid	Ahe
2-Aminoisobutyric acid	Aib
3-Aminoisobutyric acid	bAib
2-Aminopimelic acid	Apm
t-butylalanine	t-BuA
Citrulline	Cit
Cyclohexylalanine	Cha
2,4-Diaminobutyric acid	Dbu
Desmosine	Des
2,21-Diaminopimelic acid	Dpm
2,3-Diaminopropionic acid	Dpr
N-Ethylglycine	EtGly
N-Ethylasparagine	EtAsn
Homoarginine	hArg
Homocysteine	hCys

TABLE 4-continued

Modified Amino Acid Residues	
Modified Amino Acid Residue	Abbreviation
Homoserine	hSer
Hydroxylysine	Hyl
Allo-Hydroxylysine	aHyl
3-Hydroxyproline	3Hyp
4-Hydroxyproline	4Hyp
Isodesmosine	Ide
allo-Isoleucine	alle
Methionine sulfoxide	MSO
N-Methylglycine, sarcosine	MeGly
N-Methyl isoleucine	Melle
6-N-Methyllysine	MeLys
N-Methylvaline	MeVal
2-Naphthylalanine	2-Nal
Norvaline	Nva
Norleucine	Nle
Ornithine	Orn
4-Chlorophenylalanine	Phe(4-Cl)
2-Fluorophenylalanine	Phe(2-F)
3-Fluorophenylalanine	Phe(3-F)
4-Fluorophenylalanine	Phe(4-F)
Phenylglycine	Phg
Beta-2-thienylalanine	Thi

[0062] Further, the non-naturally occurring amino acid can be an “unnatural” amino acid (as described by Wang et al., *Annu Rev Biophys Biomol Struct.* 35:225-49 (2006)). These unnatural amino acids can advantageously be used to chemically link molecules of interest to the AAV capsid protein.

Modified AAV Capsid Proteins and Virus Capsids and Virus Vectors Comprising the Same.

[0063] The present disclosure provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification (e.g., a substitution) in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The inventors have discovered that the modifications described herein can confer one or more desirable properties to virus vectors comprising the modified AAV capsid protein including without limitation, the ability to evade neutralizing antibodies. Thus, the present disclosure addresses some of the limitations associated with conventional AAV vectors.

[0064] Accordingly, in one aspect, the present disclosure provides an adeno-associated virus (AAV) capsid protein, comprising one or more amino acid substitutions, wherein the one or more substitutions modify one or more antigenic sites on the AAV capsid protein. The modification of the one or more antigenic sites results in inhibition of binding by an antibody to the one or more antigenic sites and/or inhibition of neutralization of infectivity of a virus particle comprising said AAV capsid protein. The one or more amino acid substitutions can be in one or more antigenic footprints identified by peptide epitope mapping and/or cryo-electron microscopy studies of AAV-antibody complexes containing AAV capsid proteins. In some embodiments, the one or more antigenic sites are common antigenic motifs or CAMs as described in WO 2017/058892, which is incorporated herein by reference in its entirety. In some embodiments, the antigenic sites are in a variable region (VR) of the AAV capsid protein, such as VR-I, VR-II, VR-III, VR-IV, VR-V,

VR-VI, VR-VII, VR-VIII, VR-IX. In some embodiments, one or more antigenic sites is in the HI loop of the AAV capsid protein.

[0065] In some embodiments, the modified antigenic site can prevent antibodies from binding or recognizing or neutralizing AAV capsids, wherein the antibody is an IgG (including IgG1, IgG2a, IgG2b, IgG3), IgM, IgE or IgA.

[0066] In some embodiments, an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8,

AAVrh10, AAV10, AAV11, AAV12, AAVrh32.22, bovine AAV, or Avian AAV capsid protein comprises an amino acid substitution in one or more of the regions identified in Table 5, below. In some embodiments, the amino acid substitution is selected from the group consisting of SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, and 411-421. In some embodiments, the amino acid substitution has at least 95% , 95% , 96%, 97%, 98%, or 99% sequence homology with SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, or 411-421.

TABLE 5

Exemplary antigenic or other regions on various AAV capsids that may be partially or fully substituted/replaced. Respective VP1 numbering of residues is shown.									
AAV1 Sequence (amino acid numbers)	SEQ ID NO	AAV2 Sequence (amino acid numbers)	SEQ ID NO	AAV3 Sequence (amino acid numbers)	SEQ ID NO	AAV4 Sequence (amino acid numbers)	SEQ ID NO	AAV5 Sequence (amino acid numbers)	SEQ ID NO
SASTGAS (262-268)	613	SQSGAS (262-267)	623	SQSGAS (262-267)	633	RLGESLQ S (253-260)	643	EIKSGSVD S (249- 258)	653
VFMIPQY GYL (370- 379)	614	VFMVPQY GYL (369- 378)	624	VFMVPQY GYL (369- 378)	634	VFMVPOY GYC (360- 369)	644	VFTLPQY GYA (360- 369)	654
NQSGSA QNK (451-459)	615	TPSGTTT QS (450- 458)	625	TTSGTTN QS (451- 459)	635	GTTLNAG TA (445- 453)	645	STNNTGG VQ (440- 448)	655
SV (472- 473)	616	RD (471- 472)	626	SL (472- 473)	636	SN (466- 467)	646	AN (458- 459)	656
KTDNNN SN (493- 500)	617	SADNNNS E (492- 499)	627	ANDNNNS N (493- 500)	637	ANQNYKI PATGS (487-498)	647	SGVNRAS (479-485)	657
KDDEDK F (528- 534)	618	KDDEEKF (527-533)	628	KDDEEKF (528-534)	638	GPADSKF (527-533)	648	LQGSNTY (515-521)	658
SAGASN (547-552)	619	GSEKTN (546-551)	629	GTTASN (547-552)	639	QNGNTA (545-560)	649	ANPGTTA T (534- 541)	659
STDPATG DVH (588- 597)	620	NRQAATA DVN (587- 596)	630	NTAPTGT VN (588- 597)	640	SNLPTVD RLT (583- 595)	650	TTAPATG TYN (577- 586)	660
AN (709- 710)	621	VN (708- 709)	631	VN (709- 710)	641	NS (707- 708)	651	QF (697- 698)	661
DNNGLY T (716- 722)	622	DTNGVYS (715-721)	632	DTNGVYS (716-722)	642	DAAGKYT (714-720)	652	DSTGEYR (704-710)	662
AAV6 (amino acid numbers)	SEQ ID NO	AAV7 (amino acid numbers)	SEQ ID NO	AAV8 (amino acid numbers)	SEQ ID NO	AAV9 (amino acid numbers)	SEQ ID NO	AAVrh8 (amino acid numbers)	SEQ ID NO
SASTGAS (262-268)	663	SETAGST (263-269)	673	NGTSGG AT (263- 270)	683	NSTSGG SS (262- 269)	693	NGTSGGS T (262- 269)	703
VFMIPQY GYL (370- 379)	664	VFMIPQY GYL (371- 380)	674	VFMIPQY GYL (372- 381)	684	VFMIPQY GYL (371-380)	694	VFMVPQY GYL (371- 380)	704
NQSGSA QNK (451-459)	665	NPGGTA GNR (453- 461)	675	TTGGTA NTQ (453-461)	685	INGSGQ NQQ (451-459)	695	QTTGTGG TQ (451- 459)	705

TABLE 5-continued

Exemplary antigenic or other regions on various AAV capsids that may be partially or fully substituted/replaced. Respective VP1 numbering of residues is shown.									
SV (472-473)	666	AN (474-475)	676	AN (474-475)	686	AV (472-473)	696	AN (472-473)	706
KTDNNN SN (493-500)	667	LDQNNNS N (495-502)	677	TGQNNN SN (495-502)	687	VTQNNN SE (493-500)	697	TNQNNNS N (493-500)	707
KDDKDK F (528-534)	668	KDDEDRF (530-536)	678	KDDEER F (530-536)	688	KEGEDR F (528-534)	698	KDDDDRF (528-534)	708
SAGASN (547-552)	669	GATNKT (549-554)	679	NAARDN (549-554)	689	GTGRDN (547-552)	699	GAGNDG (547-552)	709
STDPATG DVH (588-897)	670	NTAAQTQ VVN (589-598)	680	NTAPQIG TVNS (590-600)	690	QAQAQT GWVQ (588-597)	700	NTQAQTG LVH (588-597)	710
AN (709-710)	671	TG (710-711)	681	TS (711-712)	691	NN (709-710)	701	TN (709-710)	711
DNNGLY T (716-722)	672	DSQGVY S (717-723)	682	NTEGVY S (718-724)	692	NTEGVY S (716-722)	702	NTEGVYS (716-722)	712
AAVrh10 (amino acid numbers)	SEQ ID NO	AAV10 (amino acid numbers)	SEQ ID NO	AAV11 (amino acid numbers)	SEQ ID NO	AAV12 (amino acid numbers)	SEQ ID NO	AAVrh32.33 (amino acid numbers)	SEQ ID NO
NGTSGGS T (263-270)	713	NGTSGG ST (263-270)	723	RLGTTSS S (253-260)	733	RIGTTAN S (262-269)	743	RLGTTSENS (253-260)	753
VFMIPQY GYL (372-381)	714	VFMIPQY GYL (372-381)	724	VFMVPQ YGYC (360-369)	734	VFMVPQ YGYC (369-378)	744	VFMVPQYG YC (360-369)	754
STGGTAG TQ (453-461)	715	STGGTQ GTQ (453-461)	725	GETLNQ GNA (444-452)	735	GNSLNQ GTA (453-461)	745	GETLNQGN A (444-452)	755
SA (474-475)	716	SA (474-475)	726	AF (465-466)	736	AY (474-475)	746	AF (465-466)	756
LSQNNNS N (495-502)	717	LSQNNNS N (495-502)	727	ASQNYKI PASGG (486-497)	737	ANQNYKI PASGG (495-506)	747	ASQNYKIPA SGG (486-497)	757
KDDEERF (530-536)	718	KDDEERF (530-536)	728	GPSDGD F (526-532)	738	GAGDSD F (535-541)	748	GPSDGD F (526-532)	758
GAGKDN (549-554)	719	GAGRDN (549-554)	729	VTGNTT (544-549)	739	PSGNTT (553-558)	749	VTGNTT (544-549)	759
NAAPIVG AVN (590-599)	720	NTGPIVG NVN (590-599)	730	TTAPITG NVT (585-594)	740	TTAPHIA NLD (594-503)	750	TTAPITGNV T (585-594)	760
TN (711-712)	721	TN (711-712)	731	SS (706-707)	741	NS (715-716)	751	SS (706-707)	761
NTDGTYS (718-724)	722	NTEGTYS (718-724)	732	DTTGKYT (713-719)	742	DNAGNY H (722-728)	752	DTTGKYT (713-719)	762

TABLE 5-continued

Exemplary antigenic or other regions on various AAV capsids that may be partially or fully substituted/replaced. Respective VP1 numbering of residues is shown.			
Bovine AAV (amino acid numbers)	SEQ ID NO	Avian AAV (amino acid numbers)	SEQ ID NO
RLGSSN AS (255-262)	763	RIQGSPSG G (265-272)	773
VFMVPQ YGYC (362-371)	764	IYTIPQYG YC (375-384)	774
GGTLNQ GNS (447-455)	765	VSQAGS SGR (454-462)	775
SG (468-469)	766	AA (475-476)	776
ASQNYKI PQGRN (489-500)	767	ASNITKN NVFSV (496-507)	777
ANDATDF (529-535)	768	FSGEPDR (533-539)	778
ITGNTT (547-552)	769	VYDQTTA T (552-559)	779
TTVPTVD DVD (588-597)	770	VTPGTRA AVN (595-604)	780
DS (709-710)	771	AD (716-717)	781
DNAGAY K (716-722)	772	SDTGSYS (723-729)	782

[0067] In some embodiments, the amino acid substitution replaces any six, seven, or eight amino acids in an AAV capsid protein from any one of the following serotypes: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, AAVrh10, AAV10, AAV11, AAV12, AAVrh32.22, bovine AAV, or Avian AAV. For example, the amino acid substitution may replace the following amino acids (VP1 numbering) in any of the above-listed AAV serotypes: 280-286, 279-293, 294-300, 301-307, 308-314, 315-321, 322-328, 329-335, 336-342, 343-349, 350-356, 357-363, 364-370, 371-377, 378-384, 385-391, 392-398, 399-405, 406-412, 143-149, 420-426, 427-433, 434-440, 441-447, 448-454, 455-461, 462-468, 469-475, 476-482, 483-489, 490-496, 497-503, 504-510, 511-517, 518-524, 525-531, 532-538, 539-545, 546-552, 553-559, 560-566, 567-573, 574-580, 581-587, 588-594, 595-601, 602-608, 609-615, 616-622, 623-629, 630-636, 637-643, 644-650, 651-657, 658-664, 665-671, 672-678, 679-685, 686-692, 693-699. In embodiments, the amino acid substitution may replace the following amino acids (VP1 numbering) in any of the above-listed AAV serotypes: 294-301, 302-309, 310-317, 318-325, 326-333, 334-331, 342-349, 350-357, 358-365, 366-373, 374-381, 382-389, 390-397, 398-405, 406-413, 414-421, 422-429, 430-437, 438-445, 446-453, 454-

461, 462-469, 470-477, 478-485, 486-493, 494-501, 502-509, 210-517, 518-525, 526-533, 534-541, 542-549, 550-557, 558-565, 566-573, 574-581, 582-589, 590-597, 598-605, 506-613, 614-621, 622-629, 630-637, 638-645, 646-653, 654-661, 662-669, 670-677, 678-685, 686-693, 694-701. In embodiments, the amino acid substitution may replace the following amino acids (VP1 numbering) in any of the above-listed AAV serotypes: 400-405, 406-411, 412-417, 418-423, 424-429, 430-435, 436-441, 442-447, 448-453, 454-459, 460-465, 466-471, 472-477, 478-483, 484-489, 490-495, 484-489, 490-495, 496-501, 502-507, 508-513, 514-519, 520-525, 526-531, 532-537, 538-543, 544-549, 550-555, 556-561, 562-567, 568-573, 574-579, 580-585, 586-591, 592-597, 598-603, 604-609, 610-615, 616-621, 622-627, 628-633, 634-639, 640-645, 646-651, 652-657, 658-663, 664-669, 670-675, 676-681, 682-687, 688-693, 694-699, 700-705.

[0068] In some embodiments, the substitution introduces a deletion into the AAV capsid sequence. For example, a sequence of 6, 7, 8, or 9 amino acids are substituted to replace 7, 8, 9, or 10 amino acids, respectively, of a native amino acid capsid sequence. In some embodiments, the substitution introduces an insertion into the AAV capsid sequence. For example, a sequence of 6, 7, 8, or 9 amino

acids are substituted to replace 5, 6, 7, or 8 amino acids, respectively, of a native amino acid capsid sequence.

[0069] The capsid proteins of this disclosure are modified to produce an AAV capsid that is present in an AAV virus particle or AAV virus vector that has a phenotype of evading neutralizing antibodies. The AAV virus particle or vector of this disclosure can also have a phenotype of enhanced or maintained transduction efficiency in addition to the phenotype of evading neutralizing antibodies.

[0070] In some embodiments, the one or more substitutions of the one or more antigenic sites can introduce one or more antigenic sites from a capsid protein of a first AAV serotype into the capsid protein of a second AAV serotype that is different from said first AAV serotype.

[0071] The AAV capsid protein of this disclosure can be a capsid protein of an AAV serotype selected from AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh.8, AAVrh.10, AAVrh.32.33, AAVrh74, bovine AAV, avian AAV or any other AAV now known or later identified. In some embodiments, the AAV capsid protein is chimeric.

[0072] Several examples of a modified AAV capsid protein of this disclosure are provided herein. In the following examples, the capsid protein can comprise the specific substitutions described and in some embodiments can comprise fewer or more substitutions than those described. As used herein, “substitution” may refer to a single amino acid substitution, or a substitution of more than one amino acid. For example in some embodiments, a capsid protein of this disclosure can comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc., single amino acid substitutions. In some embodiments, a capsid protein of this disclosure can comprise one or more substitutions of multiple contiguous amino acids, such as one or more substitutions of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 contiguous amino acids.

[0073] Furthermore, in the embodiments described herein wherein an amino acid residue is substituted by any amino acid residue other than the amino acid residue present in the wild type or native amino acid sequence, said any other amino acid residue can be any natural or non-natural amino acid residue known in the art (see, e.g., Tables 3 and 4). In some embodiments, the substitution can be a conservative substitution and in some embodiments, the substitution can be a nonconservative substitution.

[0074] In some embodiments, an AAV capsid protein comprises one or more amino acid substitutions, wherein the amino acid substitutions are selected from the sequences listed in Table 6.1.

TABLE 6.1

AMINO ACID SUBSTITUTIONS	
Sequence Substitution	SEQ ID NO.
SNGRGV	9
NLAENFKY	10
VLSGDHSA	11
MSAASGSG	12
GTNLGKEQ	13
SSHSGTNQ	14

TABLE 6.1-continued

AMINO ACID SUBSTITUTIONS	
Sequence Substitution	SEQ ID NO.
VATRDGQL	15
ALNADTGT	16
VMEPTR	17
VVGNNGVV	297
NFREMPIG	298
RRSEDMGTI	299
YPLQNNNS	411
YPLENFKY	412
YPLGDHSA	413
YPLASGSG	414
YPLLGKEQ	415
YPLSGTNQ	416
YPLRDGQL	417
YPLADTGT	418
YPLNGGVV	419
YPLEMPIG	420
YPLEDMGTI	421

[0075] In some embodiments, the AAV capsid protein comprises a first amino acid substitution and a second amino acid substitution, wherein the first amino acid substitution and the second amino acid substitution each modify a different antigenic site on the AAV capsid protein. In some embodiments, the first amino acid substitution and the second amino acid substitution are each selected from SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, and 411-421.

[0076] In some embodiments, the AAV capsid protein comprises a first amino acid substitution, a second amino acid substitution, and a third amino acid substitution, wherein the first amino acid substitution, the second amino acid substitution, and the third amino acid substitution each modify a different antigenic site on the AAV capsid protein. In some embodiments, the first amino acid substitution, the second amino acid substitution and the third amino acid substitution are each selected from SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, and 411-421. In some embodiments, the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises one of SEQ ID NO. 10, 11, 12, 13, 14, 15, 16, 297, 298, 299 or 411-421; and the third amino acid substitution comprises SEQ ID NO. 17. In some embodiments, the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises one of SEQ ID NO. 10; and the third amino acid substitution comprises SEQ ID NO. 17. In some embodiments, the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises one of SEQ ID NO. 14; and the third amino acid substitution comprises SEQ ID NO. 17.

[0077] In some embodiments, the AAV capsid protein comprises the sequence of any one of SEQ ID NOs: 18-80, 300-410, 422-612, or 783-785. In some embodiments, the AAV capsid protein comprises the sequence of any one of SEQ ID NO: 18-80, 300-410, 422-612, or 783-785. In some embodiments, the AAV capsid protein has at least 95%, 95%, 96%, 97%, 98%, or 99% sequence homology with any one of SEQ ID NOs: 18-80, 300-410, 422-612, or 783-785.

[0078] In some embodiments, the AAV capsid protein comprises SEQ ID NO: 49. In some embodiments, the AAV capsid protein has at least 95%, 95%, 96%, 97%, 98%, or 99% sequence homology with SEQ ID NO: 49. In some embodiments, the AAV capsid protein is modified by replacing the region spanning amino acids 454-460 of SEQ ID NO: 49 with SEQ ID NO: 9. In some embodiments, the AAV capsid protein is modified by replacing the region spanning amino acids 493-500 of SEQ ID NO: 49 with one of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421. In some embodiments, the AAV capsid protein is modified by replacing the region spanning amino acids 585-590 of SEQ ID NO: 49 with SEQ ID NO: 17. In some embodiments, the AAV capsid protein is modified by replacing the region spanning amino acids 454-460 of SEQ ID NO: 49 with SEQ ID NO: 9, the region spanning amino acids 493-500 of SEQ ID NO: 49 with one of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421, and the region spanning amino acids 585-590 of SEQ ID NO: 49 with SEQ ID NO: 17.

[0079] Any of the AAV capsids described herein may further comprise a modification (e.g., a substitution or a deletion) in the HI loop. The HI loop is a prominent domain on the AAV capsid surface, between β strands β H and β I, that extends from each viral protein (VP) subunit overlapping the neighboring fivefold VP. In some embodiments, an AAV capsid comprises one, two, three, four, five, six, seven, or eight amino acid substitutions in the HI loop. In some embodiments, the AAV capsid comprises one or more of the following substitutions in the HI loop: P661R, T662S, Q666G, S667D, wherein the numbering corresponds to the wildtype AAV8 capsid (SEQ ID NO: 6). In some embodiments, the AAV capsid comprises one or more of the following substitutions in the HI loop: P659R, T660S, A661T, K664G, wherein the numbering corresponds to the wildtype AAV9 capsid (SEQ ID NO: 7).

[0080] In some embodiments, an AAV capsid protein comprises one, two, three, or four amino acid substitutions, wherein each substitution modifies a different antigenic site on the AAV capsid protein, and wherein at least one of the amino acid substitutions modifies the HI loop of the capsid protein.

[0081] In some embodiments, an AAV capsid protein comprises a first, a second, a third, and a fourth amino acid substitution. In embodiments, the first amino acid substitution, the second amino acid substitution and the third amino acid substitution are each selected from SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, and 411-421, and the fourth amino acid substitution modifies the HI loop of the capsid protein. In some embodiments, the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises one of SEQ ID NO. 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421; the third amino acid substitution comprises SEQ ID NO. 17, and the fourth amino acid substitution modifies the HI loop of the capsid protein. In some embodiments, the AAV capsid

comprises one or more of the following substitutions in the HI loop: P661R, T662S, Q666G, S667D, wherein the numbering corresponds to the wildtype AAV8 capsid (SEQ ID NO: 6); or P659R, T660S, A661T, K664G, wherein the numbering corresponds to the wildtype AAV9 capsid (SEQ ID NO: 7).

[0082] In some embodiments, an AAV capsid protein may comprise a first substitution, a second substitution, and optionally a third substitution, as shown in Table 6.2.

TABLE 6.2

COMBINATIONS OF AMINO ACID SUBSTITUTIONS		
First Substitution (SEQ ID NO)	Second Substitution (SEQ ID NO)	Third Substitution (SEQ ID NO)
9	10	17
9	11	17
9	12	17
9	13	17
9	14	17
9	15	17
9	16	17
9	297	17
9	298	17
9	299	17
9	411	17
9	412	17
9	413	17
9	414	17
9	415	17
9	416	17
9	417	17
9	418	17
9	419	17
9	420	17
9	421	17
9	10	
9	11	
9	12	
9	13	
9	14	
9	15	
9	16	
9	297	
9	298	
9	299	
9	411	
9	412	
9	413	
9	414	
9	415	
9	416	
9	417	
9	418	
9	419	
9	420	
9	421	
9	17	
10	17	
11	17	
12	17	
13	17	
14	17	
15	17	
16	17	
297	17	
298	17	
299	17	
411	17	
412	17	
413	17	
414	17	
415	17	
416	17	

TABLE 6.2-continued

COMBINATIONS OF AMINO ACID SUBSTITUTIONS		
First Substitution (SEQ ID NO)	Second Substitution (SEQ ID NO)	Third Substitution (SEQ ID NO)
417	17	
418	17	
419	17	
420	17	
421	17	

[0083] In some embodiments, a recombinant capsid protein has a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 6 (AAV8) or SEQ ID NO: 7 (AAV9) and comprises a first substitution, a second substitution, and optionally a third substitution, as shown in Table 6.2.

[0084] In some embodiments, a recombinant capsid protein has a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 6 (AAV8) and comprises one or more of the following amino acid substitutions: G455S, G456N, G456S, T457G, T457N, A458R, A458G, N459G, N459R, T460V, T460G, N459R, Q461V, T494N, T494V, T494M, T494G, T494S, T494A, T494R, T494Y, T495L, T495S, T495T, T495S, T495V, T495F, T495R, T495P, G496A, G496S, G496N, G496H, G496T, G496N, G496R, G496L, Q497E, Q497G, Q497A, Q497L, Q497S, Q497R, Q497A, Q497N, Q497E, Q497E, N498D, N498S, N498G, N498M, N499F, N499H, N499G, N499K, N499T, N499P, N499M, N500K, N500S, N500E, N500N, N500Q, N500G, N500V, N500I, N500T, S501Y, S501A, S501G, S501Q, S501L, S501T, S501V, S501G, S501I, L586V, Q587M, Q588E, Q589P, N590T, T591R. In some embodiments, a recombinant capsid protein has a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 6 (AAV8) and comprises the following amino acid substitutions: T494Y, T495P, and/or G496L.

[0085] In some embodiments, a recombinant capsid protein has a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the sequences of SEQ ID NO: 380, 384, 783, 784, or 785.

[0086] The present disclosure also provides a nucleotide sequence, or an expression vector comprising the same, that encodes one or more of the AAV capsid proteins of the disclosure. The nucleotide sequence may be a DNA sequence or an RNA sequence. The present disclosure also provides a cell that comprises one or more nucleotide sequences or expression vectors of the disclosure.

[0087] Also provided is an AAV capsid comprising an AAV capsid protein of this disclosure. Further provided herein is a viral vector comprising an AAV capsid of this disclosure as well as a composition comprising the AAV capsid protein, AAV capsid and/or viral vector of this disclosure in a pharmaceutically acceptable carrier.

[0088] In some embodiments, modification of the one or more antigenic sites results in inhibition of binding by an antibody to the one or more antigenic sites. In some embodiments, modification of the one or more antigenic sites results in inhibition of neutralization of infectivity of a virus particle comprising the AAV capsid protein.

[0089] As described herein, the nucleic acid and amino acid sequences of the capsid proteins from a number of AAV are known in the art. Thus, the amino acids “corresponding” to amino acid positions of the native AAV capsid protein can be readily determined for any other AAV (e.g., by using sequence alignments).

[0090] The disclosure contemplates that the modified capsid proteins can be produced by modifying the capsid protein of any AAV now known or later discovered.

[0091] Further, the AAV capsid protein that is to be modified can be a naturally occurring AAV capsid protein (e.g., an AAV2, AAV3a or 3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 or AAV11 capsid protein or any of the AAV shown in Table 2) but is not so limited. Those skilled in the art will understand that a variety of manipulations to the AAV capsid proteins are known in the art and the disclosure is not limited to modifications of naturally occurring AAV capsid proteins. For example, the capsid protein to be modified may already have alterations as compared with naturally occurring AAV (e.g., is derived from a naturally occurring AAV capsid protein, e.g., AAV2, AAV3a, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12 or any other AAV now known or later discovered). In some embodiments, the capsid protein may be a chimeric capsid protein. In some embodiments, the capsid protein may be an engineered AAV, such as AAV2i8, AAV2g9, AAV-LK03, AAV7m8, AAV Anc80, AAV PHP.B. Such AAV capsid proteins are also within the scope of the present disclosure.

[0092] Thus, in particular embodiments, the AAV capsid protein to be modified can be derived from a naturally occurring AAV but further comprises one or more foreign sequences (e.g., that are exogenous to the native virus) that are inserted and/or substituted into the capsid protein and/or has been altered by deletion of one or more amino acids.

[0093] Accordingly, when referring herein to a specific AAV capsid protein (e.g., an AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 or AAV11 capsid protein or a capsid protein from any of the AAV shown in Table 2, etc.), it is intended to encompass the native capsid protein as well as capsid proteins that have alterations other than the modifications of the disclosure. Such alterations include substitutions, insertions and/or deletions. In particular embodiments, the capsid protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60, or less than 70 amino acids inserted therein (other than the insertions of the present disclosure) as compared with the native AAV capsid protein sequence. In embodiments, the capsid protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60, or less than 70 amino acid substitutions (other than the amino acid substitutions according to the present disclosure) as compared with the native AAV capsid protein sequence, in embodiments of the disclosure, the capsid protein comprises a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60, or less than 70 amino acids (other than the amino acid deletions of the disclosure) as compared with the native AAV capsid protein sequence.

[0094] Methods of determining sequence similarity or identity between two or more amino acid sequences are known in the art. Sequence similarity or identity may be

determined using standard techniques known in the art, including, but not limited to, the local sequence identity algorithm of Smith & Waterman, *Adv. Appl. Math.* 2, 482 (1981), by the sequence identity alignment algorithm of Needleman & Wunsch, *J Mol. Biol.* 48,443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85,2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux et al., *Nucl. Acid Res.* 12, 387-395 (1984), or by inspection.

[0095] Another suitable algorithm is the BLAST algorithm, described in Altschul et al., *J Mol. Biol.* 215, 403-410, (1990) and Karlin et al., *Proc. Natl. Acad. Sci. USA* 90, 5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program which was obtained from Altschul et al., *Methods in Enzymology*, 266, 460-480 (1996); <http://blast.wustl.edu/blast/README.html>. WU-BLAST-2 uses several search parameters, which are optionally set to the default values. The parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity.

[0096] Further, an additional useful algorithm is gapped BLAST as reported by Altschul et al, (1997) *Nucleic Acids Res.* 25, 3389-3402.

[0097] The disclosure also provides a virus capsid comprising, consisting essentially of, or consisting of the modified AAV capsid protein of the disclosure. In particular embodiments, the virus capsid is a parvovirus capsid, which may further be an autonomous parvovirus capsid or a dependovirus capsid. Optionally, the virus capsid is an AAV capsid. In particular embodiments, the AAV capsid is an AAV1, AAV2, AAV3a, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, bovine AAV capsid, avian AAV capsid or any other AAV now known or later identified. A nonlimiting list of AAV serotypes is shown in Table 2, and an AAV capsid of this disclosure can be any AAV serotype listed in Table 2 or derived from any of the foregoing by one or more insertions, substitutions and/or deletions. The modified virus capsids can be used as "capsid vehicles," as has been described, for example, in U.S. Pat. No. 5,863,541. Molecules that can be packaged by the modified virus capsid and transferred into a cell include heterologous DNA, RNA, polypeptides, small organic molecules, metals, or combinations of the same.

[0098] Heterologous molecules are defined as those that are not naturally found in an AAV infection, e.g., those not encoded by a wild-type AAV genome. Further, therapeutically useful molecules can be associated with the outside of the chimeric virus capsid for transfer of the molecules into host target cells. Such associated molecules can include DNA, RNA, small organic molecules, metals, carbohydrates, lipids and/or polypeptides. In one embodiment of the disclosure the therapeutically useful molecule is covalently linked (i.e., conjugated or chemically coupled) to the capsid proteins. Methods of covalently linking molecules are known by those skilled in the art.

[0099] The modified virus capsids of the disclosure also find use in raising antibodies against the novel capsid structures. As a further alternative, an exogenous amino acid sequence may be inserted into the modified virus capsid for antigen presentation to a cell, e.g., for administration to a subject to produce an immune response to the exogenous amino acid sequence.

[0100] In other embodiments, the virus capsids can be administered to block certain cellular sites prior to and/or concurrently with (e.g., within minutes or hours of each other) administration of a virus vector delivering a nucleic acid encoding a polypeptide or functional RNA of interest. For example, the inventive capsids can be delivered to block cellular receptors on liver cells and a delivery vector can be administered subsequently or concurrently, which may reduce transduction of liver cells, and enhance transduction of other targets (e.g., skeletal, cardiac and/or diaphragm muscle).

[0101] According to representative embodiments, modified virus capsids can be administered to a subject prior to and/or concurrently with a modified virus vector according to the present disclosure. Further, the disclosure provides compositions and pharmaceutical formulations comprising the inventive modified virus capsids; optionally, the composition also comprises a modified virus vector of the disclosure.

[0102] The disclosure also provides nucleic acids (optionally, isolated nucleic acids) encoding the modified virus capsids and capsid proteins of the disclosure. Further provided are vectors comprising the nucleic acids, and cells (in vivo or in culture) comprising the nucleic acids and/or vectors of the disclosure. As one example, the present disclosure provides a virus vector comprising: (a) a modified AAV capsid of this disclosure; and (b) a nucleic acid comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by the AAV capsid.

[0103] Other suitable vectors include without limitation viral vectors (e.g., adenovirus, AAV, herpesvirus, vaccinia, poxviruses, baculoviruses, and the like), plasmids, phage, YACs, BACs, and the like. Such nucleic acids, vectors and cells can be used, for example, as reagents (e.g., helper packaging constructs or packaging cells) for the production of modified virus capsids or virus vectors as described herein.

[0104] Virus capsids according to the disclosure can be produced using any method known in the art, e.g., by expression from a baculovirus (Brown et al., (1994) *Virology* 198:477-488).

[0105] The modifications to the AAV capsid protein according to the present disclosure are "selective" modifications. This approach is in contrast to previous work with whole subunit or large domain swaps between AAV serotypes (see, e.g., international patent publication WO 00/28004 and Hauck et al., (2003) *J. Virology* 77:2768-2774). In particular embodiments, a "selective" modification results in the insertion and/or substitution and/or deletion of less than or equal to about 20, 18, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 contiguous amino acids.

[0106] The modified capsid proteins and capsids of the disclosure can further comprise any other modification, now known or later identified.

[0107] For example, the AAV capsid proteins and virus capsids of the disclosure can be chimeric in that they can comprise all or a portion of a capsid subunit from another

virus, optionally another parvovirus or AAV, e.g., as described in international patent publication WO 00/28004.

[0108] In some embodiments of this disclosure, the virus capsid can be a targeted virus capsid, comprising a targeting sequence (e.g., substituted or inserted in the viral capsid) that directs the virus capsid to interact with cell-surface molecules present on desired target tissue(s) (see, e.g., International patent publication WO 00/28004 and Hauck et al., (2003) *J. Virology* 77:2768-2774); Shi et al., *Human Gene Therapy* 17:353-361 (2006) [describing insertion of the integrin receptor binding motif RGD at positions 520 and/or 584 of the AAV capsid subunit]; and U.S. Pat. No. 7,314,912 [describing insertion of the PI peptide containing an RGD motif following amino acid positions 447, 534, 573 and 587 of the AAV2 capsid subunit]. Other positions within the AAV capsid subunit that tolerate insertions are known in the art (e.g., positions 449 and 588 described by Grifman et al., *Molecular Therapy* 3:964-975 (2001)).

[0109] For example, a virus capsid of this disclosure may have relatively inefficient tropism toward certain target tissues of interest (e.g., liver, skeletal muscle, heart, diaphragm muscle, kidney, brain, stomach, intestines, skin, endothelial cells, and/or lungs). A targeting sequence can advantageously be incorporated into these low-transduction vectors to thereby confer to the virus capsid a desired tropism and, optionally, selective tropism for particular tissue(s). AAV capsid proteins, capsids and vectors comprising targeting sequences are described, for example in international patent publication WO 00/28004. As another example, one or more non-naturally occurring amino acids as described by Wang et al., *Annu Rev Biophys Biomol Struct.* 35:225-49 (2006) can be incorporated into an AAV capsid subunit of this disclosure at an orthogonal site as a means of redirecting a low-transduction vector to desired target tissue(s). These unnatural amino acids can advantageously be used to chemically link molecules of interest to the AAV capsid protein including without limitation: glycans (mannose-dendritic cell targeting); RGD, bombesin or a neuropeptide for targeted delivery to specific cancer cell types; RNA aptamers or peptides selected from phage display targeted to specific cell surface receptors such as growth factor receptors, integrins, and the like.

[0110] Methods of chemically modifying amino acids are known in the art (see, e.g., Greg T. Hermanson, *Bioconjugate Techniques*, 1st edition, Academic Press, 1996).

[0111] In some embodiments, the targeting sequence may be a virus capsid sequence (e.g., an autonomous parvovirus capsid sequence, AAV capsid sequence, or any other viral capsid sequence) that directs infection to a particular cell type(s).

[0112] As another nonlimiting example, a heparin or heparan sulfate binding domain (e.g., the respiratory syncytial virus heparin binding domain) may be inserted or substituted into a capsid subunit that does not typically bind HS receptors (e.g., AAV4, AAV5) to confer heparin and/or heparan sulfate binding to the resulting mutant.

[0113] B19 infects primary erythroid progenitor cells using globoside as its receptor (Brown et al, (1993) *Science* 262:114). The structure of B19 has been determined to 8 Å resolution (Agbandje-McKenna et al, (1994) *Virology* 203: 106). The region of the B19 capsid that binds to globoside has been mapped between amino acids 399-406 (Chapman et al, (1993) *Virology* 194:419), a looped out region between β -barrel structures E and F (Chipman et al, (1996) *Proc. Nat. Acad. Sci. USA* 93:7502). Accordingly, the globoside receptor binding domain of the B19 capsid may be substituted into

an AAV capsid protein of this disclosure to target a virus capsid or virus vector comprising the same to erythroid cells.

[0114] In some embodiments, the exogenous targeting sequence may be any amino acid sequence encoding a peptide that alters the tropism of a virus capsid or virus vector comprising the modified AAV capsid protein. In particular embodiments, the targeting peptide or protein may be naturally occurring or, alternately, completely or partially synthetic. Exemplary targeting sequences include ligands and other peptides that bind to cell surface receptors and glycoproteins, such as ROD peptide sequences, bradykinin, hormones, peptide growth factors (e.g., epidermal growth factor, nerve growth factor, fibroblast growth factor, platelet-derived growth factor, insulin-like growth factors I and II, etc.), cytokines, melanocyte stimulating hormone (e.g., α , β or γ), neuropeptides and endorphins, and the like, and fragments thereof that retain the ability to target cells to their cognate receptors. Other illustrative peptides and proteins include substance P, keratinocyte growth factor, neuropeptide Y, gastrin releasing peptide, interleukin 2, hen egg white lysozyme, erythropoietin, gonadolibcrin, corticostatin, β -endorphin, leu-enkephalin, rimorphin, alpha-neo-enkephalin, angiotensin, pneumadin, vasoactive intestinal peptide, neurotensin, motilin, and fragments thereof as described above. As yet a further alternative, the binding domain from a toxin (e.g., tetanus toxin or snake toxins, such as alpha-bungarotoxin, and the like) can be substituted into the capsid protein as a targeting sequence. In a yet further representative embodiment, the AAV capsid protein can be modified by substitution of a "nonclassical" import/export signal peptide (e.g., fibroblast growth factor-1 and -2, interleukin 1, HIV-1 Tat protein, herpes virus VP22 protein, and the like) as described by Cleves (*Current Biology* 7:R318 (1997)) into the AAV capsid protein. Also encompassed are peptide motifs that direct uptake by specific cells, e.g., a FVFLP (SEQ ID NO: 83) peptide motif triggers uptake by liver cells.

[0115] Phage display techniques, as well as other techniques known in the art, may be used to identify peptides that recognize any cell type of interest.

[0116] The targeting sequence may encode any peptide that targets to a cell surface binding site, including receptors (e.g., protein, carbohydrate, glycoprotein or proteoglycan). Examples of cell surface binding sites include, but are not limited to, heparan sulfate, chondroitin sulfate, and other glycosaminoglycans, sialic acid moieties found on mucins, glycoproteins, and gangliosides, MHC 1 glycoproteins, carbohydrate components found on membrane glycoproteins, including, mannose, N-acetyl-galactosamine, N-acetyl-glucosamine, fucose, galactose, and the like.

[0117] In particular embodiments, a heparan sulfate (HS) or heparin binding domain is substituted into the virus capsid (for example, in an AAV capsid that otherwise does not bind to HS or heparin). It is known in the art that HS/heparin binding is mediated by a "basic patch" that is rich in arginines and/or lysines. In exemplary embodiments, a sequence following the motif BXXB (SEQ ID NO: 84), where "B" is a basic residue and X is neutral and/or hydrophobic can be employed. As a nonlimiting example, BXXB can be RGNR (SEQ ID NO: 85). As another nonlimiting example, BXXB is substituted for amino acid positions 262 through 265 in the native AAV2 capsid protein or at the corresponding position(s) in the capsid protein of another AAV serotype.

[0118] Table 7 shows other nonlimiting examples of suitable targeting sequences.

TABLE 7

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
NSVRDL(G/S)	86	Muller et al., Nature Biotechnology 21: 1040-1046 (2003)
PRSVTVP	87	Muller et al., Nature Biotechnology 21: 1040-1046 (2003)
NSVSSX(S/A)	88	Muller et al., Nature Biotechnology 21: 1040-1046 (2003)
NGRAHA	89	Grifman et al., Molecular Therapy 3:964-975 (2001)
QPEHSST	90	Work et al., Molecular Therapy 13:683-693 (2006)
VNTANST	91	Work et al., Molecular Therapy 13:683-693 (2006)
HGPMQS	92	Work et al., Molecular Therapy 13:683-693 (2006)
PHKPPLA	93	Work et al., Molecular Therapy 13:683-693 (2006)
IKNNEMW	94	Work et al., Molecular Therapy 13:683-693 (2006)
RNLDTPM	95	Work et al., Molecular Therapy 13:683-693 (2006)
VDSHRQS	96	Work et al., Molecular Therapy 13:683-693 (2006)
YDSKTKT	97	Work et al., Molecular Therapy 13:683-693 (2006)
SQLPHQK	98	Work et al., Molecular Therapy 13:683-693 (2006)
STMQQNT	99	Work et al., Molecular Therapy 13:683-693 (2006)
TERYMTQ	100	Work et al., Molecular Therapy 13:683-693 (2006)
QPEHSST	101	Work et al., Molecular Therapy 13:683-693 (2006)
DASLSTS	102	Work et al., Molecular Therapy 13:683-693 (2006)
DLPNKT	103	Work et al., Molecular Therapy 13:683-693 (2006)
DLTAARL	104	Work et al., Molecular Therapy 13:683-693 (2006)
EPHQFNY	105	Work et al., Molecular Therapy 13:683-693 (2006)
EPQSNHT	106	Work et al., Molecular Therapy 13:683-693 (2006)
MSSWPSQ	107	Work et al., Molecular Therapy 13:683-693 (2006)
NPKHNAT	108	Work et al., Molecular Therapy 13:683-693 (2006)
PDGMRTT	109	Work et al., Molecular Therapy 13:683-693 (2006)
PNNKTT	110	Work et al., Molecular Therapy 13:683-693 (2006)
QSTTHDS	111	Work et al., Molecular Therapy 13:683-693 (2006)
TGSKQKQ	112	Work et al., Molecular Therapy 13:683-693 (2006)
SLKHQAL	113	Work et al., Molecular Therapy 13:683-693 (2006)
SPIDGEQ	114	Work et al., Molecular Therapy 13:683-693 (2006)
WIFPWIQL	115	Hajitou et al., TCM 16:80-88 (2006)
CDCRGDCFC	116	Hajitou et al., TCM 16:80-88 (2006)
CNGRC	117	Hajitou et al., TCM 16:80-88 (2006)

TABLE 7-continued

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
CPRECES	118	Hajitou et al., TCM 16:80-88 (2006)
CTHWGFTLC	119	Hajitou et al., TCM 16:80-88 (2006)
CGRRAGGSC	120	Hajitou et al., TCM 16:80-88 (2006)
CKGGRAKDC	121	Hajitou et al., TCM 16:80-88 (2006)
CVPELGHEC	122	Hajitou et al., TCM 16:80-88 (2006)
CRRETAWAK	123	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
VSWFSHRYSPFAV S	124	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
GYRDGYAGPILYN	125	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
XXXY*XXX	126	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
Y*E/MNW	127	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
RPLPLPLP	128	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
APPLPPR	129	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
DVFYPPYASGS	130	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
MYWYPY	131	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
DITWDQLWDLMK	132	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CWDD (G/L)WLC	133	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
EWCEYLGGYLRCY A	134	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
YXCXGPTXWXCX P	135	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
IEGPTLRQWLAARA	136	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
LWXX (Y/W/F/H)	137	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
XFXXYLW	138	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
RWGLCD	139	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
MSRPACPPNDKYE	140	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CLRSGRGC	141	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CHWMFSPWC	142	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
WXXF	143	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CSSRLDAC	144	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CLPVASC	145	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CGFECVRQCPERC	146	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CVALCREACGEGC	147	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
SWCEPGWCR	148	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
YSGGW	149	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
GLSGGRS	150	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
LMLPRAD	151	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CSCFRDVCC	152	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)

TABLE 7-continued

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
CRDVVSVIC	153	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
CNGRC	154	Koivunen et al., J. Nucl. Med. 40:883-888 (1999)
MARSGL	155	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MARAKE	156	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MSRTMS	157	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
KCCYSL	158	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MYWGDShWLQYW YE	159	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MQLPLAT	160	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
EWLS	161	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SNEW	162	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
TNYL	163	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
WIFPWIQL	164	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
WDLAWMFRLPVG	165	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CTVALPGGYVRVC	166	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CVPELGHEC	167	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CGRRAGGSC	168	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CVAYCIEHHCWTC	169	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CVFAHNYDYLVLC	170	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CVFTSNYAFPC	171	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)

TABLE 7-continued

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
VHSPNKK	172	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CDCRGDCFC	173	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CRGDGWC	174	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
XRGCDX	175	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
PXX(S/T)	176	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CTTHWGFTLC	177	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SGKGPQRITAL	178	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
A(A/Q)(N/A)(L/Y) (T/V/M/R)(R/K)	179	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
VYMSPF	180	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MQLPLAT	181	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
ATWLPPR	182	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
HTMYHHYQHHL	183	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SEVGCRAGPLQWL CEKYFG	184	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CGLLPVGRPDRNV WRWLC	185	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CKGQCDRFKGLPW EC	186	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SGRSA	187	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
WGFP	188	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
LWXXAr	189	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)

TABLE 7-continued

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
XFFXYLW	190	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
AEPMPHSLNFSQYL WYT	191	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
WAY(W/F)SP	192	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
IELLQAR	193	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
DITWDQLWDLMK	194	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
AYTKCSRQWRTCM TTH	195	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
PQNSKIPGPTFLDP H	196	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SMEPALPDWVWK MFK	197	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
ANTPCGPYTHDCP VKR	198	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
TACHQHVVRMP	199	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
VPWMEPAYQRFL	200	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
DPRATPGS	201	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
FRPNRAQDYNTN	202	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CTKNSYLMC	203	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
C(R/Q)L/RT(G/N) XXG(A/V)GC	204	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
CPIEDRPMC	205	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
HEWSYLAPYPWF	206	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
MCPKHLGC	207	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)

TABLE 7-continued

AAV Targeting sequences		
Sequence	SEQ ID NO	Reference
RMWPSSTVNLSAG RR	208	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SAKTAVSQRVWLP SHRGGEP	209	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
KSREHVNNSACPS KRITAAAL	210	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
EGFR	211	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
AGLGVR	212	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
GTRQGHTMRLGVS DG	213	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
IAGLATPGWSHWLA L	214	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
SMSIARL	215	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
HTFEPGV	216	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
NTSLKRISNKR1RR K	217	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)
LRIKRKRKRKRKTR K	218	Newton & Deutscher, Phage Peptide Display in Handbook of Experimental Pharmacology, pages 145-163, Springer-Verlag, Berlin (2008)

[0119] As yet a further embodiment, the targeting sequence may be a peptide that can be used for chemical coupling (e.g., can comprise arginine and/or lysine residues that can be chemically coupled through their R groups) to another molecule that targets entry into a cell.

[0120] As another embodiment, the AAV capsid protein or virus capsid of the disclosure can comprise a mutation as described in WO 2006/066066. For example, the capsid protein can comprise a selective amino acid substitution at amino acid position 263, 705, 708 and/or 716 of the native AAV2 capsid protein or a corresponding change(s) in a capsid protein from another AAV serotype.

[0121] Additionally, or alternatively, in representative embodiments, the capsid protein, virus capsid or vector comprises a selective amino acid insertion directly following amino acid position 264 of the AAV2 capsid protein or a corresponding change in the capsid protein from other AAV. By “directly following amino acid position X” it is intended that the insertion immediately follows the indicated amino acid position (for example, “following amino acid position 264” indicates a point insertion at position 265 or a larger insertion, e.g., from positions 265 to 268, etc.).

[0122] Furthermore, in representative embodiments, the capsid protein, virus capsid or vector of this disclosure can comprise amino acid modifications such as described in PCT Publication No. WO 2010/093784 (e.g., 2i8) and/or in PCT Publication No. WO 2014/144229 (e.g., dual glycan).

[0123] In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have equivalent or enhanced transduction efficiency relative to the transduction efficiency of the AAV serotype from which the capsid protein, virus capsid or vector of this disclosure originated. In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have reduced transduction efficiency relative to the transduction efficiency of the AAV serotype from which the capsid protein, virus capsid or vector of this disclosure originated. In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have equivalent or enhanced tropism relative to the tropism of the AAV serotype from which the capsid protein, virus capsid or vector of this disclosure originated. In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have an altered or

different tropism relative to the tropism of the AAV serotype from which the capsid protein, virus capsid or vector of this disclosure originated. In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have or be engineered to have tropism for brain tissue. In some embodiments of this disclosure, the capsid protein, virus capsid or vector of this disclosure can have or be engineered to have tropism for liver tissue.

[0124] The foregoing embodiments can be used to deliver a heterologous nucleic acid to a cell or subject as described herein. For example, the modified vector can be used to treat a lysosomal storage disorder such as a mucopolysaccharidosis disorder (e.g., Sly syndrome [β -glucuronidase], Hurler Syndrome [α -L-iduronidase], Scheie Syndrome [α -L-iduronidase], Hurler-Scheie Syndrome [α -L-iduronidase], Hunter's Syndrome [iduronate sulfatase], Sanfilippo Syndrome A [heparan sulfamidase], B [N-acetylglucosaminidase], C [acetyl-CoA:alpha-glucosaminide acetyltransferase], D [N-acetylglucosamine 6-sulfatase], Morquio Syndrome A [galactose-6-sulfate sulfatase], B [β -galactosidase], Maroteaux-Lamy Syndrome [N-acetylgalactosamine-4-sulfatase], etc.), Fabry disease (a-galactosidase), Gaucher's disease (glucocerebrosidase), or a glycogen storage disorder (e.g., Pompe disease; lysosomal acid alpha-glucosidase) as described herein.

[0125] Those skilled in the art will appreciate that for some AAV capsid proteins the corresponding modification will be an insertion and/or a substitution, depending on whether the corresponding amino acid positions are partially or completely present in the virus or, alternatively, are completely absent. As discussed elsewhere herein, the corresponding amino acid position(s) will be readily apparent to those skilled in the art using well-known techniques.

[0126] The disclosure also encompasses virus vectors comprising the modified capsid proteins and capsids of the disclosure. In particular embodiments, the virus vector is a parvovirus vector (e.g., comprising a parvovirus capsid and/or vector genome), for example, an AAV vector (e.g., comprising an AAV capsid and/or vector genome). In representative embodiments, the virus vector comprises a modified AAV capsid comprising a modified capsid subunit of the disclosure and a vector genome.

[0127] For example, in representative embodiments, the virus vector comprises: (a) a modified virus capsid (e.g., a modified AAV capsid) comprising a modified capsid protein of the disclosure; and (b) a nucleic acid comprising a terminal repeat sequence (e.g., an AAV TR), wherein the nucleic acid comprising the terminal repeat sequence is encapsidated by the modified virus capsid. The nucleic acid can optionally comprise two terminal repeats (e.g., two AAV TRs).

[0128] In representative embodiments, the virus vector is a recombinant virus vector comprising a heterologous nucleic acid encoding a polypeptide or functional RNA of interest. Recombinant virus vectors are described in more detail below.

[0129] In particular embodiments, the virus vectors of the disclosure (i) have reduced transduction of liver as compared with the level of transduction by a virus vector without the modified capsid protein; (ii) exhibit enhanced systemic transduction by the virus vector in an animal subject as compared with the level observed by a virus vector without the modified capsid protein; (iii) demonstrate enhanced movement across endothelial cells as compared with the

level of movement by a virus vector without the modified capsid protein, and/or (iv) exhibit a selective enhancement in transduction of muscle tissue (e.g., skeletal muscle, cardiac muscle and/or diaphragm muscle), (v) exhibit a selective enhancement in transduction of liver tissue, and/or (vi) reduced transduction of brain tissues (e.g., neurons) as compared with the level of transduction by a virus vector without the modified capsid protein. In particular embodiments, the virus vector has systemic transduction toward liver.

[0130] It will be understood by those skilled in the art that the modified capsid proteins, virus capsids and virus vectors of the disclosure exclude those capsid proteins, capsids and virus vectors that have the indicated amino acids at the specified positions in their native state (i.e., are not mutants).

Methods of Producing Virus Vectors

[0131] The present disclosure further provides methods of producing the inventive virus vectors. Thus, in one embodiment, the present disclosure provides a method of producing an AAV vector that evades neutralizing antibodies, comprising: a) identifying contact amino acid residues that form a three dimensional antigenic footprint on an AAV capsid protein; b) generating a library of AAV capsid proteins comprising amino acid substitutions of the contact amino acid residues identified in (a); c) producing AAV particles comprising capsid proteins from the library of AAV capsid proteins of (b); d) contacting the AAV particles of (c) with cells under conditions whereby infection and replication can occur; e) selecting AAV particles that can complete at least one infectious cycle and replicate to titers similar to control AAV particles: 1) contacting the AAV particles selected in (e) with neutralizing antibodies and cells under conditions whereby infection and replication can occur; and g) selecting AAV particles that are not neutralized by the neutralizing antibodies of (f). Nonlimiting examples of methods for identifying contact amino acid residues include peptide epitope mapping and/or cryo-electron microscopy.

[0132] Resolution and identification of the antibody contact residues within the three dimensional antigenic footprint allows for their subsequent modification through random, rational and/or degenerate mutagenesis to generate antibody-evading AAV capsids that can be identified through further selection and/or screening.

[0133] Thus, in a further embodiment, the present disclosure provides a method of producing an AAV vector that evades neutralizing antibodies, comprising: a) identifying contact amino acid residues that form a three dimensional antigenic footprint on an AAV capsid protein; b) generating AAV capsid proteins comprising amino acid substitutions of the contact amino acid residues identified in (a) by random, rational and/or degenerate mutagenesis; c) producing AAV particles comprising capsid proteins from the AAV capsid proteins of (b); d) contacting the AAV particles of (c) with cells under conditions whereby infection and replication can occur; e) selecting AAV particles that can complete at least one infectious cycle and replicate to titers similar to control AAV particles; f) contacting the AAV particles selected in (e) with neutralizing antibodies and cells under conditions whereby infection and replication can occur; and g) selecting AAV particles that are not neutralized by the neutralizing antibodies of (f).

[0134] Nonlimiting examples of methods for identifying contact amino acid residues include peptide epitope map-

ping and/or cryo-electron microscopy. Methods of generating AAV capsid proteins comprising amino acid substitutions of contact amino acid residues by random, rational and/or degenerate mutagenesis are known in the art.

[0135] This comprehensive approach presents a platform technology that can be applied to modifying any AAV capsid. Application of this platform technology yields AAV antigenic variants derived from the original AAV capsid template without loss of transduction efficiency. As one advantage and benefit, application of this technology will expand the cohort of patients eligible for gene therapy with AAV vectors.

[0136] In one embodiment, the present disclosure provides a method of producing a virus vector, the method comprising providing to a cell: (a) a nucleic acid template comprising at least one TR sequence (e.g., AAV TR sequence), and (b) AAV sequences sufficient for replication of the nucleic acid template and encapsidation into AAV capsids (e.g., AAV rep sequences and AAV cap sequences encoding the AAV capsids of the disclosure). Optionally, the nucleic acid template further comprises at least one heterologous nucleic acid sequence. In particular embodiments, the nucleic acid template comprises two AAV ITR sequences, which are located 5' and 3' to the heterologous nucleic acid sequence (if present), although they need not be directly contiguous thereto.

[0137] The nucleic acid template and AAV rep and cap sequences are provided under conditions such that virus vector comprising the nucleic acid template packaged within the AAV capsid is produced in the cell. The method can further comprise the step of collecting the virus vector from the cell. The virus vector can be collected from the medium and/or by lysing the cells.

[0138] The cell can be a cell that is permissive for AAV viral replication. Any suitable cell known in the art may be employed. In particular embodiments, the cell is a mammalian cell. As another option, the cell can be a trans-complementing packaging cell line that provides functions deleted from a replication-defective helper virus, e.g., 293 cells or other E1a trans-complementing cells.

[0139] The AAV replication and capsid sequences may be provided by any method known in the art. Current protocols typically express the AAV rep/cap genes on a single plasmid. The AAV replication and packaging sequences need not be provided together, although it may be convenient to do so. The AAV rep and/or cap sequences may be provided by any viral or non-viral vector. For example, the rep/cap sequences may be provided by a hybrid adenovirus or herpesvirus vector (e.g., inserted into the E1a or E3 regions of a deleted adenovirus vector). EBV vectors may also be employed to express the AAV cap and rep genes. One advantage of this method is that EBV vectors are episomal, yet will maintain a high copy number throughout successive cell divisions (i.e., are stably integrated into the cell as extra-chromosomal elements, designated as an "EBV based nuclear episome," see Margolski, (1992) *Curr. Top. Microbiol. Immun.* 158: 67).

[0140] As a further alternative, the rep/cap sequences may be stably incorporated into a cell.

[0141] Typically the AAV rep/cap sequences will not be flanked by the TRs, to prevent rescue and/or packaging of these sequences.

[0142] The nucleic acid template can be provided to the cell using any method known in the art. For example, the

template can be supplied by a non-viral (e.g., plasmid) or viral vector. In particular embodiments, the nucleic acid template is supplied by a herpesvirus or adenovirus vector (e.g., inserted into the E1a or E3 regions of a deleted adenovirus). As another illustration, Palombo et al., (1998) *J. Virology* 72:5025, describes a baculovirus vector carrying a reporter gene flanked by the AAV TRs. EBV vectors may also be employed to deliver the template, as described above with respect to the rep/cap genes.

[0143] In another representative embodiment, the nucleic acid template is provided by a replicating rAAV virus. In still other embodiments, an AAV provirus comprising the nucleic acid template is stably integrated into the chromosome of the cell.

[0144] To enhance virus titers, helper virus functions (e.g., adenovirus or herpesvirus) that promote a productive AAV infection can be provided to the cell. Helper virus sequences necessary for AAV replication are known in the art. Typically, these sequences will be provided by a helper adenovirus or herpesvirus vector. Alternatively, the adenovirus or herpesvirus sequences can be provided by another non-viral or viral vector, e.g., as a noninfectious adenovirus miniplasmid that carries all of the helper genes that promote efficient AAV production as described by Ferrari et al., (1997) *Nature Med.* 3:1295, and U.S. Pat. Nos. 6,040,183 and 6,093,570.

[0145] Further, the helper virus functions may be provided by a packaging cell with the helper sequences embedded in the chromosome or maintained as a stable extrachromosomal element. Generally, the helper virus sequences cannot be packaged into AAV virions, e.g., are not flanked by TRs.

[0146] Those skilled in the art will appreciate that it may be advantageous to provide the

[0147] AAV replication and capsid sequences and the helper virus sequences (e.g., adenovirus sequences) on a single helper construct. This helper construct may be a non-viral or viral construct. As one nonlimiting illustration, the helper construct can be a hybrid adenovirus or hybrid herpesvirus comprising the AAV rep/cap genes.

[0148] In one particular embodiment, the AAV rep/cap sequences and the adenovirus helper sequences are supplied by a single adenovirus helper vector. This vector further can further comprise the nucleic acid template. The AAV rep/cap sequences and/or the rAAV template can be inserted into a deleted region (e.g., the E1a or E3 regions) of the adenovirus.

[0149] In a further embodiment, the AAV rep/cap sequences and the adenovirus helper sequences are supplied by a single adenovirus helper vector. According to this embodiment, the rAAV template can be provided as a plasmid template.

[0150] In another illustrative embodiment, the AAV rep/cap sequences and adenovirus helper sequences are provided by a single adenovirus helper vector, and the rAAV template is integrated into the cell as a provirus. Alternatively, the rAAV template is provided by an EBV vector that is maintained within the cell as an extrachromosomal element (e.g., as an EBV based nuclear episome).

[0151] In a further exemplary embodiment, the AAV rep/cap sequences and adenovirus helper sequences are provided by a single adenovirus helper. The rAAV template can be provided as a separate replicating viral vector. For example, the rAAV template can be provided by a rAAV particle or a second recombinant adenovirus particle.

[0152] According to the foregoing methods, the hybrid adenovirus vector typically comprises the adenovirus 5' and 3' cis sequences sufficient for adenovirus replication and packaging (i.e., the adenovirus terminal repeats and PAC sequence). The AAV rep/cap sequences and, if present, the rAAV template are embedded in the adenovirus backbone and are flanked by the 5' and 3' cis sequences, so that these sequences may be packaged into adenovirus capsids. As described above, the adenovirus helper sequences and the AAV rep/cap sequences are generally not flanked by TRs so that these sequences are not packaged into the AAV virions.

[0153] Zhang et al., ((2001) *Gene Ther.* 18:704-12) describe a chimeric helper comprising both adenovirus and the AAV rep and cap genes.

[0154] Herpesvirus may also be used as a helper virus in AAV packaging methods. Hybrid herpesviruses encoding the AAV Rep protein(s) may advantageously facilitate scalable AAV vector production schemes. A hybrid herpes simplex virus type I (HSV-1) vector expressing the AAV-2 rep and cap genes has been described (Conway et al., (1999) *Gene Therapy* 6:986 and WO 00/17377).

[0155] As a further alternative, the virus vectors of the disclosure can be produced in insect cells using baculovirus vectors to deliver the rep/cap genes and rAAV template as described, for example, by Urabe et al., (2002) *Human Gene Therapy* 13:1935-43.

[0156] AAV vector stocks free of contaminating helper virus may be obtained by any method known in the art. For example, AAV and helper virus may be readily differentiated based on size. AAV may also be separated away from helper virus based on affinity for a heparin substrate (Zolotukhin et al. (1999) *Gene Therapy* 6:973). Deleted replication-defective helper viruses can be used so that any contaminating helper virus is not replication competent. As a further alternative, an adenovirus helper lacking late gene expression may be employed, as only adenovirus early gene expression is required to mediate packaging of AAV virus. Adenovirus mutants defective for late gene expression are known in the art (e.g., ts100K and ts149 adenovirus mutants).

Recombinant Virus Vectors

[0157] The virus vectors of the present disclosure are useful for the delivery of nucleic acids to cells in vitro, ex vivo, and in vivo. In particular, the virus vectors can be advantageously employed to deliver or transfer nucleic acids to animal, including mammalian, cells. Thus, in some embodiments, a nucleic acid ("cargo nucleic acid") may be encapsidated by a capsid protein of the disclosure.

[0158] In some embodiments, the disclosure provides an AAV vector comprising a recombinant capsid protein with at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, with any one of SEQ ID NO: 18-80, 300-410, 422-612, or 783-785. In some embodiments, an AAV vector comprises a recombinant capsid protein with at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, with SEQ ID NO: 380 or 384. In some embodiments, an AAV viral vector comprises a recombinant capsid protein with at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, with any one of SEQ ID NO: 18-80, 300-410, 422-612, or 783-785 and further comprises a cargo nucleic acid encapsidated by the capsid protein. In some embodi-

ments, an AAV viral vector comprises a recombinant capsid protein with at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, with SEQ ID NO: 380 or 384 and further comprises a cargo nucleic acid encapsidated by the capsid protein.

[0159] The cargo nucleic acid sequence delivered in the virus vectors of the present disclosure may be any heterologous nucleic acid sequence(s) of interest. Nucleic acids of interest include nucleic acids encoding polypeptides, including therapeutic (e.g., for medical or veterinary uses) or immunogenic (e.g., for vaccines) polypeptides or RNAs.

[0160] Therapeutic polypeptides include, but are not limited to, cystic fibrosis transmembrane regulator protein (CFTR), dystrophin (including mini- and micro-dystrophins, see, e.g., Vincent et al, (1993) *Nature Genetics* 5:130; U.S. Patent Publication No. 2003/017131; International publication WO/2008/088895, Wang et al., *Proc. Natl. Acad. Sci. USA* 97:1 3714-13719 (2000); and Gregorevic et al., *Mol. Ther.* 16:657-64 (2008)), myostatin propeptide, follistatin, activin type 11 soluble receptor, IGF-1, apolipoproteins such as apoA (apoA1, apoA2, apoA4, apoA-V), apoB (apoB100, ApoB48), apoC (apoCI, apoCII, apoCIII, apoCIV), apoD, apoE, apoH, apoL, apo(a), anti-inflammatory polypeptides such as the I kappa B dominant mutant, sarcospan, utrophin (Tinsley et al, (1996) *Nature* 384:349), mini-utrophin, clotting factors (e.g., Factor VIII, Factor IX, Factor X, etc.), erythropoietin, angiostatin, endostatin, catalase, tyrosine hydroxylase, superoxide dismutase, leptin, the LDL receptor, lipoprotein lipase, progranulin, ornithine transcarbamylase, β -globin, α -globin, spectrin, alpha-1-antitrypsin, adenosine deaminase, hypoxanthine guanine phosphoribosyl transferase, glucocerebrosidase, amyloid beta, tau, battenin, sphingomyelinase, lysosomal hexosaminidase A, branched-chain keto acid dehydrogenase, frataxin, RP65 protein, cytokines (e.g., alpha-interferon, beta-interferon, gamma-interferon, interleukin-2, interleukin-4, alpha synuclein, parkin, granulocyte-macrophage colony stimulating factor, lymphotoxin, and the like), peptide growth factors, neurotrophic factors and hormones (e.g., somatotropin, insulin, insulin-like growth factors 1 and 2, platelet derived growth factor, epidermal growth factor, fibroblast growth factor, nerve growth factor, neurotrophic factor-3 and -4, brain-derived neurotrophic factor, bone morphogenic proteins [including RANKL and VEGF], glial derived growth factor, transforming growth factor- α and - β , and the like), huntingtin, lysosomal acid alpha-glucosidase, iduronate-2-sulfatase, N-sulfoglucosamine sulfohydrolase, alpha-galactosidase A, receptors (e.g., the tumor necrosis growth factor soluble receptor), S100A1, ubiquitin protein ligase E3, parvalbumin, adenylyl cyclase type 6, a molecule that modulates calcium handling (e.g., SERCA_{2A}, Inhibitor 1 of PP1 and fragments thereof [e.g., WO 2006/029319 and WO 2007/100465]), a molecule that effects G-protein coupled receptor kinase type 2 knockdown such as a truncated constitutively active bARKct, anti-inflammatory factors such as IRAP, anti-myostatin proteins, aspartoacylase, monoclonal antibodies (including single chain monoclonal antibodies; an exemplary Mab is the Herceptin® Mab), neuropeptides and fragments thereof (e.g., galanin, Neuropeptide Y (see, U.S. Pat. No. 7,071,172), angiogenesis inhibitors such as Vasohibins and other VEGF inhibitors (e.g., Vasohibin 2 [see, WO JP2006/073052]). Other illustrative heterologous nucleic acid sequences encode suicide gene products (e.g., thymidine kinase, cytosine deaminase,

diphtheria toxin, and tumor necrosis factor), proteins that enhance or inhibit transcription of host factors (e.g., nuclease-dead Cas9 linked to a transcription enhancer or inhibitor element, zinc-finger proteins linked to a transcription enhancer or inhibitor element, transcription activator-like (TAL) effectors linked to a transcription enhancer or inhibitor element), proteins conferring resistance to a drug used in cancer therapy, tumor suppressor gene products (e.g., p53, Rb, Wt-1), TRAIL, FAS-ligand, and any other polypeptide that has a therapeutic effect in a subject in need thereof. AAV vectors can also be used to deliver monoclonal antibodies and antibody fragments, for example, an antibody or antibody fragment directed against myostatin (see, e.g., Fang et al., *Nature Biotechnology* 23:584-590 (2005)). Heterologous nucleic acid sequences encoding polypeptides include those encoding reporter polypeptides (e.g., an enzyme). Reporter polypeptides are known in the art and include, but are not limited to, Green Fluorescent Protein, β -galactosidase, alkaline phosphatase, luciferase, and chloramphenicol acetyltransferase gene.

[0161] Optionally, the heterologous nucleic acid encodes a secreted polypeptide (e.g., a polypeptide that is a secreted polypeptide in its native state or that has been engineered to be secreted, for example, by operable association with a secretory signal sequence as is known in the art).

[0162] Alternatively, in particular embodiments of this disclosure, the heterologous nucleic acid may encode an antisense nucleic acid, a ribozyme (e.g., as described in U.S. Pat. No. 5,877,022), RNAs that effect spliceosome-mediated/ram-splicing (see, Puttaraju et al. (1999) *Nature Biotech.* 17:246; U.S. Pat. Nos. 6,013,487; 6,083,702), interfering RNAs (RNAi) including siRNA, shRNA or miRNA that mediate gene silencing (see, Sharp et al. (2000) *Science* 287:2431), and other non-translated RNAs, such as "guide" RNAs (Gorman et al. (1998) *Proc. Nat. Acad. Sci. USA* 95:4929; U.S. Pat. No. 5,869,248 to Yuan et al.), and the like. Exemplary untranslated RNAs include RNAi against a multiple drug resistance (MDR) gene product (e.g., to treat and/or prevent tumors and/or for administration to the heart to prevent damage by chemotherapy), RNAi against myostatin (e.g., for Duchenne muscular dystrophy), RNAi against VEGF (e.g., to treat and/or prevent tumors), RNAi against phospholamban (e.g., to treat cardiovascular disease, see, e.g., Andino et al., *J. Gene Med.* 10:132-142 (2008) and Li et al., *Acta Pharmacol Sin.* 26:51-55 (2005)); phospholamban inhibitory or dominant-negative molecules such as phospholamban S16E (e.g., to treat cardiovascular disease, see, e.g., Hoshijima et al. *Nat. Med.* 8:864-871 (2002)), RNAi to adenosine kinase (e.g., for epilepsy), and RNAi directed against pathogenic organisms and viruses (e.g., hepatitis B and/or C virus, human immunodeficiency virus, CMV, herpes simplex virus, human papilloma virus, etc.).

[0163] Further, a nucleic acid sequence that directs alternative splicing can be delivered. To illustrate, an antisense sequence (or other inhibitory sequence) complementary to the 5' and/or 3' splice site of dystrophin exon 51 can be delivered in conjunction with a U1 or U7 small nuclear (sn) RNA promoter to induce skipping of this exon. For example, a DNA sequence comprising a U1 or U7 snRNA promoter located 5' to the antisense/inhibitory sequence(s) can be packaged and delivered in a modified capsid of the disclosure.

[0164] In some embodiments, a nucleic acid sequence that directs gene editing can be delivered. For example, the

nucleic acid may encode a guide RNA. In some embodiments, the guide RNA is a single guide RNA (sgRNA) comprising a crRNA sequence and a tracrRNA sequence. In some embodiments, the nucleic acid may encode a nuclease. In some embodiments, the nuclease is a zinc-finger nuclease, a homing endonuclease, a TALEN (transcription activator-like effector nuclease), a NgAgo (agrionaut endonuclease), a SGN (structure-guided endonuclease), a RGN (RNA-guided nuclease), or modified or truncated variants thereof. In some embodiments, the RNA-guided nuclease is a Cas9 nuclease, a Cas12(a) nuclease (Cpf1), a Cas12b nuclease, a Cas12c nuclease, a TrpB-like nuclease, a Cas13a nuclease (C2c2), a Cas13b nuclease, or modified or truncated variants thereof. In some embodiments, the Cas9 nuclease is isolated or derived from *S. pyogenes* or *S. aureus*.

[0165] In some embodiments, a nucleic acid sequence that directs gene knockdown can be delivered. For example, the nucleic acid sequence may encode a siRNA, an shRNA, a microRNA, or an antisense nucleic acid.

[0166] The virus vector may also comprise a heterologous nucleic acid that shares homology with and recombines with a locus on a host chromosome. This approach can be utilized, for example, to correct a genetic defect in the host cell.

[0167] The present disclosure also provides virus vectors that express an immunogenic polypeptide, e.g., for vaccination. The nucleic acid may encode any immunogen of interest known in the art including, but not limited to, immunogens from human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), influenza virus, HIV or SIV gag proteins, tumor antigens, cancer antigens, bacterial antigens, viral antigens, and the like.

[0168] The use of parvoviruses as vaccine vectors is known in the art (see, e.g., Miyamura et al. (1994) *Proc. Nat. Acad. Sci. USA* 91:8507; U.S. Pat. No. 5,916,563 to Young et al, U.S. Pat. No. 5,905,040 to Mazzara et al, U.S. Pat. No. 5,882,652, U.S. Pat. No. 5,863,541 to Samulski et al). The antigen may be presented in the parvovirus capsid.

[0169] Alternatively, the antigen may be expressed from a heterologous nucleic acid introduced into a recombinant vector genome. Any immunogen of interest as described herein and/or as is known in the art can be provided by the virus vector of the present disclosure.

[0170] An immunogenic polypeptide can be any polypeptide suitable for eliciting an immune response and/or protecting the subject against an infection and/or disease, including, but not limited to, microbial, bacterial, protozoal, parasitic, fungal and/or viral infections and diseases. For example, the immunogenic polypeptide can be an orthomyxovirus immunogen (e.g., an influenza virus immunogen, such as the influenza virus hemagglutinin (HA) surface protein or the influenza virus nucleoprotein, or an equine influenza virus immunogen) or a lentivirus immunogen (e.g., an equine infectious anemia virus immunogen, a Simian Immunodeficiency Virus (SIV) immunogen, or a Human Immunodeficiency Virus (HIV) immunogen, such as the HIV or SIV envelope GP 160 protein, the HIV or SIV matrix/capsid proteins, and the HIV or SIV gag, pol and env genes products). The immunogenic polypeptide can also be an arenavirus immunogen (e.g., Lassa fever virus immunogen, such as the Lassa fever virus nucleocapsid protein and the Lassa fever envelope glycoprotein), a poxvirus immunogen (e.g., a vaccinia virus immunogen, such as the vaccinia L1 or L8 gene products), a flavivirus immunogen (e.g.,

a yellow fever virus immunogen or a Japanese encephalitis virus immunogen), a filovirus immunogen (e.g., an Ebola virus immunogen, or a Marburg virus immunogen, such as NP and GP gene products), a bunyavirus immunogen (e.g., RVFV, CCHF, and/or SFS virus immunogens), or a coronavirus immunogen (e.g., an infectious human coronavirus immunogen, such as the human coronavirus envelope glycoprotein, or a porcine transmissible gastroenteritis virus immunogen, or an avian infectious bronchitis virus immunogen). The immunogenic polypeptide can further be a polio immunogen, a herpes immunogen (e.g., CMV, EBV, HSV immunogens), a mumps immunogen, a measles immunogen, a rubella immunogen, a diphtheria toxin or other diphtheria immunogen, a pertussis antigen, a hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, etc.) immunogen, and/or any other vaccine immunogen now known in the art or later identified as an immunogen.

[0171] Alternatively, the immunogenic polypeptide can be any tumor or cancer cell antigen. Optionally, the tumor or cancer antigen is expressed on the surface of the cancer cell.

[0172] Exemplary cancer and tumor cell antigens are described in S. A. Rosenberg (Immunity 10:281 (1991)). Other illustrative cancer and tumor antigens include, but are not limited to: BRCA1 gene product, BRCA2 gene product, gp100, tyrosinase, GAGE-1/2, BALE, RAGE, LAGE, NY-ESO-1, CDK-4, β -catenin, MUM-1, Caspase-8, KIAA0205, HPVE, SART-1, FRAME, p15, melanoma tumor antigens (Kawakami et al., (1994) Proc. Natl. Acad. Sci. USA 91:3515; Kawakami et al., (1994) J. Exp. Med., 180:347; Kawakami et al., (1994) Cancer Res. 54:3124), MART-1, gp100, MAGE-1, MAGE-2, MAGE-3, CEA, TRP-1, TRP-2, P-15, tyrosinase (Brichard et al., (1993) J Exp. Med. 178:489); HER-2/neu gene product (U.S. Pat. No. 4,968, 603), CA 125, LK26, FB5 (endosialin), TAG 72, AFP, CA 19-9, NSE, DU-PAN-2, CA50, SPan-1, CA72-4, HCG, STN (sialyl Tn antigen), c-erbB-2 proteins, PSA, L-CanAg, estrogen receptor, milk fat globulin, p53 tumor suppressor protein (Levine, (1993) Ann. Rev. Biochem. 62:623); mucin antigens (International Patent Publication No. WO 90/05142); telomerases; nuclear matrix proteins; prostatic acid phosphatase; papilloma virus antigens; and/or antigens now known or later discovered to be associated with the following cancers: melanoma, adenocarcinoma, thymoma, lymphoma (e.g., non-Hodgkin's lymphoma, Hodgkin's lymphoma), sarcoma, lung cancer, liver cancer, colon cancer, leukemia, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer and any other cancer or malignant condition or metastasis thereof now known or later identified (see, e.g., Rosenberg, (1996) Ann. Rev. Med. 47:481-91).

[0173] As a further alternative, the heterologous nucleic acid can encode any polypeptide that is desirably produced in a cell in vitro, ex vivo, or in vivo. For example, the virus vectors may be introduced into cultured cells and the expressed gene product isolated therefrom.

[0174] It will be understood by those skilled in the art that the heterologous nucleic acid(s) of interest can be operably associated with appropriate control sequences. For example, the heterologous nucleic acid can be operably associated with expression control elements, such as transcription/translation control signals, origins of replication, polyadenylation signals, internal ribosome entry sites (IRES), promoters, and/or enhancers, and the like.

[0175] Further, regulated expression of the heterologous nucleic acid(s) of interest can be achieved at the post-transcriptional level, e.g., by regulating selective splicing of different introns by the presence or absence of an oligonucleotide, small molecule and/or other compound that selectively blocks splicing activity at specific sites (e.g., as described in WO 2006/119137).

[0176] Those skilled in the art will appreciate that a variety of promoter/enhancer elements can be used depending on the level and tissue-specific expression desired. The promoter/enhancer can be constitutive or inducible, depending on the pattern of expression desired. The promoter/enhancer can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced.

[0177] In particular embodiments, the promoter/enhancer elements can be native to the target cell or subject to be treated. In representative embodiments, the promoters/enhancer element can be native to the heterologous nucleic acid sequence. The promoter/enhancer element is generally chosen so that it functions in the target cell(s) of interest. Further, in particular embodiments the promoter/enhancer element is a mammalian promoter/enhancer element. The promoter/enhancer element may be constitutive or inducible.

[0178] Inducible expression control elements are typically advantageous in those applications in which it is desirable to provide regulation over expression of the heterologous nucleic acid sequence(s). Inducible promoters/enhancer elements for gene delivery can be tissue-specific or -preferred promoter/enhancer elements, and include muscle specific or preferred (including cardiac, skeletal and/or smooth muscle specific or preferred), neural tissue specific or preferred (including brain-specific or preferred), eye specific or preferred (including retina-specific and cornea-specific), liver specific or preferred, bone marrow specific or preferred, pancreatic specific or preferred, spleen specific or preferred, and lung specific or preferred promoter/enhancer elements. Other inducible promoter/enhancer elements include hormone-inducible and metal-inducible elements. Exemplary inducible promoters/enhancer elements include, but are not limited to, a Tet on/off element, a RU486-inducible promoter, an ecdysone-inducible promoter, a rapamycin-inducible promoter, and a metallothionein promoter.

[0179] In embodiments wherein the heterologous nucleic acid sequence(s) is transcribed and then translated in the target cells, specific initiation signals are generally included for efficient translation of inserted protein coding sequences. These exogenous translational control sequences, which may include the ATG initiation codon and adjacent sequences, can be of a variety of origins, both natural and synthetic.

[0180] The virus vectors according to the present disclosure provide a means for delivering heterologous nucleic acids into a broad range of cells, including dividing and non-dividing cells. The virus vectors can be employed to deliver a nucleic acid of interest to a cell in vitro, e.g., to produce a polypeptide in vitro or for ex vivo gene therapy. The virus vectors are additionally useful in a method of delivering a nucleic acid to a subject in need thereof e.g., to express an immunogenic or therapeutic polypeptide or a functional RNA. In this manner, the polypeptide or func-

tional RNA can be produced in vivo in the subject. The subject can be in need of the polypeptide because the subject has a deficiency of the polypeptide. Further, the method can be practiced because the production of the polypeptide or functional RNA in the subject may impart some beneficial effect.

[0181] The virus vectors can also be used to produce a polypeptide of interest or functional RNA in cultured cells or in a subject (e.g., using the subject as a bioreactor to produce the polypeptide or to observe the effects of the functional RNA on the subject, for example, in connection with screening methods).

[0182] In general, the virus vectors of the present disclosure can be employed to deliver a heterologous nucleic acid encoding a polypeptide or functional RNA to treat and/or prevent any disease state for which it is beneficial to deliver a therapeutic polypeptide or functional RNA. Illustrative disease states include, but are not limited to: cystic fibrosis (cystic fibrosis transmembrane regulator protein) and other diseases of the lung, hemophilia A (Factor VIII), hemophilia B (Factor IX), thalassemia (β -globin), anemia (erythropoietin) and other blood disorders. Alzheimer's disease (GDF; neprilysin), multiple sclerosis (β -interferon), Parkinson's disease (glial-cell line derived neurotrophic factor [GDNF]), Huntington's disease (RNAi to remove repeats), Canavan's disease, amyotrophic lateral sclerosis, epilepsy (galanin, neurotrophic factors), and other neurological disorders, cancer (endostatin, angiostatin, TRAIL, FAS-ligand, cytokines including interferons; RNAi including RNAi against VEGF or the multiple drug resistance gene product, mir-26a [e.g., for hepatocellular carcinoma]), diabetes mellitus (insulin), muscular dystrophies including Duchenne (dystrophin, mini-dystrophin, insulin-like growth factor I, a sarcoglycan [e.g., α , β , γ]), RNAi against myostatin propeptide, follistatin, activin type II soluble receptor, anti-inflammatory polypeptides such as the β 1kappa B dominant mutant, sarcospan, utrophin, mini-utrophin, antisense or RNAi against splice junctions in the dystrophin gene to induce exon skipping [see, e.g., WO/2003/095647], antisense against U7 snRNAs to induce exon skipping [see, e.g., WO/2006/021724], and antibodies or antibody fragments against myostatin or myostatin propeptide) and Becker, Gaucher disease (glucocerebrosidase), Hurler's disease (α -L-iduronidase), adenosine deaminase deficiency (adenosine deaminase), glycogen storage diseases (e.g., Fabry disease [α -galactosidase] and Pompe disease [lysosomal acid α -glucosidase]) and other metabolic disorders, congenital emphysema (α -1-antitrypsin), Lesch-Nyhan Syndrome (hypoxanthine guanine phosphoribosyl transferase), Niemann-Pick disease (sphingomyelinase), Tay-Sachs disease (lysosomal hexosaminidase A), Maple Syrup Urine Disease (branched-chain keto acid dehydrogenase), retinal degenerative diseases (and other diseases of the eye and retina; e.g., PDGF for macular degeneration and/or vasohibin or other inhibitors of VEGF or other angiogenesis inhibitors to treat/prevent retinal disorders, e.g., in Type I diabetes), diseases of solid organs such as brain (including Parkinson's Disease [GDNF], astrocytomas [endostatin, angiostatin and/or RNAi against VEGF], glioblastomas [endostatin, angiostatin and/or RNAi against VEGF]), liver, kidney, heart including congestive heart failure or peripheral artery disease (PAD) (e.g., by delivering protein phosphatase inhibitor 1 (I-1) and fragments thereof (e.g., IIC), serca2a, zinc finger proteins that regulate the phospholamban gene, Barkct, [32-adrener-

gic receptor, 2-adrenergic receptor kinase (BARK), phosphoinositide-3 kinase (PI3 kinase), S100A1, parvalbumin, adenylyl cyclase type 6, a molecule that effects G-protein coupled receptor kinase type 2 knockdown such as a truncated constitutively active bARKct; calsarcin, RNAi against phospholamban; phospholamban inhibitory or dominant-negative molecules such as phospholamban S16E, etc.), arthritis (insulin-like growth factors), joint disorders (insulin-like growth factor 1 and/or 2), intimal hyperplasia (e.g., by delivering enos, inos), improve survival of heart transplants (superoxide dismutase), AIDS (soluble CD4), muscle wasting (insulin-like growth factor I), kidney deficiency (erythropoietin), anemia (erythropoietin), arthritis (anti-inflammatory factors such as I RAP and TNFa soluble receptor), hepatitis (a-interferon), LDL receptor deficiency (LDL receptor), hyperammonemia (ornithine transcarbamylase), Krabbe's disease (galactocerebrosidase), Batten's disease, spinal cerebral ataxias including SCA1, SCA2 and SCA3, phenylketonuria (phenylalanine hydroxylase), autoimmune diseases, and the like. The disclosure can further be used following organ transplantation to increase the success of the transplant and/or to reduce the negative side effects of organ transplantation or adjunct therapies (e.g., by administering immunosuppressant agents or inhibitory nucleic acids to block cytokine production). As another example, bone morphogenic proteins (including BNP 2, 7, etc., RANKL and/or VEGF) can be administered with a bone allograft, for example, following a break or surgical removal in a cancer patient.

[0183] In some embodiments, the virus vectors of the present disclosure can be employed to deliver a heterologous nucleic acid encoding a polypeptide or functional RNA to treat and/or prevent a liver disease or disorder. The liver disease or disorder may be, for example, primary biliary cirrhosis, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hepatitis B, hepatitis C, alcoholic liver disease, fibrosis, jaundice, primary sclerosing cholangitis (PSC), Budd-Chiari syndrome, hemochromatosis, Wilson's disease, alcoholic fibrosis, non-alcoholic fibrosis, liver steatosis, Gilbert's syndrome, biliary atresia, alpha-1-antitrypsin deficiency, alagille syndrome, progressive familial intrahepatic cholestasis, Hemophilia B, Hereditary Angioedema (HAE), Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), Von Gierke's Disease (GSD I), Hemophilia A, Methylmalonic Acidemia, Propionic Acidemia, Homocystinuria, Phenylketonuria (PKU), Tyrosinemia Type 1, Arginase 1 Deficiency, Argininosuccinate Lyase Deficiency, Carbamoyl-phosphate synthetase 1 deficiency, Citrullinemia Type 1, Citrin Deficiency, Crigler-Najjar Syndrome Type 1, Cystinosis, Fabry Disease, Glycogen Storage Disease 1b, LPL Deficiency, N-Acetylglutamate Synthetase Deficiency, Ornithine Transcarbamylase Deficiency, Ornithine Translocase Deficiency, Primary Hyperoxaluria Type 1, or ADA SCID.

[0184] The disclosure can also be used to produce induced pluripotent stem cells (iPS). For example, a virus vector of the disclosure can be used to deliver stem cell associated nucleic acid(s) into a non-pluripotent cell, such as adult fibroblasts, skin cells, liver cells, renal cells, adipose cells, cardiac cells, neural cells, epithelial cells, endothelial cells, and the like.

[0185] Nucleic acids encoding factors associated with stem cells are known in the art. Nonlimiting examples of

such factors associated with stem cells and pluripotency include Oct-3/4, the SOX family (e.g., SOX 1, SOX2, SOX3 and/or SOX 15), the Klf family (e.g., Klf1, Klf4 and/or Klf5), the Myc family (e.g., C-myc, L-myc and/or N-myc), NANOG and/or LIN28.

[0186] The disclosure can also be practiced to treat and/or prevent a metabolic disorder such as diabetes (e.g., insulin), hemophilia (e.g., Factor IX or Factor VIII), a lysosomal storage disorder such as a mucopolysaccharidosis disorder (e.g., Sly syndrome [β -glucuronidase], Hurler Syndrome [α -L-iduronidase], Scheie Syndrome [α -L-iduronidase], Hunter-Scheie Syndrome [α -L-iduronidase], Hunter's Syndrome [iduronate sulfatase], Sanfilippo Syndrome A [heparan sulfamidase], B [N-acetylglucosaminidase], C [acetyl-CoA: α -glucosaminide acetyltransferase], D [N-acetylglucosamine 6-sulfatase], Morquio Syndrome A [galactoses-sulfate sulfatase], B [β -galactosidase], Maroteaux-Lamy Syndrome [N-acetylgalactosamine-4-sulfatase], etc.), Fabry disease (α -galactosidase), Gaucher's disease (glucocerebrosidase), or a glycogen storage disorder (e.g., Pompe disease; lysosomal acid α -glucosidase).

[0187] Gene transfer has substantial use for understanding and providing therapy for disease states. There are a number of inherited diseases in which defective genes are known and have been cloned. In general, the above disease states fall into two classes: deficiency states, usually of enzymes, which are generally inherited in a recessive manner, and unbalanced states, which may involve regulatory or structural proteins, and which are typically inherited in a dominant manner. For deficiency state diseases, gene transfer can be used to bring a normal gene into affected tissues for replacement therapy, as well as to create animal models for the disease using antisense mutations. For unbalanced disease states, gene transfer can be used to create a disease state in a model system, which can then be used in efforts to counteract the disease state. Thus, virus vectors according to the present disclosure permit the treatment and/or prevention of genetic diseases.

[0188] The virus vectors according to the present disclosure may also be employed to provide a functional RNA to a cell in vitro or in vivo. The functional RNA may be, for example, a non-coding RNA. In some embodiments, expression of the functional RNA in the cell can diminish expression of a particular target protein by the cell. Accordingly, functional RNA can be administered to decrease expression of a particular protein in a subject in need thereof. In some embodiments, expression of the functional RNA in the cell can increase expression of a particular target protein by the cell. Accordingly, functional RNA can be administered to increase expression of a particular protein in a subject in need thereof. In some embodiments, expression of the functional RNA can regulate splicing of a particular target RNA in a cell. Accordingly, functional RNA can be administered to regulate splicing of a particular RNA in a subject in need thereof. In some embodiments, expression of the functional RNA in the cell can regulate the function of a particular target protein by the cell. Accordingly, functional RNA can be administered to regulate the function of a particular protein in a subject in need thereof. Functional RNA can also be administered to cells in vitro to regulate gene expression and/or cell physiology, e.g., to optimize cell or tissue culture systems or in screening methods.

[0189] In addition, virus vectors according to the instant disclosure find use in diagnostic and screening methods, whereby a nucleic acid of interest is transiently or stably expressed in a cell culture system, or alternatively, a transgenic animal model.

[0190] The virus vectors of the present disclosure can also be used for various non-therapeutic purposes, including but not limited to use in protocols to assess gene targeting, clearance, transcription, translation, etc., as would be apparent to one skilled in the art. The virus vectors can also be used for the purpose of evaluating safety (spread, toxicity, immunogenicity, etc.). Such data, for example, are considered by the United States Food and Drug Administration as part of the regulatory approval process prior to evaluation of clinical efficacy.

[0191] As a further aspect, the virus vectors of the present disclosure may be used to produce an immune response in a subject. According to this embodiment, a virus vector comprising a heterologous nucleic acid sequence encoding an immunogenic polypeptide can be administered to a subject, and an active immune response is mounted by the subject against the immunogenic polypeptide. Immunogenic polypeptides are as described hereinabove. In some embodiments, a protective immune response is elicited.

[0192] Alternatively, the virus vector may be administered to a cell ex vivo and the altered cell is administered to the subject. The virus vector comprising the heterologous nucleic acid is introduced into the cell, and the cell is administered to the subject, where the heterologous nucleic acid encoding the immunogen can be expressed and induce an immune response in the subject against the immunogen. In particular embodiments, the cell is an antigen-presenting cell (e.g., a dendritic cell).

[0193] An "active immune response" or "active immunity" is characterized by "participation of host tissues and cells after an encounter with the immunogen. It involves differentiation and proliferation of immunocompetent cells in lymphoreticular tissues, which lead to synthesis of antibody or the development of cell-mediated reactivity, or both." Herbert B. Herscovitz, *Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation*, in *IMMUNOLOGY: BASIC PROCESSES* 1 17 (Joseph A. Bellanti ed., 1985). Alternatively stated, an active immune response is mounted by the host after exposure to an immunogen by infection or by vaccination. Active immunity can be contrasted with passive immunity, which is acquired through the transfer of preformed substances (antibody, transfer factor, thymic graft, interleukin-2) from an actively immunized host to a non-immune host.

[0194] A "protective" immune response or "protective" immunity as used herein indicates that the immune response confers some benefit to the subject in that it prevents or reduces the incidence of disease. Alternatively, a protective immune response or protective immunity may be useful in the treatment and/or prevention of disease, in particular cancer or tumors (e.g., by preventing cancer or tumor formation, by causing regression of a cancer or tumor and/or by preventing metastasis and/or by preventing growth of metastatic nodules). The protective effects may be complete or partial, as long as the benefits of the treatment outweigh any disadvantages thereof.

[0195] In particular embodiments, the virus vector or cell comprising the heterologous nucleic acid can be administered in an immunogenically effective amount, as described below.

[0196] The virus vectors of the present disclosure can also be administered for cancer immunotherapy by administration of a virus vector expressing one or more cancer cell antigens (or an immunologically similar molecule) or any other immunogen that produces an immune response against a cancer cell. To illustrate, an immune response can be produced against a cancer cell antigen in a subject by administering a virus vector comprising a heterologous nucleic acid encoding the cancer cell antigen, for example to treat a patient with cancer and/or to prevent cancer from developing in the subject. The virus vector may be administered to a subject in vivo or by using ex vivo methods, as described herein.

[0197] Alternatively, the cancer antigen can be expressed as part of the virus capsid or be otherwise associated with the virus capsid (e.g., as described above).

[0198] As another alternative, any other therapeutic nucleic acid (e.g., RNAi) or polypeptide (e.g., cytokine) known in the art can be administered to treat and/or prevent cancer.

[0199] As used herein, the term “cancer” encompasses tumor-forming cancers. Likewise, the term “cancerous tissue” encompasses tumors. A “cancer cell antigen” encompasses tumor antigens.

[0200] The term “cancer” has its understood meaning in the art, for example, an uncontrolled growth of tissue that has the potential to spread to distant sites of the body (i.e., metastasize). Exemplary cancers include, but are not limited to melanoma, adenocarcinoma, thymoma, lymphoma (e.g., non-Hodgkin’s lymphoma, Hodgkin’s lymphoma), sarcoma, lung cancer, liver cancer, colon cancer, leukemia, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer and any other cancer or malignant condition now known or later identified. In representative embodiments, the disclosure provides a method of treating and/or preventing tumor-forming cancers.

[0201] The term “tumor” is also understood in the art, for example, as an abnormal mass of undifferentiated cells within a multicellular organism. Tumors can be malignant or benign. In representative embodiments, the methods disclosed herein are used to prevent and treat malignant tumors.

[0202] By the terms “treating cancer,” “treatment of cancer” and equivalent terms it is intended that the severity of the cancer is reduced or at least partially eliminated and/or the progression of the disease is slowed and/or controlled and/or the disease is stabilized. In particular embodiments, these terms indicate that metastasis of the cancer is prevented or reduced or at least partially eliminated and/or that growth of metastatic nodules is prevented or reduced or at least partially eliminated.

[0203] By the terms “prevention of cancer” or “preventing cancer” and equivalent terms it is intended that the methods at least partially eliminate or reduce and/or delay the incidence and/or severity of the onset of cancer. Alternatively stated, the onset of cancer in the subject may be reduced in likelihood or probability and/or delayed.

[0204] In particular embodiments, cells may be removed from a subject with cancer and contacted with a virus vector expressing a cancer cell antigen according to the instant

disclosure. The modified cell is then administered to the subject, whereby an immune response against the cancer cell antigen is elicited. This method can be advantageously employed with immunocompromised subjects that cannot mount a sufficient immune response in vivo (i.e., cannot produce enhancing antibodies in sufficient quantities).

[0205] It is known in the art that immune responses may be enhanced by immunomodulatory cytokines (e.g., alpha-interferon, beta-interferon, gamma-interferon, omega-interferon, tau-interferon, interleukin-1-alpha, interleukin-1 β , interleukin-2, interleukin-3, interleukin-4, interleukin 5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-18, B cell Growth factor, CD40 Ligand, tumor necrosis factor-alpha, tumor necrosis factor- β , monocyte chemoattractant protein-1, granulocyte-macrophage colony stimulating factor, and lymphotoxin). Accordingly, immunomodulatory cytokines (preferably, CTL inductive cytokines) may be administered to a subject in conjunction with the virus vector. Cytokines may be administered by any method known in the art. Exogenous cytokines may be administered to the subject, or alternatively, a nucleic acid encoding a cytokine may be delivered to the subject using a suitable vector, and the cytokine produced in vivo.

Subjects, Pharmaceutical Formulations, and Modes of Administration

[0206] Virus vectors and capsids according to the present disclosure find use in both veterinary and medical applications. Suitable subjects include both avians and mammals. The term “avian” as used herein includes, but is not limited to, chickens, ducks, geese, quail, turkeys, pheasant, parrots, parakeets, and the like. The term “mammals” as used herein includes, but is not limited to, humans, non-human primates, bovines, ovines, caprines, equines, felines, canines, lagomorphs, etc. Human subjects include neonates, infants, juveniles, adults and geriatric subjects. In some embodiments, a human subject can be less than 6 months old, less than 2 years old, less than 5 years old, less than 10 years old, 10-18 years old, 19-29 years old, 30-35 years old, 36-40 years old, or older than 40 years old.

[0207] In representative embodiments, the subject is “in need” of the methods described herein.

[0208] In particular embodiments, a pharmaceutical composition is provided comprising a virus vector and/or capsid and/or capsid protein and/or virus particle of the disclosure in a pharmaceutically acceptable carrier and, optionally, other medicinal agents, pharmaceutical agents, stabilizing agents, buffers, carriers, adjuvants, diluents, etc. For injection, the carrier will typically be a liquid. For other methods of administration, the carrier may be either solid or liquid. For inhalation administration, the carrier will be respirable, and optionally can be in solid or liquid particulate form.

[0209] By “pharmaceutically acceptable” it is meant a material that is not toxic or otherwise undesirable, i.e., the material may be administered to a subject without causing any undesirable biological effects.

[0210] One aspect of the present disclosure is a method of transferring a nucleic acid to a cell in vitro. The virus vector may be introduced into the cells at the appropriate multiplicity of infection according to standard transduction methods suitable for the particular target cells. Titers of virus vector to administer can vary, depending upon the target cell

type and number, and the particular virus vector, and can be determined by those of skill in the art without undue experimentation. In representative embodiments, at least about 10^3 infectious units, optionally at least about 10^5 infectious units are introduced to the cell.

[0211] The cell(s) into which the virus vector is introduced can be of any type, including but not limited to neural cells (including cells of the peripheral and central nervous systems, in particular, brain cells such as neurons and oligodendrocytes), lung cells, cells of the eye (including retinal cells, retinal pigment epithelium, and corneal cells), epithelial cells (e.g., gut and respiratory epithelial cells), muscle cells (e.g., skeletal muscle cells, cardiac muscle cells, smooth muscle cells and/or diaphragm muscle cells), dendritic cells, pancreatic cells (including islet cells), hepatic cells, myocardial cells, bone cells (e.g., bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, germ cells, and the like. In representative embodiments, the cell can be any progenitor cell. As a further possibility, the cell can be a stem cell (e.g., neural stem cell, liver stem cell). As still a further alternative, the cell can be a cancer or tumor cell. Moreover, the cell can be from any species of origin, as indicated above.

[0212] The virus vector can be introduced into cells in vitro for the purpose of administering the modified cell to a subject. In particular embodiments, the cells have been removed from a subject, the virus vector is introduced therein, and the cells are then administered back into the subject. Methods of removing cells from subject for manipulation *ex vivo*, followed by introduction back into the subject are known in the art (see, e.g., U.S. Pat. No. 5,399,346). Alternatively, the recombinant virus vector can be introduced into cells from a donor subject, into cultured cells, or into cells from any other suitable source, and the cells are administered to a subject in need thereof (i.e., a "recipient" subject).

[0213] Suitable cells for *ex vivo* nucleic acid delivery are as described above. Dosages of the cells to administer to a subject will vary upon the age, condition and species of the subject, the type of cell, the nucleic acid being expressed by the cell, the mode of administration, and the like. Typically, at least about 10^2 to about 10^8 cells or at least about 10^3 to about 10^6 cells will be administered per dose in a pharmaceutically acceptable carrier. In particular embodiments, the cells transduced with the virus vector are administered to the subject in a therapeutically effective amount in combination with a pharmaceutical carrier.

[0214] In some embodiments, the virus vector is introduced into a cell and the cell can be administered to a subject to elicit an immunogenic response against the delivered polypeptide (e.g., expressed as a transgene or in the capsid). Typically, a quantity of cells expressing an immunogenically effective amount of the polypeptide in combination with a pharmaceutically acceptable carrier is administered. An "immunogenically effective amount" is an amount of the expressed polypeptide that is sufficient to evoke an active immune response against the polypeptide in the subject to which the pharmaceutical formulation is administered. In particular embodiments, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or

permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any disadvantages thereof.

[0215] Thus, the present disclosure provides a method of administering a nucleic acid to a cell, the method comprising contacting the cell with the virus vector, virus particle and/or composition of this disclosure.

[0216] A further aspect of the disclosure is a method of administering the virus vector, virus particle and/or virus capsid of this disclosure to a subject. Thus, the present disclosure also provides a method of delivering a nucleic acid to a subject, comprising administering to the subject a virus particle, virus vector and/or composition of this disclosure. Administration of the virus vectors, virus particles and/or capsids according to the present disclosure to a human subject or an animal in need thereof can be by any means known in the art. Optionally, the virus vector, virus particle and/or capsid is delivered in a therapeutically effective dose in a pharmaceutically acceptable carrier. In preferred embodiments, a therapeutically effective amount of the virus vector, virus particle and/or capsid is delivered.

[0217] The virus vectors and/or capsids of the disclosure can further be administered to elicit an immunogenic response (e.g., as a vaccine). Typically, immunogenic compositions of the present disclosure comprise an immunogenically effective amount of virus vector and/or capsid in combination with a pharmaceutically acceptable carrier. Optionally, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any disadvantages thereof. Subjects and immunogens are as described above.

[0218] Dosages of the virus vector and/or capsid to be administered to a subject depend upon the mode of administration, the disease or condition to be treated and/or prevented, the individual subject's condition, the particular virus vector or capsid, and the nucleic acid to be delivered, and the like, and can be determined in a routine manner. Exemplary doses for achieving therapeutic effects are titers of at least about 10^5 , about 10^6 , about 10^7 , about 10^8 , about 10^9 , about 10^{10} , about 10^{11} , about 10^{12} , about 10^{13} , about 10^{14} , about 10^{15} transducing units, optionally about 10^8 - 10^{13} transducing units.

[0219] In particular embodiments, more than one administration (e.g., two, three, four or more administrations) may be employed to achieve the desired level of gene expression over a period of various intervals, e.g., daily, weekly, monthly, yearly, etc.

[0220] Exemplary modes of administration include oral, rectal, transmucosal, intranasal, inhalation (e.g., via an aerosol), buccal (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, in utero (or in ovo), parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular [including administration to skeletal, diaphragm and/or cardiac muscle], intradermal, intrapleural, intracerebral, and intra-articular), topical (e.g., to both skin and mucosal surfaces, including airway surfaces, and transdermal administration), intralymphatic, and the like, as well as direct tissue or organ injection (e.g., to liver, skeletal muscle, cardiac muscle, diaphragm muscle or brain). Administration can also be to a tumor (e.g., in or near a tumor or a lymph node). The most suitable route in any given case will depend on the nature

and severity of the condition being treated and/or prevented and on the nature of the particular vector that is being used.

[0221] Administration to skeletal muscle according to the present disclosure includes but is not limited to administration to skeletal muscle in the limbs (e.g., upper arm, lower arm, upper leg, and/or lower leg), back, neck, head (e.g., tongue), thorax, abdomen, pelvis/perineum, and/or digits. Suitable skeletal muscles include but are not limited to abductor digiti minimi (in the hand), abductor digiti minimi (in the foot), abductor hallucis, abductor ossis metatarsi quinti, abductor pollicis brevis, abductor pollicis longus, adductor brevis, adductor hallucis, adductor longus, adductor magnus, adductor pollicis, anconeus, anterior scalene, articularis genus, biceps brachii, biceps femoris, brachialis, brachioradialis, buccinator, coracobrachialis, corrugator supercilii, deltoid, depressor anguli oris, depressor labii inferioris, digastric, dorsal interossei (in the hand), dorsal interossei (in the foot), extensor carpi radialis brevis, extensor carpi radialis longus, extensor carpi ulnaris, extensor digiti minimi, extensor digitorum, extensor digitorum brevis, extensor digitorum longus, extensor hallucis brevis, extensor hallucis longus, extensor indicis, extensor pollicis brevis, extensor pollicis longus, flexor carpi radialis, flexor carpi ulnaris, flexor digiti minimi brevis (in the hand), flexor digiti minimi brevis (in the foot), flexor digitorum brevis, flexor digitorum longus, flexor digitorum profundus, flexor digitorum superficialis, flexor hallucis brevis, flexor hallucis longus, flexor pollicis brevis, flexor pollicis longus, frontalis, gastrocnemius, geniohyoid, gluteus maximus, gluteus medius, gluteus minimus, gracilis, iliocostalis cervicis, iliocostalis lumborum, iliocostalis thoracis, iliacus, inferior gemellus, inferior oblique, inferior rectus, infraspinatus, interspinalis, intertransversi, lateral pterygoid, lateral rectus, latissimus dorsi, levator anguli oris, levator labii superioris, levator labii superioris alaeque nasi, levator palpebrae superioris, levator scapulae, long rotators, longissimus capitis, longissimus cervicis, longissimus thoracis, longus capitis, longus colli, lumbricals (in the hand), lumbricals (in the foot), masseter, medial pterygoid, medial rectus, middle scalene, multifidus, mylohyoid, obliquus capitis inferior, obliquus capitis superior, obturator externus, obturator internus, occipitalis, omohyoid, opponens digiti minimi, opponens pollicis, orbicularis oculi, orbicularis oris, palmar interossei, palmaris brevis, palmaris longus, pectineus, pectoralis major, pectoralis minor, peroneus brevis, peroneus longus, peroneus tertius, piriformis, plantar interossei, plantaris, platysma, popliteus, posterior scalene, pronator quadratus, pronator teres, psoas major, quadratus femoris, quadratus plantae, rectus capitis anterior, rectus capitis lateralis, rectus capitis posterior major, rectus capitis posterior minor, rectus femoris, rhomboid major, rhomboid minor, risorius, sartorius, scalenus minimus, semimembranosus, semispinalis capitis, semispinalis cervicis, semispinalis thoracis, semitendinosus, serratus anterior, short rotators, soleus, spinalis capitis, spinalis cervicis, spinalis thoracis, splenius capitis, splenius cervicis, sternocleidomastoid, sternohyoid, sternothyroid, stylohyoid, subclavius, subscapularis, superior gemellus, superior oblique, superior rectus, supinator, supraspinatus, temporalis, tensor fascia lata, teres major, teres minor, thoracis, thyrohyoid, tibialis anterior, tibialis posterior, trapezius, triceps brachii, vastus intermedius, vastus lateralis, vastus medialis, zygomaticus major, and zygomaticus minor, and any other suitable skeletal muscle as known in the art.

[0222] The virus vector and/or capsid can be delivered to skeletal muscle by intravenous administration, intra-arterial administration, intraperitoneal administration, limb perfusion, (optionally, isolated limb perfusion of a leg and/or arm; see, e.g. Arruda et al., (2005) Blood 105:3458-3464), and/or direct intramuscular injection. In particular embodiments, the virus vector and/or capsid is administered to a limb (arm and/or leg) of a subject (e.g., a subject with muscular dystrophy such as DMD) by limb perfusion, optionally isolated limb perfusion (e.g., by intravenous or intra-articular administration). In embodiments of the disclosure, the virus vectors and/or capsids of the disclosure can advantageously be administered without employing “hydrodynamic” techniques. Tissue delivery (e.g., to muscle) of prior art vectors is often enhanced by hydrodynamic techniques (e.g., intravenous/intravenous administration in a large volume), which increase pressure in the vasculature and facilitate the ability of the vector to cross the endothelial cell barrier. In particular embodiments, the viral vectors and/or capsids of the disclosure can be administered in the absence of hydrodynamic techniques such as high volume infusions and/or elevated intravascular pressure (e.g., greater than normal systolic pressure, for example, less than or equal to a 5%, 10%, 15%, 20%, 25% increase in intravascular pressure over normal systolic pressure). Such methods may reduce or avoid the side effects associated with hydrodynamic techniques such as edema, nerve damage and/or compartment syndrome. Administration to cardiac muscle includes administration to the left atrium, right atrium, left ventricle, right ventricle and/or septum. The virus vector and/or capsid can be delivered to cardiac muscle by intravenous administration, intra-arterial administration such as intra-aortic administration, direct cardiac injection (e.g., into left atrium, right atrium, left ventricle, right ventricle), and/or coronary artery perfusion.

[0223] Administration to diaphragm muscle can be by any suitable method including intravenous administration, intra-arterial administration, and/or intra-peritoneal administration.

[0224] Delivery to a target tissue can also be achieved by delivering a depot comprising the virus vector and/or capsid. In representative embodiments, a depot comprising the virus vector and/or capsid is implanted into skeletal, cardiac and/or diaphragm muscle tissue or the tissue can be contacted with a film or other matrix comprising the virus vector and/or capsid. Such implantable matrices or substrates are described in U.S. Pat. No. 7,201,898.

[0225] In particular embodiments, a virus vector and/or virus capsid according to the present disclosure is administered to skeletal muscle, diaphragm muscle and/or cardiac muscle (e.g., to treat and/or prevent muscular dystrophy, heart disease [for example, PAD or congestive heart failure]).

[0226] In representative embodiments, the disclosure is used to treat and/or prevent disorders of skeletal, cardiac and/or diaphragm muscle.

[0227] In a representative embodiment, a method of treating and/or preventing muscular dystrophy in a subject in need thereof is provided, the method comprising: administering a treatment or prevention effective amount of a virus vector of the disclosure to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid encoding dystrophin, a mini-dystrophin, a micro-dystrophin, myostatin propeptide, follistatin, activin type II soluble receptor,

IGF-1, anti-inflammatory polypeptides such as the κ B dominant mutant, sarcospan, utrophin, a micro-dystrophin, laminin- α 2, alpha-sarcoglycan, beta-sarcoglycan, gamma-sarcoglycan, delta-sarcoglycan, IGF-1, an antibody or antibody fragment against myostatin or myostatin propeptide, and/or RNAi against myostatin. In particular embodiments, the virus vector can be administered to skeletal, diaphragm and/or cardiac muscle as described elsewhere herein.

[0228] Alternatively, the disclosure can be practiced to deliver a nucleic acid to skeletal, cardiac or diaphragm muscle, which is used as a platform for production of a polypeptide (e.g., an enzyme) or functional RNA (e.g., RNAi, micro RNA, antisense RNA) that normally circulates in the blood or for systemic delivery to other tissues to treat and/or prevent a disorder (e.g., a metabolic disorder, such as diabetes [e.g., insulin], hemophilia [e.g., Factor IX or Factor VIII], a mucopolysaccharide disorder [e.g., Sly syndrome, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie Syndrome, Hunter's Syndrome, Sanfilippo Syndrome A, B, C, D, Morquio Syndrome, Maroteaux-Lamy Syndrome, etc.] or a lysosomal storage disorder such as Gaucher's disease [glucocerebrosidase] or Fabry disease [α -galactosidase A] or a glycogen storage disorder such as Pompe disease [lysosomal acid α glucosidase]). Other suitable proteins for treating and/or preventing metabolic disorders are described herein. The use of muscle as a platform to express a nucleic acid of interest is described in U.S. Patent publication US 2002/0192189.

[0229] Thus, as one aspect, the disclosure further encompasses a method of treating and/or preventing a metabolic disorder in a subject in need thereof, the method comprising: administering a treatment or prevention effective amount of a virus vector of the disclosure to skeletal muscle of a subject, wherein the virus vector comprises a heterologous nucleic acid encoding a polypeptide, wherein the metabolic disorder is a result of a deficiency and/or defect in the polypeptide. Illustrative metabolic disorders and heterologous nucleic acids encoding polypeptides are described herein. Optionally, the polypeptide is secreted (e.g., a polypeptide that is a secreted polypeptide in its native state or that has been engineered to be secreted, for example, by operable association with a secretory signal sequence as is known in the art). Without being limited by any particular theory of the disclosure, according to this embodiment, administration to the skeletal muscle can result in secretion of the polypeptide into the systemic circulation and delivery to target tissue(s). Methods of delivering virus vectors to skeletal muscle is described in more detail herein.

[0230] The disclosure can also be practiced to produce noncoding RNA, such as antisense RNA, RNAi or other functional RNA (e.g., a ribozyme) for systemic delivery.

[0231] The disclosure also provides a method of treating and/or preventing congenital heart failure or PAD in a subject in need thereof, the method comprising administering a treatment or prevention effective amount of a virus vector of the disclosure to a mammalian subject, wherein the virus vector comprises a heterologous nucleic acid encoding, for example, a sarcoplasmic endoreticulum Ca^{2+} -ATPase (SERCA2a), an angiogenic factor, phosphatase inhibitor 1 (I-1) and fragments thereof (e.g., I1C), RNAi against phospholamban; a phospholamban inhibitory or dominant-negative molecule such as phospholamban S16E, a zinc finger protein that regulates the phospholamban gene, beta-2-adrenergic receptor, beta-2-adrenergic receptor kinase

(BARK), PI3 kinase, calsarcin, a β -adrenergic receptor kinase inhibitor (PARKct), inhibitor 1 of protein phosphatase 1 and fragments thereof (e.g., I1 C), S100A1, parvalbumin, adenylyl cyclase type 6, a molecule that effects G-protein coupled receptor kinase type 2 knockdown such as a truncated constitutively active bARKct, Pim-1, PGC-1 α , SOD-1, SOD-2, EC-SOD, kallikrein, HIF, thymosin-p4, mir-I, mir-I 33, mir-206, mir-208 and/or mir-26a.

[0232] Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Alternatively, one may administer the virus vector and/or virus capsids of the disclosure in a local rather than systemic manner, for example, in a depot or sustained-release formulation. Further, the virus vector and/or virus capsid can be delivered adhered to a surgically implantable matrix (e.g., as described in U.S. Patent Publication No. US-2004-0013645-A1).

[0233] The virus vectors and/or virus capsids disclosed herein can be administered to the lungs of a subject by any suitable means, optionally by administering an aerosol suspension of respirable particles comprised of the virus vectors and/or virus capsids, which the subject inhales. The respirable particles can be liquid or solid. Aerosols of liquid particles comprising the virus vectors and/or virus capsids may be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is known to those of skill in the art. See, e.g., U.S. Pat. No. 4,501,729. Aerosols of solid particles comprising the virus vectors and/or capsids may likewise be produced with any solid particulate medicament aerosol generator, by techniques known in the pharmaceutical art.

[0234] The virus vectors and virus capsids can be administered to tissues of the CNS (e.g., brain, eye) and may advantageously result in broader distribution of the virus vector or capsid than would be observed in the absence of the present disclosure.

[0235] In particular embodiments, the delivery vectors described herein may be administered to treat diseases of the CNS, including genetic disorders, neurodegenerative disorders, psychiatric disorders and tumors. Illustrative diseases of the CNS include, but are not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, Canavan disease, Leigh's disease, Refsum disease, Tourette syndrome, primary lateral sclerosis, amyotrophic lateral sclerosis, progressive muscular atrophy, Pick's disease, muscular dystrophy, multiple sclerosis, myasthenia gravis, Binswanger's disease, trauma due to spinal cord or head injury, Tay Sachs disease, Lesch-Nyhan disease, epilepsy, cerebral infarcts, psychiatric disorders including mood disorders (e.g., depression, bipolar affective disorder, persistent affective disorder, secondary mood disorder), schizophrenia, drug dependency (e.g., alcoholism and other substance dependencies), neuroses (e.g., anxiety, obsessional disorder, somatoform disorder, dissociative disorder, grief, post-partum depression), psychosis (e.g., hallucinations and delusions), dementia, paranoia, attention deficit disorder, psychosexual disorders, sleeping disorders, pain disorders, eating or weight disorders (e.g., obesity, cachexia, anorexia nervosa, and bulimia) and cancers and tumors (e.g., pituitary tumors) of the CNS.

[0236] Disorders of the CNS include ophthalmic disorders involving the retina, posterior tract, and optic nerve (e.g.,

retinitis pigmentosa, diabetic retinopathy and other retinal degenerative diseases, uveitis, age-related macular degeneration, glaucoma).

[0237] Most, if not all, ophthalmic diseases and disorders are associated with one or more of three types of indications: (1) angiogenesis, (2) inflammation, and (3) degeneration. The delivery vectors of the present disclosure can be employed to deliver anti-angiogenic factors; anti-inflammatory factors; factors that retard cell degeneration, promote cell sparing, or promote cell growth and combinations of the foregoing.

[0238] Diabetic retinopathy, for example, is characterized by angiogenesis. Diabetic retinopathy can be treated by delivering one or more anti-angiogenic factors either intraocularly (e.g., in the vitreous) or periorcularly (e.g., in the sub-Tenon's region). One or more neurotrophic factors may also be co-delivered, either intraocularly (e.g., intravitreally) or periorcularly.

[0239] Uveitis involves inflammation. One or more anti-inflammatory factors can be administered by intraocular (e.g., vitreous or anterior chamber) administration of a delivery vector of the disclosure.

[0240] Retinitis pigmentosa, by comparison, is characterized by retinal degeneration. In representative embodiments, retinitis pigmentosa can be treated by intraocular (e.g., vitreal administration) of a delivery vector encoding one or more neurotrophic factors.

[0241] Age-related macular degeneration involves both angiogenesis and retinal degeneration. This disorder can be treated by administering the inventive delivery vectors encoding one or more neurotrophic factors intraocularly (e.g., vitreous) and/or one or more anti-angiogenic factors intraocularly or periorcularly (e.g., in the sub-Tenon's region).

[0242] Glaucoma is characterized by increased ocular pressure and loss of retinal ganglion cells. Treatments for glaucoma include administration of one or more neuroprotective agents that protect cells from excitotoxic damage using the inventive delivery vectors. Such agents include N-methyl-D-aspartate (NMDA) antagonists, cytokines, and neurotrophic factors, delivered intraocularly, optionally intravitreally.

[0243] In other embodiments, the present disclosure may be used to treat seizures, e.g., to reduce the onset, incidence or severity of seizures. The efficacy of a therapeutic treatment for seizures can be assessed by behavioral (e.g., shaking, ticks of the eye or mouth) and/or electrographic means (most seizures have signature electrographic abnormalities). Thus, the disclosure can also be used to treat epilepsy, which is marked by multiple seizures over time.

[0244] In one representative embodiment, somatostatin (or an active fragment thereof) is administered to the brain using a delivery vector of the disclosure to treat a pituitary tumor. According to this embodiment, the delivery vector encoding somatostatin (or an active fragment thereof) is administered by microinfusion into the pituitary. Likewise, such treatment can be used to treat acromegaly (abnormal growth hormone secretion from the pituitary). The nucleic acid (e.g., GenBank Accession No. J00306) and amino acid (e.g., GenBank Accession No. P01166; contains processed active peptides somatostatin-28 and somatostatin-14) sequences of somatostatins are known in the art.

[0245] In particular embodiments, the vector can comprise a secretory signal as described in U.S. Pat. No. 7,071,172.

[0246] In representative embodiments of the disclosure, the virus vector and/or virus capsid is administered to the CNS (e.g., to the brain or to the eye). The virus vector and/or capsid may be introduced into the spinal cord, brainstem (medulla oblongata, pons), midbrain (hypothalamus, thalamus, epithalamus, pituitary gland, substantia nigra, pineal gland), cerebellum, telencephalon (corpus striatum, cerebrum including the occipital, temporal, parietal and frontal lobes, cortex, basal ganglia, hippocampus and portamygdala), limbic system, neocortex, corpus striatum, cerebrum, and inferior colliculus. The virus vector and/or capsid may also be administered to different regions of the eye such as the retina, cornea and/or optic nerve.

[0247] The virus vector and/or capsid may be delivered into the cerebrospinal fluid (e.g., by lumbar puncture) for more disperse administration of the delivery vector. The virus vector and/or capsid may further be administered intravascularly to the CNS in situations in which the blood-brain barrier has been perturbed (e.g., brain tumor or cerebral infarct).

[0248] The virus vector and/or capsid can be administered to the desired region(s) of the CNS by any route known in the art, including but not limited to, intrathecal, intra-ocular, intracerebral, intraventricular, intravenous (e.g., in the presence of a sugar such as mannitol), intranasal, intra-aural, intra-ocular (e.g., intra-vitreous, sub-retinal, anterior chamber) and peri-ocular (e.g., sub-Tenon's region) delivery as well as intramuscular delivery with retrograde delivery to motor neurons. In particular embodiments, the virus vector and/or capsid is administered in a liquid formulation by direct injection (e.g., stereotactic injection) to the desired region or compartment in the CNS. In other embodiments, the virus vector and/or capsid may be provided by topical application to the desired region or by intra-nasal administration of an aerosol formulation. Administration to the eye, may be by topical application of liquid droplets. As a further alternative, the virus vector and/or capsid may be administered as a solid, slow-release formulation (see, e.g., U.S. Pat. No. 7,201,898).

[0249] In yet additional embodiments, the virus vector can be used for retrograde transport to treat and/or prevent diseases and disorders involving motor neurons (e.g., amyotrophic lateral sclerosis (ALS); spinal muscular atrophy (SMA), etc.). For example, the virus vector can be delivered to muscle tissue from which it can migrate into neurons.

Numbered Embodiments

[0250] The following numbered embodiments are included within the scope of the disclosure.

[0251] 1. A recombinant adeno-associated virus (AAV) capsid protein, wherein the capsid protein comprises a substitution in an antigenic site of the AAV capsid protein, wherein the substitution has a sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, or 411-421.

[0252] 2. The recombinant AAV capsid protein of embodiment 1, wherein the substitution comprises a sequence of any one of SEQ ID NO: 9, 10, 14, or 17.

[0253] 3. The recombinant AAV capsid protein of embodiment 1 or 2, wherein the AAV capsid protein comprises a first amino acid substitution and a second amino acid substitution, wherein the first amino acid substitution and the second amino acid substitution each modify a different antigenic site on the AAV capsid protein, wherein the first

amino acid substitution and the second amino acid substitution each comprise any one of SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, or 411-421.

[0254] 4. The recombinant AAV capsid protein of embodiment 1 or 2, wherein the AAV capsid protein comprises a first acid substitution, a second amino acid substitution, and a third amino acid substitution, wherein the first amino acid substitution, the second amino acid substitution, and the third amino acid substitution each modify a different antigenic site on the AAV capsid protein, wherein the first amino acid substitution, the second amino acid substitution and the third amino acid substitution each comprise any one of SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 297, 298, 299, or 411-421.

[0255] 5. The recombinant AAV capsid of embodiment 4, wherein the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises any one of SEQ ID NO. 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421; and the third amino acid substitution comprises SEQ ID NO. 17.

[0256] 6. The recombinant AAV capsid of embodiment 5, wherein the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises SEQ ID NO. 10; and the third amino acid substitution comprises SEQ ID NO. 17.

[0257] 7. The recombinant AAV capsid of embodiment 5, wherein the first amino acid substitution comprises SEQ ID NO. 9; the second amino acid substitution comprises SEQ ID NO. 14; and the third amino acid substitution comprises SEQ ID NO. 17.

[0258] 8. The recombinant AAV capsid protein of any one of embodiments 1-7, wherein the AAV capsid protein further comprises a substitution that modifies the HI loop of the capsid.

[0259] 9. The recombinant AAV capsid protein of embodiment 8, wherein the AAV capsid comprises one or more of the following substitutions in the HI loop:

[0260] P661R, T662S, Q666G, S667D, wherein the numbering corresponds to the wildtype AAV8 capsid (SEQ ID NO: 6); or

[0261] P659R, T660S, A661T, K664G, wherein the numbering corresponds to the wildtype AAV9 capsid (SEQ ID NO: 7).

[0262] 10. The recombinant AAV capsid protein of any one of embodiment 1 to 9, wherein the AAV capsid protein is of an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAVS, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh.8, AAVrh.10, AAVrh32.33, AAVrh74, bovine AAV and avian AAV.

[0263] 11. The recombinant AAV capsid protein of any one of embodiments 1 to 9, wherein the AAV capsid protein is chimeric.

[0264] 12. The recombinant AAV capsid protein of embodiment 11, wherein the AAV capsid protein comprises sequences derived from two or more AAV serotypes.

[0265] 13. The recombinant AAV capsid protein of embodiment 12, wherein the AAV capsid protein comprises sequences derived from three or more AAV serotypes.

[0266] 14. The recombinant AAV capsid protein of any one of embodiments 1-10, wherein the AAV capsid protein comprises an amino acid sequence that has at least 90% sequence identity with any one of SEQ ID NOs: 18-80, 300-410, 422-612, or 783-785.

[0267] 15. The recombinant AAV capsid protein of embodiment 14, wherein the AAV capsid protein comprises an amino acid sequence of any one of SEQ ID NOs: 18-80, 300-410, 422-612, or 783-785.

[0268] 16. The recombinant AAV capsid protein of embodiment 15, wherein the AAV capsid protein comprises an amino acid sequence of SEQ ID NO: 380 or SEQ ID NO: 384.

[0269] 17. The recombinant AAV capsid protein of any one of embodiments 1 to 16, wherein the modification of the one or more antigenic sites results in inhibition of binding by an antibody to the one or more antigenic sites.

[0270] 18. The recombinant AAV capsid protein of any one of embodiments 1 to 17, wherein the modification of the one or more antigenic sites results in inhibition of neutralization of infectivity of a virus particle comprising said AAV capsid protein.

[0271] 19. A recombinant AAV capsid protein comprising the amino acid sequence of SEQ ID NO: 49.

[0272] 20. The recombinant AAV capsid protein of embodiment 19, wherein the AAV capsid protein is modified by replacing the region spanning amino acids 454-460 of SEQ ID NO: 49 with SEQ ID NO: 9.

[0273] 21. The recombinant AAV capsid protein of any one of embodiments 19 or 20, wherein the AAV capsid protein is modified by replacing the region spanning amino acids 493-500 of SEQ ID NO: 49 with any one of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421.

[0274] 22. The recombinant AAV capsid protein of any one of embodiments 19 to 21, wherein the AAV capsid protein is modified by replacing the region spanning amino acids 585-590 of SEQ ID NO: 49 with SEQ ID NO: 17.

[0275] 23. The recombinant AAV capsid protein of any one of embodiments 19 to 22, wherein the AAV capsid protein is modified by replacing the region spanning amino acids 454-460 of SEQ ID NO: 49 with SEQ ID NO: 9, the region spanning amino acids 493-500 of SEQ ID NO: 49 with any one of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 297, 298, 299, or 411-421, and the region spanning amino acids 585-590 of SEQ ID NO: 49 with SEQ ID NO: 17.

[0276] 24. The recombinant AAV capsid protein of any one of embodiments 19 to 23, wherein the modification results in inhibition of binding by an antibody to the AAV capsid protein.

[0277] 25. The recombinant AAV capsid protein of any one of embodiments 19 to 24, wherein the modification results in inhibition of neutralization of infectivity of a virus particle comprising the AAV capsid protein.

[0278] 26. A recombinant AAV capsid protein comprising the amino acid sequence of any one of SEQ ID NO: 18-80, 300-410, 422-612, or 783-785.

[0279] 27. A recombinant AAV capsid protein comprising the amino acid sequence of SEQ ID NO: 380 or SEQ ID NO: 384.

[0280] 28. A nucleotide sequence encoding a recombinant AAV capsid protein of any one of embodiments 1 to 27.

[0281] 29. The nucleotide sequence of embodiment 28, wherein the nucleotide sequence is a DNA sequence.

[0282] 30. The nucleotide sequence of embodiment 28, wherein the nucleotide sequence is an RNA sequence.

[0283] 31. An expression vector comprising the nucleotide sequence of any one of embodiments 28-30.

[0284] 32. A cell comprising the nucleotide sequence of any one of embodiments 28-30, or the expression vector of embodiment 31.

[0285] 33. An AAV viral vector comprising the recombinant capsid protein of any one of embodiments 1 to 27.

[0286] 34. The AAV viral vector of embodiment 33, further comprising a cargo nucleic acid encapsidated by the capsid protein.

[0287] 35. The AAV viral vector of embodiment 34, wherein the cargo nucleic acid encodes a therapeutic protein or RNA.

[0288] 36. The AAV viral vector of any one of embodiments 34-35, wherein the cargo nucleic acid encodes a gene-editing molecule.

[0289] 37. The AAV viral vector of embodiment 36, wherein the gene-editing molecule is a nuclease.

[0290] 38. The AAV viral vector of embodiment 37, wherein the gene-editing molecule is a Cas9 nuclease.

[0291] 39. The AAV viral vector of embodiment 37, wherein the gene-editing molecule is a Cpf1 nuclease.

[0292] 40. The AAV viral vector of embodiment 36, wherein the gene-editing molecule is a single guide RNA.

[0293] 41. A pharmaceutical composition comprising the AAV viral vector of any one of embodiment 33 to 40.

[0294] 42. The pharmaceutical composition of embodiment 41, wherein the composition further comprises a pharmaceutically acceptable carrier.

[0295] 43. A pharmaceutical composition comprising the cell of embodiment 32 or the expression vector of embodiment 31.

[0296] 44. The pharmaceutical composition of embodiment 43 wherein the composition further comprises a pharmaceutically acceptable carrier.

[0297] 45. A method of treating a patient in need thereof comprising administering to the patient a therapeutically effective amount of an AAV viral vector of any one of embodiments 33-40 or the pharmaceutical composition of any one of embodiments 41-44.

[0298] 46. The method of embodiment 45, wherein the patient has a liver disease or disorder.

[0299] 47. The method of embodiment 46, wherein the liver disease or disorder is primary biliary cirrhosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hepatitis B, hepatitis C, alcoholic liver disease, fibrosis, jaundice, primary sclerosing cholangitis (PSC), Budd-Chiari syndrome, hemochromatosis, Wilson's disease, alcoholic fibrosis, non-alcoholic fibrosis, liver steatosis, Gilbert's syndrome, biliary atresia, alpha-1-antitrypsin deficiency, alagille syndrome, progressive familial intrahepatic cholestasis, Hemophilia B, Hereditary Angioedema (HAE), Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), Von Gierke's Disease (GSD I), Hemophilia A, Methylmalonic Acidemia, Propionic Acidemia, Homocystinuria, Phenylketonuria (PKU), Tyrosinemia Type I, Arginase I Deficiency, Argininosuccinate Lyase Deficiency, Carbamoyl-phosphate synthetase 1 deficiency, Citrullinemia Type 1, Citrin Deficiency, Crigler-Najjar Syndrome Type 1, Cystinosis, Fabry Disease, Glycogen Storage Disease Ib, LPL Deficiency, N-Acetylglutamate Synthetase Deficiency, Ornithine Transcarbamylase Deficiency, Ornithine Translocase Deficiency, Primary Hyperoxaluria Type I, or ADA SCID.

[0300] 48. The method of embodiment 46, wherein the liver disease or disorder is liver cancer or metastasis.

[0301] 49. The method of any one of embodiments 45-48, wherein the patient is a mammal.

[0302] 50. The method of embodiment 49, wherein the patient is a human.

[0303] 51. A method of introducing a nucleic acid molecule into a cell, comprising contacting the cell with the AAV viral vector of any one of embodiments 33-40.

[0304] 52. An AAV viral vector of any one of embodiments 33-40 for use as a medicament.

[0305] 53. An AAV viral vector of any one of embodiments 33-40 for use in a method of treatment.

EXAMPLES

[0306] The following examples, which are included herein for illustration purposes only, are not intended to be limiting.

Example 1. Combinatorial Engineering and Selection of Antibody-Evading AAV Vectors

[0307] The method for generating antibody evading AAV mutants is as follows. The first step involves identification of conformational 3D antigenic epitopes on the AAV capsid surface, for example using cryo-electron microscopy. Selected residues within antigenic motifs are then subjected to mutagenesis using degenerate primers with each codon substituted by nucleotides NNK and gene fragments combined together by Gibson assembly and/or multistep PCR. Capsid-encoding genes containing a degenerate library of mutated antigenic motifs are cloned into a wild type AAV genome to replace the original Cap encoding DNA sequence, yielding a plasmid library. Plasmid libraries are then transfected into 293 producer cell lines with an adenoviral helper plasmid to generate AAV libraries (i.e. libraries of AAVs comprising the mutated AAV capsids described above), which can then be subjected to selection. Successful generation of AAV libraries is confirmed via DNA sequencing.

[0308] In order to select for new AAV strains that can escape neutralizing antibodies (NAbs), AAV libraries are subjected to multiple rounds of infection in non-human primates. At each stage, tissues of interest are isolated from animal subjects. Cell lysates harvested from the tissues of interest are sequenced to identify AAV isolates escaping antibody neutralization. After multiple rounds of infection in non-human primates, the isolated sequences from each mutagenized region are combined in all permutations and combinations. Each round of infection, tissue isolation, and sequencing is referred to herein as a round of evolution.

[0309] As a nonlimiting specific example, common antigenic motifs on an AAV capsid protein were subjected to mutagenesis as described above. The degenerate libraries of recombinant AAVs comprising the mutated capsids were then subjected to a first round of infection in non-human primates (FIG. 1A, FIG. 2A). Liver was harvested at day 7 post-infection and sequenced to identify single recombinant AAV isolates (FIG. 1B, FIG. 2B).

[0310] The AAVs isolated during this first round of evolution (FIG. 2B) were then reintroduced into a second non-human primate. Liver was harvested at day 7 post-infection and sequenced to identify single recombinant AAV isolates (FIG. 2C).

[0311] The AAVs isolated during the second round of evolution (FIG. 2C) were then reintroduced into a third non-human primate. Liver was harvested at day 7 post-infection and sequenced to identify single recombinant AAV isolates (FIG. 2D).

[0312] After each round of evolution, various recombinant AAV isolates were identified in liver samples. A description of various isolates is provided in Table 8 and in Table 6.1, above.

TABLE 8

Recombinant AAV Isolated from Liver	
Sequence Replacing Antigenic Sequence	Full Capsid Sequence
SNGRGV (SEQ ID NO: 9)	SEQ ID NO: 18
NLAENFKY (SEQ ID NO: 10)	SEQ ID NO: 19
VLSGDHSA (SEQ ID NO: 11)	SEQ ID NO: 20
MSAASGSG (SEQ ID NO: 12)	SEQ ID NO: 21
GTNLGKEQ (SEQ ID NO: 13)	SEQ ID NO: 22
SSHSGTNQ (SEQ ID NO: 14)	SEQ ID NO: 23
VATRDGQL (SEQ ID NO: 15)	SEQ ID NO: 24
ALNADTGT (SEQ ID NO: 16)	SEQ ID NO: 25
VMEPTR (SEQ ID NO: 17)	SEQ ID NO: 26
VVGNGGVV (SEQ ID NO: 297)	SEQ ID NO: 300
NFREMPIG (SEQ ID NO: 298)	SEQ ID NO: 301
RRSEDMGTI (SEQ ID NO: 299)	SEQ ID NO: 302

Example 2. Recombinant AAV Vectors Transduce Cells in Culture

[0313] To confirm whether various AAV vectors isolated from liver in Example 1 are generally infective and able to transduce cells in culture, various AAV vectors packaging a GFP transgene were prepared (AAV8, AAV-SB1 (SEQ ID NO. 380), AAV-SB6 (SEQ ID NO: 437). The AAV vectors were contacted with U87 cells (primary glioblastoma cell line) maintained under standard culture conditions. The cells were infected at a multiplicity of infection (MOI) of 40,000 vg/cell. 48 hours later, the cells were imaged using a fluorescent microscope.

[0314] As shown in FIG. 8, all AAV vectors tested were able to successfully transduce U87 cells in culture, resulting in expression of their packaged transgene (GFP) in the cells. This data confirms that the recombinant AAV vectors are infective and can be used to deliver a transgene to a cell of interest.

Example 3. In Vitro Characterization of Recombinant AAVs Targeting Liver

[0315] Five recombinant capsid proteins comprising one or more of the substitutions identified in Example 1, above, were selected for in vitro characterization following in vivo evolution: SB1 (SEQ ID NO: 380), SB2 (SEQ ID NO: 384), SB3 (SEQ ID NO: 783), SB4 (SEQ ID NO: 784), SB5 (SEQ ID NO: 785). Recombinant AAV vectors were prepared that comprised the recombinant capsid proteins and packaged a luciferase transgene. These AAV vectors (AAV-SB1, AAV-SB2, AAV-SB3, AAV-SB4, and AAV-SB5) were derived from a parental AAV8 strain.

[0316] The five recombinant AAV vectors were contacted with HepG2 cells and Huh7 cells in culture, at a multiplicity of infection (MOI) of 10,000 vg/cell. Subsequently, the cells were lysed, and the lysate was contacted with a bioluminescent substrate, and RFUs were measured. As shown in FIG. 3, all five AAVs had improved tropism for human hepatocytes in vitro compared to the parental AAV8 strain, with AAV-SB1 showing up to 2-logs increase in luciferase expression.

[0317] To test for improved escape of neutralizing antibodies over the parental AAV8, the five AAV-luciferase constructs were incubated with or without 0.25 mg/mL human intravenous immunoglobulin (IVIG) prior to transduction of U87 human glioblastoma cells. Shown in FIG. 4 is the percent transduction as compared to no IVIG incubation as measured by luciferase expression. AAV-SB1, AAV-SB2, and AAV-SB5 showed the greatest improvement in transduction efficiency in the presence of IVIG compared with parental AAV8. Further IVIG dose ranging analyses demonstrated that higher concentrations of IVIG are necessary to neutralize AAV-SB1 compared to parental AAV8 (FIG. 5).

[0318] Together, these data confirm the significant improvement in liver cell tropism in vitro and improvement in antibody escape of the recombinant AAVs compared with the parental AAV8 serotype.

Example 4. Human Serum Screen for AAV Neutralizing Antibodies

[0319] Parental AAV8, AAV-SB1, AAV-SB2, and three other liver-targeting capsids (AAV5, HSC15, and LK03) were tested in a neutralization assay against 100 samples of donor serum. The transduction efficiency of each AAV on U87 cells in the presence of a 1:5 dilution of serum was compared to transduction efficiency without serum as measured by levels of luciferase expression. A serum sample that reduced luciferase expression of an AAV vector to less than 50% of luciferase levels without serum was considered neutralizing.

[0320] FIG. 6A shows the percentage of samples that were neutralizing (strongly-neutralizing, <20% transduction efficiency; moderately-neutralizing, 20-50% transduction efficiency) to the indicated AAV. AAV-SB1 was neutralized by the fewest samples (15%), whereas the parental AAV8 capsid was neutralized by 25% of samples. Of the other capsids, LK03 was neutralized by the greatest number of samples (40%) and AAV5 by the fewest (20%). Notably, with one exception, all samples that were seropositive for AAV-SB01 were seropositive for all of the other capsids. The one exception had a percent-transduction efficiency of 49.58% (just slightly below the 50% cut-off).

[0321] The breakdown of donors who are seropositive for the indicated capsid by age groups is shown below in FIG. 6B. A similar pattern of distribution among the age groups is seen with the age 30-35 group having the greatest number of seropositive donors and the age 36-40 group having the least number.

Example 5. Biodistribution of Recombinant AAVs in Normal Mice

[0322] This study was performed to assess whether evolution of capsid tropism to liver in non-human primates (NHP) would impact liver tropism in mice, which is important for the execution of proof-of-concept studies in available mouse models. A small study was conducted in normal B1/6 mice. The study design is illustrated in Table 9 below. Mice were injected IV with one of two doses, and tissues were collected 30 days post-injection for immunohistochemistry (IHC) analysis for GFP expression, and for vector genome (vg) quantification by qPCR.

TABLE 9

Mouse biodistribution study design				
Group		Dose Level	Number of Animals	
Number	AAV	(vg/kg)	Male	Female
1	AAB-SB1-GFP	3×10^{12}	2	2
2	AAV8 (parental)-GFP	3×10^{12}	2	2

[0323] Tropism of AAV-SB1-GFP for mouse liver was confirmed to be similar to that of the parental AAV8 vector. IHC staining (FIG. 7) demonstrated similar levels of GFP

expression between AAV8 and AAV-SB1, but expected differences between genders. Table 10 below shows the vg copy number per μg total DNA for each tissue. Each column represents a different mouse.

TABLE 10

tissues	Vector genome (per μg DNA) distribution in normal mice			
	Group 1 (AAV-SB1-GFP, 3×10^{12} vg/mL)			
Pancreas	1.03×10^{-03}	3.35×10^{-04}	1.86×10^{-03}	2.19×10^{-03}
Spleen	0.017	0.142	0.015	0.017
Brain	3.70×10^{-04}	2.00×10^{-04}	6.15×10^{-04}	8.40×10^{-04}
(cortex)				
Heart	6.49×10^{-03}	3.23×10^{-03}	0.013	0.014
Kidney, left	8.47×10^{-03}	2.25×10^{-03}	0.027	0.021
Muscle*	0.013	0.013	0.018	0.021
Liver,	1.730	0.477	0.627	0.573
pooled				
	Group 2 (AAV8-GFP, 3×10^{12} vg/mL)			
Pancreas	3.65×10^{-04}	5.85×10^{-04}	1.03×10^{-03}	1.52×10^{-03}
Spleen	5.87×10^{-03}	5.78×10^{-03}	5.94×10^{-03}	8.55×10^{-03}
Brain	3.05×10^{-04}	5.75×10^{-04}	5.50×10^{-04}	4.20×10^{-04}
(cortex)				
Heart	4.93×10^{-03}	4.41×10^{-03}	7.64×10^{-03}	7.36×10^{-03}
Kidney, left	3.68×10^{-03}	4.63×10^{-03}	0.014	8.55×10^{-03}
Muscle*	8.34×10^{-03}	3.23×10^{-03}	7.98×10^{-03}	8.71×10^{-03}
Liver,	0.993	0.887	0.454	0.342
pooled				

*muscle, gastrocnemius
BL0D=below limit of detection

[0324] The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

SEQUENCE LISTING

```

Sequence total quantity: 785
SEQ ID NO: 1          moltype = AA length = 736
FEATURE              Location/Qualifiers
source                1..736
                     mol_type = protein
                     note = Dependovirus adeno-associated virus 1
                     organism = unidentified

SEQUENCE: 1
MAADGYLPDW LEDNLSEGI EWWDLKP GAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEFVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADA EF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRPVVEQSP QEPDSSSGIG KTGQQPAKRR LNFGQTGDSE 180
SVPDPQPLGE PPATPAAVGP TTMASGGGAP MADNNEGADG VGNASGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SSASTGASND NHYFGYSTPW GYDFNRFHC HFSPRDWQRL 300
INNHWGFRPK RLNFKLFNIQ VKEVTINDGV TTIANNLTST VQVFSDESYQ LPYVLGSAHQ 360
GCLPPFPADV FMIPQYGYLT LNNGSQAVGR SSPYCLEYFP SMLRGTGNNF TFSYTFEEVP 420
FHSSYAHSQS LDRLMNP LID QYLYYLNRTQ NQSGSAQNKD LLFSRGSPPAG MSVQPKNWLP 480
GPCYRQQRVS KTKTDNNSN FTWTGASKYN LNGRESIINP GTAMASHKDD EDKFPFMSGV 540
MIFGKESAGA SNTALDNVMI TDEEIKATN PVATERPGTV AVNFQSSSTD PATGDVHAMG 600
ALPGMVWQDR DVYLQGIWA KIPHTDGHFH PSPLMGGFGL KNPPQILIK NTPVPANPPA 660
EFSATKFA SF ITQYSTGQVS VEIEWELQKE NSKRWNPEVQ YTSNYAKSAN VDFTVDNNGL 720
YTEPRPIGTR YLTRPL 736

SEQ ID NO: 2          moltype = AA length = 735
FEATURE              Location/Qualifiers
source                1..735
                     mol_type = protein
                     note = Dependovirus adeno-associated virus 2
                     organism = unidentified

SEQUENCE: 2
MAADGYLPDW LEDTLSEGI QWWKLGKPPP PPKPAERHKD DSRGLVLPGY KYLGPFNGLD 60
KGEFVNEADA AALEHDKAYD RQLDSGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEPVKTAP GKRPVVEHSP VEPDSSSGTG KAGQQPARKR LNFGQTDGAD 180
SVPDPQPLGQ PPAAPSGLGT NTMATGSGAP MADNNEGADG VGNSSGNWHC DSTWMDRVI 240
    
```

-continued

TTSTRTWALP	TYNNHLYKQI	SSQSGASNDN	HYFGYSTPWG	YFDNFRFHCH	FSPRDWQRLI	300
NNNWGFRPKR	LNFKLFNIQV	KEVTQNDGTT	TIANNLTSTV	QVFTDSEYQL	PYVLGSAHQG	360
CLPPFPADV	MVPQYGYLTL	NNGSQAVGRS	SFYCLEYFPPS	QMLRTGNNFT	FSYTFEDVFP	420
HSSYAHSQSL	DRLMNLPLDQ	YLYYLSRTNT	PSGTTTQSR	QFSQAGASDI	RDQSRNWLPG	480
PCYRQQRVSK	TSADNNNSEY	SWGATKYHL	NGRDSLVPNG	PAMASHKDE	EKFFPQSGVL	540
IFGKQGSSEKT	NVDIEKVMIT	DEEEIRTTNP	VATEQYGSVS	TNLQRGNRQA	ATADVNTQGV	600
LPGMVWQDRD	VYLQGPWAK	IPHTDGHFHP	SPLMGGFGLK	HPPQILIKN	TPVPANPSTT	660
FSAAKFASFI	TQYSTGQVSV	EIEWELQKEN	SKRWNPFIQY	TSNYNKSVMV	DFTVDTNGVY	720
SEPRPIGTRY	LTRNL					735

SEQ ID NO: 3 moltype = AA length = 736
 FEATURE Location/Qualifiers
 source 1..736
 mol_type = protein
 note = Dependovirus adeno-associated virus 3
 organism = unidentified

SEQUENCE: 3

MAADGYLPDW	LEDNLSEGIR	EWWALKPGVP	QPKANQQHQD	NRRLVLPFGY	KYLGPGNGLD	60
KGEPVNEADA	AALHDKAYD	QQLKAGDNPY	LKYNHADAEP	QERLQEDTSF	GGNLGRAVFQ	120
AKKRILEPLG	LVEEAAKTAP	GKKRPVDQSP	QEPDSSSGVG	KSGKQPARKR	LNFQGTGDS	180
SVPDPQPLGE	PPAAPTSLGS	NTMASGGGAP	MADNNEGADG	VGNSSGNWHC	DSQWLGDRI	240
TTSTRTWALP	TYNNHLYKQI	SSQSGASNDN	HYFGYSTPWG	YFDNFRFHCH	FSPRDWQRLI	300
NNNWGFRPKK	LNFKLFNIQV	KEVTQNDGTT	TIANNLTSTV	QVFTDSEYQL	PYVLGSAHQG	360
CLPPFPADV	MVPQYGYLTL	NNGSQAVGRS	SFYCLEYFPPS	QMLRTGNNFT	FSYTFEDVFP	420
HSSYAHSQSL	DRLMNLPLDQ	YLYYLNRTQG	TSGTTNQSR	LLFSQAGPQS	MSLQARNWLP	480
GPCYRQQRSL	KTANDNNNSN	FPWTAASKYH	LNGRDSLVP	GPAMASHKDD	EKFFPMMHGN	540
LIFGKEGTTA	SNAELDNVMI	TDEEEIRTTN	PVATEQYGTV	ANNLQSSNTA	PTTRTVNDQG	600
ALPGMVWQDR	DVYLQGPWAK	KIPHTDGHFH	PSPLMGGFGL	KHPPQILIK	NTVPANPPT	660
TFSPAKFASF	ITQYSTGQVSV	VEIEWELQKE	NSKRWNPEIQ	YTSNYNKSVM	VDFTVDTNGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 4 moltype = AA length = 736
 FEATURE Location/Qualifiers
 source 1..736
 mol_type = protein
 note = Dependovirus adeno-associated virus 6
 organism = unidentified

SEQUENCE: 4

MAADGYLPDW	LEDNLSEGIR	EWWDLKPAGP	KPKANQQQKD	DGRGLVLPFGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLKAGDNPY	LRYNHADAEP	QERLQEDTSF	GGNLGRAVFQ	120
AKKRILEPLG	LVEEGAKTAP	GKKRPVEQSP	QEPDSSSGIG	KTGQQPAKRR	LNFQGTGDS	180
SVPDPQPLGE	PPATPAAVGP	TTMASGGGAP	MADNNEGADG	VGNASGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SSASTGASND	NHYFGYSTPW	GYFDNFRFHCH	HFSPRDWQRL	300
IMNNWGRPKR	RLNFKLFNIQ	VKEVTTNDGV	TTIANNLTST	VQVFSDSYEQ	LPYVLGSAHQ	360
GCLPPFPADV	FMIPOYGYLT	LNNGSQAVGR	SSFYCLEYFP	SQMLRTGNNF	TFSYTFEDVP	420
FHSSYAHSQS	DRLMNLPLDQ	QYLYYLNRTQ	NQSGSAQNKD	LLFSRGSFAG	MSVQPKNWL	480
GPCYRQQRVS	KTKTDNNNSN	FTWTGASKYN	LNGRESTIINP	GTAMASHKDD	KDKFFPMSGV	540
MIFGKESAGA	SNTALDNVMI	TDEEEIKATN	PVATERFGTV	AVNLQSSSTD	PATGDVHVMG	600
ALPGMVWQDR	DVYLQGPWAK	KIPHTDGHFH	PSPLMGGFGL	KHPPQILIK	NTVPANPPA	660
EFSATKFAF	ITQYSTGQVSV	VEIEWELQKE	NSKRWNPEVQ	YTSNYAKSAN	VDFTVDNGL	720
YTEPRPIGTR	YLTRPL					736

SEQ ID NO: 5 moltype = AA length = 737
 FEATURE Location/Qualifiers
 source 1..737
 mol_type = protein
 note = Dependovirus adeno-associated virus 7
 organism = unidentified

SEQUENCE: 5

MAADGYLPDW	LEDNLSEGIR	EWWDLKPAGP	KPKANQQQKD	NRRLVLPFGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLKAGDNPY	LRYNHADAEP	QERLQEDTSF	GGNLGRAVFQ	120
AKKRILEPLG	LVEEGAKTAP	AKKRPEVPS	QRSPTSSTGI	GKKGQOPARK	RLNFQGTGDS	180
ESVPDPQPLG	EPPAAPSSVG	SGTVAAGGGA	PMADNNEGAD	GVGNASGNWH	CDSTWLGDRV	240
ITSTRTWALP	TYNNHLYKQI	ISSETAGSTN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LIMNNWGRFR	KLRFKLFNI	QVKEVTTNDG	VTTIANNLTS	TIQVFSDSYEQ	QLPYVLGSAH	360
QCLPPFPADV	VFMIPQYGYL	TLNNGSQSVG	RSSFYCLEYF	PSQMLRTGNN	FEFSYSFEDV	420
PFHSSYAHSQ	SLDRLMNLPL	DQYLYYLART	QSNPGGTAGN	RELQFYQGGP	STMAEQAKNW	480
LPGPCFRQQR	VSKTLDQNNN	SNFAWTGATK	YHLNGRNSLV	NPGVAMATHK	DDEDRFFPSS	540
GVLIQKGTGA	TNKTTLENVL	MTNEEEIRPT	NPVATEEYGI	VSSNLQAANT	AAQTQVVMNQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPQILIK	KNTVPANPPT	660
EVFTPAKFAS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNFEKQT	GVDFAVDSQG	720
VYSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 6 moltype = AA length = 738
 FEATURE Location/Qualifiers
 source 1..738

-continued

```

mol_type = protein
note = Dependovirus adeno-associated virus 8
organism = unidentified

SEQUENCE: 6
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKKRPVEPSP QRSPPSSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNGWGR PKRLNFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTTTGQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTVPVADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYSK TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 7 moltype = AA length = 736
FEATURE Location/Qualifiers
source 1..736
mol_type = protein
note = Dependovirus adeno-associated virus 9
organism = unidentified

SEQUENCE: 7
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLELEPLG LVEEAAKTAP GKKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDT 180
SVPDPQPIGE PPAAPSGVGS LTMASGGGAP VADNNEGADG VGSSSGNWHC DSQWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNSTSGGSSN DNAYFGYSTP WGYDFNRFH CHFSPRDWQR 300
LINNNGWGRP KRLNFKLFNI QVKEVTDNNG VKTIANNLTS TVQVFTDSDY QLPYVLGSAH 360
EGCLPPFPAD VFMFIPQYGYL TLNDGSSQAVG RSSFYCLEYF PSQMLRTGNN FQFSYEFENV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSKT INSGSQNQQT LKFSVAGPSN MAVQGRNYIP 480
GPSYRQQRVS TTVTQNNNSE FAWPGASSWA LNGRNSLMNP GPAMASHKEG EDRFFPLSGS 540
LIFGKQGTGR DNVADAKVMI TNEEEIKTTN PVATESYGVV ATNHQSAQAQ AQTGWVQNQG 600
ILPGMVWQDR DVYLQGP IWA KIPHTDGNPH PSPLMGGFGM KHPPQILIK NTPVPADPPT 660
AFNKDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYSKNN VEFVAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 8 moltype = AA length = 738
FEATURE Location/Qualifiers
source 1..738
mol_type = protein
note = Dependovirus adeno-associated virus rh.10
organism = unidentified

SEQUENCE: 8
MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKKRPVEPSP QRSPPSSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQPIG EPPAGPSGLG SGTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGST NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNGWGR PKRLNFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFEFSYQFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQSTGGTAGT QQLLFSQAGP NNMSAQAKNW 480
LPGPCYRQQR VSTTSLQNNN SNFAWTGATK YHLNGRDSL NPGVAMATHK DDEERFFPSS 540
GVLMPGKQGA GKDNVDYSSV MLTSEEEIKT TNPVATEQYG VVADNLQQQN AAPIVGAVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTVPVADP 660
PTTFSQAKLA SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYSK TNVDFAVNTD 720
GTYSEPRPIG TRYLTRNL 738

SEQ ID NO: 9 moltype = AA length = 6
FEATURE Location/Qualifiers
REGION 1..6
note = AAV capsid protein amino acid substitution
source 1..6
mol_type = protein
organism = synthetic construct

SEQUENCE: 9
SNGRGV 6

SEQ ID NO: 10 moltype = AA length = 8
FEATURE Location/Qualifiers
REGION 1..8
note = AAV capsid protein amino acid substitution
source 1..8
mol_type = protein

```


-continued

SEQUENCE: 10	organism = synthetic construct	
NLAENFKY		8
SEQ ID NO: 11	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 11		
VLSGDHSA		8
SEQ ID NO: 12	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 12		
MSAASGSG		8
SEQ ID NO: 13	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 13		
GTNLGKEQ		8
SEQ ID NO: 14	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 14		
SSHSGTNQ		8
SEQ ID NO: 15	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 15		
VATRDGQL		8
SEQ ID NO: 16	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 16		
ALNADTGT		8
SEQ ID NO: 17	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = AAV capsid protein amino acid substitution	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 17		
VMEPTR		6
SEQ ID NO: 18	moltype = AA length = 737	
FEATURE	Location/Qualifiers	

-continued

REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 18

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STTTGQNNNS	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSSEBIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPPQILI	KNTPVPADPP	660
PTTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 19 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 19

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTNLAEFK	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEBIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPFI	IQYTSNYYKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 20 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 20

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVLSGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEBIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPFI	IQYTSNYYKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 21 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 21

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240

-continued

```

ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTMSAASGS GNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 22      moltype = AA length = 738
FEATURE          Location/Qualifiers
REGION          1..738
                note = AAV capsid variant
source          1..738
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 22
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTGTNLGKE QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 23      moltype = AA length = 738
FEATURE          Location/Qualifiers
REGION          1..738
                note = AAV capsid variant
source          1..738
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 23
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTSSHSSTN LNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 24      moltype = AA length = 738
FEATURE          Location/Qualifiers
REGION          1..738
                note = AAV capsid variant
source          1..738
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 24
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTVATRDGQ LNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

-continued

```

SEQ ID NO: 25      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source           1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 25
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTALNADTG TNAFWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLGQPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP E IQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 26      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source           1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 26
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTTTGQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLGQPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP E IQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 27      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 27
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSGRNV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYSVDM LTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTPVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP E IQYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 28      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 28
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120

```

-continued

```

AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNLAENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 29      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 29
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVLSGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 30      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 30
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMSAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 31      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 31
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STGTLNKGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720

```

-continued

VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 32 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 32
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVATRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 33 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 33
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVATRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 34 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 34
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 35 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 35

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTNLAENFK	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 36 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTVLSGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 37 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTMSAASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 38 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTDLNLSKE	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600

-continued

QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PITFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 39 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 39						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPOQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTSSHSGTN	QNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PITFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 40 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 40						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPOQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVATRDGQ	LNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PITFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 41 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 41						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPOQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTALNADTG	TNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PITFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 42 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 42
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNLAENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQON RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 43      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 43
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVLSGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQON RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 44      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 44
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMSAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQON RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 45      moltype = AA length = 737
FEATURE          Location/Qualifiers
REGION          1..737
                note = AAV capsid variant
source          1..737
                mol_type = protein
                organism = synthetic construct

```

```

SEQUENCE: 45
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STGNTLQKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 46          moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant
source              1..737
                    mol_type = protein
                    organism = synthetic construct

```

```

SEQUENCE: 46
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STSSHSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 47          moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant
source              1..737
                    mol_type = protein
                    organism = synthetic construct

```

```

SEQUENCE: 47
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVATRQQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 48          moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant
source              1..737
                    mol_type = protein
                    organism = synthetic construct

```

```

SEQUENCE: 48
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 49          moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant

```

-continued

```

source                1..737
                     mol_type = protein
                     organism = synthetic construct

SEQUENCE: 49
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 50        moltype = AA length = 736
FEATURE             Location/Qualifiers
REGION              1..736
                    note = AAV capsid variant
source              1..736
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 50
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSGRGVLT LGFSQGGENT MANQAKNWL 480
GPCYRQQRVS TTTGQNNNSN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPW AKIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 51        moltype = AA length = 737
FEATURE             Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant
source              1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 51
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNLAENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 52        moltype = AA length = 737
FEATURE             Location/Qualifiers
REGION              1..737
                    note = AAV capsid variant
source              1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 52
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360

```

-continued

QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 53 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 53

MAADGYLPDW	LEDNLSEGR	EWALKKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 54 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 54

MAADGYLPDW	LEDNLSEGR	EWALKKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 55 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 55

MAADGYLPDW	LEDNLSEGR	EWALKKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 56 moltype = AA length = 737
 FEATURE Location/Qualifiers

-continued

REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 56

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEP	QERLKEDTSF	GGNLGRAVFP	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVATRQQL	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 57 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 57

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEP	QERLKEDTSF	GGNLGRAVFP	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVATRQQL	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 58 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 58

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEP	QERLKEDTSF	GGNLGRAVFP	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVATRQQL	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMPEPT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 59 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
note = AAV capsid variant
source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 59

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEP	QERLKEDTSF	GGNLGRAVFP	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240

-continued

```

TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TTTGQNNNSN  FAWTAGTKYH  LNGRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNVMPEPTRA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPPT  660
TFNQSKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 60      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 60
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRV I  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TNLAENFKYN  FAWTAGTKYH  LNGRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPPT  660
TFNQSKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 61      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 61
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRV I  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TVLSGDHSAN  FAWTAGTKYH  LNGRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPPT  660
TFNQSKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 62      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 62
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRV I  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TMSAASGSGN  FAWTAGTKYH  LNGRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPPT  660
TFNQSKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

-continued

```

SEQ ID NO: 63      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 63
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TGTNLGKEQN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 64      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 64
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TSSHSGTNQN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 65      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 65
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TVATRDGQLN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 66      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 66
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120

```

-continued

AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGVGT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRV	TALNADTGTN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGI	ADNLQOQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPiWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 67 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 67

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWLP	480
PGPCYRQQRV	STNLAENFKY	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAAR	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPiW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPPQILI	KNTVPADPDP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 68 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 68

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWLP	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAAR	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPiW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPPQILI	KNTVPADPDP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 69 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 69

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWLP	480
PGPCYRQQRV	STMSAASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAAR	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPiW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPPQILI	KNTVPADPDP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720

-continued

VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 70 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 70
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADADEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAAKKR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STGTNLGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHDTGDNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 71 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 71
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADADEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAAKKR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STSHSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHDTGDNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 72 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 72
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADADEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAAKKR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVATRQGL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHDTGDNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 73 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 73

-continued

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQ TGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNR FH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STALNADTGT	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
LIFGKQNAAR	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGP IWA	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNSF	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYKST	SVDFAVNT EG	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 74 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQ TGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNR FH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL P	480
GPCYRQQRVS	TNLAEFNKYI	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSDV ML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR A	PQIGTVNSQ G	600
ALPGMVWQNR	DVYLQGP IWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNP EI Q	YTSNYKST S	VDFAVNTEG V	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 75 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQ TGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNR FH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL P	480
GPCYRQQRVS	TVLSGDHSAN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSDV ML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR A	PQIGTVNSQ G	600
ALPGMVWQNR	DVYLQGP IWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNP EI Q	YTSNYKST S	VDFAVNTEG V	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 76 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQ TGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNR FH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL P	480
GPCYRQQRVS	TMSAASGSGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSDV ML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR A	PQIGTVNSQ G	600

-continued

ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 77 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 77

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TGTLNGKEQN	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 78 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 78

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TGTLNGKEQN	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 79 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 79

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TVATRDLNLI	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 80 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 80
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEVNAADA AALEHDKAYD QLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAV FQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTG DSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYPGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAH SQ SLDRLMPLI DQYLYLSRT QTTSNCRGVT LGFSQGGFNT MANQAKNWLP 480
GPCYRQQRVS TALNADTGTN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSV DML TSEEEIKTTN PVATEEYGV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 81      moltype = AA length = 734
FEATURE          Location/Qualifiers
source          1..734
                mol_type = protein
                note = Dependovirus adeno-associated virus 4
                organism = unidentified

SEQUENCE: 81
MTDGYLPDWL EDNLSEGVRE WWALQPGAPK PKANQQHQDN ARGLVLPGYK YLGPNGGLDK 60
GEPVNAADAA ALEHDKAYDQ QLKAGDNPYL KYNHADA EFQ QRLQGDTSFG GNLGRAV FQA 120
KKRVLEPLGL VEQAGETAPG KKRPLIESPQ QPDSSTGIGK KGKQPAK KKL VFEDET GAGD 180
GPPEGSTSGA MSDSEMRAA AGGAAVEGGQ GADGVGNASG DWHCDSTWSE GHVTTTSTR T 240
WVLPPTYNNHL YKRLGESLQS NTYNGFSTPW GYDFNRFHC HFSPRDWRQL INN NWGM RPK 300
AMRVKIFNIQ VKEVTTNNGE TTVANNLTST VQIFADSSYE LPYVMDAGQE GSLPPFPNDV 360
FMVPQYGYCG LVTGNTSQQQ TDRNAPYCLE YFPSQMLRTG NNFEITYSFE KVPFHS MYAH 420
SQSLDRLMNP LIDQYLWGLQ STTTGTTLNA GTATTNFTKL RPTNFSNFKK NWLPGPSIKQ 480
QGFSKTANQN YKIPATGSDS LIKYETHSTL DGRWSALTPG PPMATAGPAD SKFNSNSQLIF 540
AGPKQNGNTA TVPGTLIFTS EEELAATNAT DTDMWGNLPG GDQSNSNLPT VDRLTALGAV 600
PGMVWQNRDI YYQGP IWA KI PHTDGHFHS PLIGGFGLKH PPPQIFIKNT PVPANPATT F 660
SSTPVNSFIT QYSTGQVSQV IDWEIQKERS KRWNPEVQFT SNYQQNSLL WAPDAAGKYT 720
EPRAIGTRYL THHL 734

SEQ ID NO: 82      moltype = AA length = 724
FEATURE          Location/Qualifiers
source          1..724
                mol_type = protein
                note = Dependovirus adeno-associated virus 5
                organism = unidentified

SEQUENCE: 82
MSFVDHPPDW LEEVGEGLRE FLGLEAGPPK PKPNQQHQDQ ARGLVLPGYN YLGPNGGLDR 60
GEPVNRADAV AREHDISYNE QLEAGDNPYL KYNHADA EFQ EKLADDT SFG GNLGKAV FQA 120
KKRVLEPFGL VEEGAKTAPT GKRIDDHFPK RKKARTEEDS KPSTSSDAEA GPSGSQQLQI 180
PAQPASSLGA DTMSAGGGGP LGDNNQGADG VGNASGDWHC DSTWMGDRVV TKSTRTWVLP 240
SYNNHQYREI KSGSVDSGNA NAYFGYSTPW GYDFNRFHS HWSPRDWRQL INN YWGF RPR 300
SLRVKIFNIQ VKEVTVDST TTIANNLTST VQVFTDDDYQ LPYVVNGTE GCLPAPFPQV 360
FTLPQYGYAT LNRDNTENPT ERSFPCLEY FPSKMLRTGN NFEPTYNFEE VPFHSSFAPS 420
QNLFLANPL VDQYLYRFVS TNNTGGVQFN KNLAGRYANT YKNWFPGPMG RTQGWNLGSG 480
VNRASVS AFA TTRNMELEGA SYQVPPQPNG MTNNLQGSNT YALENTMIFN SQPANPGTTA 540
TYLEGNMLIT SESETQPVNR VAYNVGGQMA TNNQSSTAP ATGTYNLQEI VPGSVVMERD 600
VYLQGP IWA KI PETGAHFHP SPAMGGFGLK HPPPMMLIKN TPVPGNITSF SDVPVSSFIT 660
QYSTGQVTVE MEWELKKENS KRWNPEIQYT NNYNDPQFVD FAPDSTGEYR TTRPIGTRYL 720
TRPL 724

SEQ ID NO: 83      moltype = AA length = 5
FEATURE          Location/Qualifiers
REGION          1..5
                note = peptide motif triggers uptake by liver cells
source          1..5
                mol_type = protein
                organism = synthetic construct

SEQUENCE: 83
FVFLP 5

SEQ ID NO: 84      moltype = length =
SEQUENCE: 84
000

SEQ ID NO: 85      moltype = AA length = 4
FEATURE          Location/Qualifiers
REGION          1..4
                note = targeting peptide

```

-continued

source	1..4 mol_type = protein organism = synthetic construct	
SEQUENCE: 85 RGNR		4
SEQ ID NO: 86 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
VARIANT	7 note = X can be G or S	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 86 NSVRDLX		7
SEQ ID NO: 87 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 87 PRSVTVP		7
SEQ ID NO: 88 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
VARIANT	7 note = X can be S or A	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 88 NSVSSXX		7
SEQ ID NO: 89 FEATURE REGION	moltype = AA length = 6 Location/Qualifiers 1..6 note = targeting peptide	
source	1..6 mol_type = protein organism = synthetic construct	
SEQUENCE: 89 NGRAHA		6
SEQ ID NO: 90 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 90 QPEHSST		7
SEQ ID NO: 91 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 91 VNTANST		7
SEQ ID NO: 92 FEATURE REGION	moltype = AA length = 6 Location/Qualifiers 1..6 note = targeting peptide	
source	1..6 mol_type = protein	

-continued

SEQUENCE: 92 HGPMQS	organism = synthetic construct	6
SEQ ID NO: 93 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 93 PHKPPLA		7
SEQ ID NO: 94 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 94 IKNNEMW		7
SEQ ID NO: 95 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 95 RNLDTPM		7
SEQ ID NO: 96 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 96 VDSHRQS		7
SEQ ID NO: 97 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 97 YDSKTKT		7
SEQ ID NO: 98 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 98 SQLPHQK		7
SEQ ID NO: 99 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 99 STMQONT		7
SEQ ID NO: 100 FEATURE	moltype = AA length = 7 Location/Qualifiers	

-continued

REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 100		
TERYMTQ		7
SEQ ID NO: 101	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 101		
QPEHSST		7
SEQ ID NO: 102	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 102		
DASLSTS		7
SEQ ID NO: 103	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
	note = targeting peptide	
source	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 103		
DLPNKT		6
SEQ ID NO: 104	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 104		
DLTAARL		7
SEQ ID NO: 105	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 105		
EPHQFNY		7
SEQ ID NO: 106	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 106		
EPQSNHT		7
SEQ ID NO: 107	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 107		

-continued

MSSWPSQ		7
SEQ ID NO: 108	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 108		7
NPKHNAT		
SEQ ID NO: 109	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 109		7
PDGMRTT		
SEQ ID NO: 110	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 110		7
PNNKTT		
SEQ ID NO: 111	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 111		7
QSTTHDS		
SEQ ID NO: 112	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 112		7
TGSKQKQ		
SEQ ID NO: 113	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 113		7
SLKHQAL		
SEQ ID NO: 114	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 114		7
SPIDGEQ		
SEQ ID NO: 115	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
	note = targeting peptide	

-continued

source	1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 115 WIFPWIQI		8
SEQ ID NO: 116 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = targeting peptide	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 116 CDCRGDCFC		9
SEQ ID NO: 117 FEATURE REGION	moltype = AA length = 5 Location/Qualifiers 1..5 note = targeting peptide	
source	1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 117 CNGRC		5
SEQ ID NO: 118 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = targeting peptide	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 118 CPRECES		7
SEQ ID NO: 119 FEATURE REGION	moltype = AA length = 10 Location/Qualifiers 1..10 note = targeting peptide	
source	1..10 mol_type = protein organism = synthetic construct	
SEQUENCE: 119 CTTHWGFTLC		10
SEQ ID NO: 120 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = targeting peptide	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 120 CGRRAGGSC		9
SEQ ID NO: 121 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = targeting peptide	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 121 CKGGRAKDC		9
SEQ ID NO: 122 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = targeting peptide	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 122 CVPELGHEC		9

-continued

SEQ ID NO: 123	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 123		9
CRRETAWAK		
SEQ ID NO: 124	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
REGION	1..14	
source	note = targeting peptide	
	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 124		14
VSWFSHRYSP FAVS		
SEQ ID NO: 125	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
source	note = targeting peptide	
	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 125		13
GYRDGYAGPI LYN		
SEQ ID NO: 126	moltype = length =	
SEQUENCE: 126		
000		
SEQ ID NO: 127	moltype = length =	
SEQUENCE: 127		
000		
SEQ ID NO: 128	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 128		7
RPLPLPLP		
SEQ ID NO: 129	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 129		7
APPLPPR		
SEQ ID NO: 130	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
source	note = targeting peptide	
	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 130		12
DVFYPPYPYAS GS		
SEQ ID NO: 131	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 131		

-continued

MYWYPY		6
SEQ ID NO: 132	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
source	note = targeting peptide	
	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 132		
DITWDQLWDL MK		12
SEQ ID NO: 133	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
VARIANT	note = targeting peptide	
	5	
source	note = X can be G or L	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 133		
CWDDXWLC		8
SEQ ID NO: 134	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
REGION	1..14	
source	note = targeting peptide	
	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 134		
EWCEYLGGYL RCYA		14
SEQ ID NO: 135	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
REGION	1..14	
source	note = targeting peptide	
	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 135		
YXCXXGPXTW XCXP		14
SEQ ID NO: 136	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
REGION	1..14	
source	note = targeting peptide	
	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 136		
IEGPTLRQWL AARA		14
SEQ ID NO: 137	moltype = length =	
SEQUENCE: 137		
000		
SEQ ID NO: 138	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 138		
XPXXYLW		7
SEQ ID NO: 139	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 139		

-continued

RWGLCD		6
SEQ ID NO: 140	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
source	note = targeting peptide	
	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 140		
MSRPACPPND KYE		13
SEQ ID NO: 141	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = targeting peptide	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 141		
CLRSGRGC		8
SEQ ID NO: 142	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 142		
CHWMFSPWC		9
SEQ ID NO: 143	moltype = length =	
SEQUENCE: 143		
000		
SEQ ID NO: 144	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = targeting peptide	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 144		
CSSRLDAC		8
SEQ ID NO: 145	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 145		
CLPVASC		7
SEQ ID NO: 146	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
source	note = targeting peptide	
	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 146		
CGFECVRQCP ERC		13
SEQ ID NO: 147	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
source	note = targeting peptide	
	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 147		
CVALCREACG EGC		13

-continued

SEQ ID NO: 148	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 148		
SWCEPGWCR		9
SEQ ID NO: 149	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 149		
YSGWGW		6
SEQ ID NO: 150	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 150		
GLSGGRS		7
SEQ ID NO: 151	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 151		
LMLPRAD		7
SEQ ID NO: 152	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 152		
CSCFRDVCC		9
SEQ ID NO: 153	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 153		
CRDVSVIC		9
SEQ ID NO: 154	moltype = AA length = 5	
FEATURE	Location/Qualifiers	
REGION	1..5	
source	note = targeting peptide	
	1..5	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 154		
CNGRC		5
SEQ ID NO: 155	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	

-continued

SEQUENCE: 155	organism = synthetic construct	
MARSGL		6
SEQ ID NO: 156	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 156		6
MARAKE		
SEQ ID NO: 157	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 157		6
MSRTMS		
SEQ ID NO: 158	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 158		6
KCCYSL		
SEQ ID NO: 159	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
REGION	1..14	
source	note = targeting peptide	
	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 159		14
MYWGDShwLQ YWYE		
SEQ ID NO: 160	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 160		7
MQLPLAT		
SEQ ID NO: 161	moltype = AA length = 4	
FEATURE	Location/Qualifiers	
REGION	1..4	
source	note = targeting peptide	
	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 161		4
EWLS		
SEQ ID NO: 162	moltype = AA length = 4	
FEATURE	Location/Qualifiers	
REGION	1..4	
source	note = targeting peptide	
	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 162		4
SNEW		
SEQ ID NO: 163	moltype = AA length = 4	
FEATURE	Location/Qualifiers	

-continued

REGION	1..4	
	note = targeting peptide	
source	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 163		
TNYL		4
SEQ ID NO: 164	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
	note = targeting peptide	
source	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 164		
WIFPWIQL		8
SEQ ID NO: 165	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 165		
WDLAWMFRLP VG		12
SEQ ID NO: 166	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
	note = targeting peptide	
source	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 166		
CTVALPGGYV RVC		13
SEQ ID NO: 167	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
	note = targeting peptide	
source	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 167		
CVPELGHEC		9
SEQ ID NO: 168	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
	note = targeting peptide	
source	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 168		
CGRRAGGSC		9
SEQ ID NO: 169	moltype = AA length = 13	
FEATURE	Location/Qualifiers	
REGION	1..13	
	note = targeting peptide	
source	1..13	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 169		
CVAYCIEHHC WTC		13
SEQ ID NO: 170	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 170		

-continued

CVFAHNYDYL VC		12
SEQ ID NO: 171	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
REGION	1..10	
source	note = targeting peptide	
	1..10	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 171		10
CVFTSNYAFC		
SEQ ID NO: 172	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 172		7
VHSPNKK		
SEQ ID NO: 173	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 173		9
CDCRGDCFC		
SEQ ID NO: 174	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 174		7
CRGDGWC		
SEQ ID NO: 175	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 175		6
XRGCDX		
SEQ ID NO: 176	moltype = length =	
SEQUENCE: 176		
000		
SEQ ID NO: 177	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
REGION	1..10	
source	note = targeting peptide	
	1..10	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 177		10
CTTHWGFTLC		
SEQ ID NO: 178	moltype = AA length = 11	
FEATURE	Location/Qualifiers	
REGION	1..11	
source	note = targeting peptide	
	1..11	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 178		11
SGKGRQITA L		

-continued

SEQ ID NO: 179	moltype = length =	
SEQUENCE: 179		
000		
SEQ ID NO: 180	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 180		6
VYMSPP		
SEQ ID NO: 181	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 181		7
MQLPLAT		
SEQ ID NO: 182	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 182		7
ATWLPPR		
SEQ ID NO: 183	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
source	note = targeting peptide	
	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 183		12
HTMYVHHYQH HL		
SEQ ID NO: 184	moltype = AA length = 19	
FEATURE	Location/Qualifiers	
REGION	1..19	
source	note = targeting peptide	
	1..19	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 184		19
SEVGCRAGPL QWLCEKYFG		
SEQ ID NO: 185	moltype = AA length = 18	
FEATURE	Location/Qualifiers	
REGION	1..18	
source	note = targeting peptide	
	1..18	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 185		18
CGLLPVGRPD RNVWRWLC		
SEQ ID NO: 186	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
source	note = targeting peptide	
	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 186		15
CKGQCDRFKG LPWEC		
SEQ ID NO: 187	moltype = AA length = 5	
FEATURE	Location/Qualifiers	

-continued

REGION	1..5	
	note = targeting peptide	
source	1..5	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 187		
SGRSA		5
SEQ ID NO: 188	moltype = AA length = 4	
FEATURE	Location/Qualifiers	
REGION	1..4	
	note = targeting peptide	
source	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 188		
WGFP		4
SEQ ID NO: 189	moltype = length =	
SEQUENCE: 189		
000		
SEQ ID NO: 190	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 190		
XFXXYLW		7
SEQ ID NO: 191	moltype = AA length = 17	
FEATURE	Location/Qualifiers	
REGION	1..17	
	note = targeting peptide	
source	1..17	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 191		
AEPMPHSLNF SQYLWYT		17
SEQ ID NO: 192	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
	note = targeting peptide	
VARIANT	4	
	note = X can be W or F	
source	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 192		
WAYXSP		6
SEQ ID NO: 193	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
	note = targeting peptide	
source	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 193		
IELLQAR		7
SEQ ID NO: 194	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 194		
DITWDQLWDL MK		12
SEQ ID NO: 195	moltype = AA length = 16	
FEATURE	Location/Qualifiers	

-continued

REGION	1..16	
	note = targeting peptide	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 195		
AYTKCSRQWR TCMTH		16
SEQ ID NO: 196	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
	note = targeting peptide	
source	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 196		
PQNSKIPGPT FLDPH		15
SEQ ID NO: 197	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
	note = targeting peptide	
source	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 197		
SMEPALPDWV WKMFK		15
SEQ ID NO: 198	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
REGION	1..16	
	note = targeting peptide	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 198		
ANTPCGPYTH DCPVKR		16
SEQ ID NO: 199	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 199		
TACHQHVRMV RP		12
SEQ ID NO: 200	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 200		
VPWMEPAYQR FL		12
SEQ ID NO: 201	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
	note = targeting peptide	
source	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 201		
DPRATPGS		8
SEQ ID NO: 202	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
	note = targeting peptide	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 202		

-continued

FRPNRAQDYN TN		12
SEQ ID NO: 203	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 203		9
CTKNSYLMC		
SEQ ID NO: 204	moltype = AA length = 11	
FEATURE	Location/Qualifiers	
REGION	1..11	
VARIANT	note = targeting peptide	
	2	
VARIANT	note = X can be R or Q	
	3	
VARIANT	note = X can be L or R	
	5	
VARIANT	note = X can be G or N	
	9	
source	note = X can be A or V	
	1..11	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 204		11
CXXTXXXGXG C		
SEQ ID NO: 205	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 205		9
CPIEDRPMC		
SEQ ID NO: 206	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
REGION	1..12	
source	note = targeting peptide	
	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 206		12
HEWSYLAPYP WF		
SEQ ID NO: 207	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = targeting peptide	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 207		9
MCPKHPLGC		
SEQ ID NO: 208	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
source	note = targeting peptide	
	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 208		15
RMWPSSTVNL SAGR		
SEQ ID NO: 209	moltype = AA length = 20	
FEATURE	Location/Qualifiers	
REGION	1..20	
source	note = targeting peptide	
	1..20	
	mol_type = protein	

-continued

SEQUENCE: 209	organism = synthetic construct	
SAKTAVSQRV WLPShRGGEP		20
SEQ ID NO: 210	moltype = AA length = 20	
FEATURE	Location/Qualifiers	
REGION	1..20	
source	note = targeting peptide	
	1..20	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 210		20
KSREHVNNNSA CPSKRITAAL		
SEQ ID NO: 211	moltype = AA length = 4	
FEATURE	Location/Qualifiers	
REGION	1..4	
source	note = targeting peptide	
	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 211		4
EGFR		
SEQ ID NO: 212	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	
source	note = targeting peptide	
	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 212		6
AGLGVR		
SEQ ID NO: 213	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
source	note = targeting peptide	
	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 213		15
GTRQGHTMRL GVSDG		
SEQ ID NO: 214	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
source	note = targeting peptide	
	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 214		15
IAGLATPGWS HWLAL		
SEQ ID NO: 215	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 215		7
SMSIARL		
SEQ ID NO: 216	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = targeting peptide	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 216		7
HTFEPGV		
SEQ ID NO: 217	moltype = AA length = 15	
FEATURE	Location/Qualifiers	

-continued

REGION	1..15	
	note = targeting peptide	
source	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 217		
NTSLKRISNK RIRRK		15
SEQ ID NO: 218	moltype = AA length = 15	
FEATURE	Location/Qualifiers	
REGION	1..15	
	note = targeting peptide	
source	1..15	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 218		
LRIKRKRKRK KKTRK		15
SEQ ID NO: 219	moltype = length =	
SEQUENCE: 219		
000		
SEQ ID NO: 220	moltype = length =	
SEQUENCE: 220		
000		
SEQ ID NO: 221	moltype = length =	
SEQUENCE: 221		
000		
SEQ ID NO: 222	moltype = length =	
SEQUENCE: 222		
000		
SEQ ID NO: 223	moltype = length =	
SEQUENCE: 223		
000		
SEQ ID NO: 224	moltype = length =	
SEQUENCE: 224		
000		
SEQ ID NO: 225	moltype = length =	
SEQUENCE: 225		
000		
SEQ ID NO: 226	moltype = length =	
SEQUENCE: 226		
000		
SEQ ID NO: 227	moltype = length =	
SEQUENCE: 227		
000		
SEQ ID NO: 228	moltype = length =	
SEQUENCE: 228		
000		
SEQ ID NO: 229	moltype = length =	
SEQUENCE: 229		
000		
SEQ ID NO: 230	moltype = length =	
SEQUENCE: 230		
000		
SEQ ID NO: 231	moltype = length =	
SEQUENCE: 231		
000		
SEQ ID NO: 232	moltype = length =	
SEQUENCE: 232		
000		
SEQ ID NO: 233	moltype = length =	
SEQUENCE: 233		

-continued

000

SEQ ID NO: 234 moltype = length =
SEQUENCE: 234
000

SEQ ID NO: 235 moltype = length =
SEQUENCE: 235
000

SEQ ID NO: 236 moltype = length =
SEQUENCE: 236
000

SEQ ID NO: 237 moltype = length =
SEQUENCE: 237
000

SEQ ID NO: 238 moltype = length =
SEQUENCE: 238
000

SEQ ID NO: 239 moltype = length =
SEQUENCE: 239
000

SEQ ID NO: 240 moltype = length =
SEQUENCE: 240
000

SEQ ID NO: 241 moltype = length =
SEQUENCE: 241
000

SEQ ID NO: 242 moltype = length =
SEQUENCE: 242
000

SEQ ID NO: 243 moltype = length =
SEQUENCE: 243
000

SEQ ID NO: 244 moltype = length =
SEQUENCE: 244
000

SEQ ID NO: 245 moltype = length =
SEQUENCE: 245
000

SEQ ID NO: 246 moltype = length =
SEQUENCE: 246
000

SEQ ID NO: 247 moltype = length =
SEQUENCE: 247
000

SEQ ID NO: 248 moltype = length =
SEQUENCE: 248
000

SEQ ID NO: 249 moltype = length =
SEQUENCE: 249
000

SEQ ID NO: 250 moltype = length =
SEQUENCE: 250
000

SEQ ID NO: 251 moltype = length =
SEQUENCE: 251
000

SEQ ID NO: 252 moltype = length =
SEQUENCE: 252

-continued

000

SEQ ID NO: 253 moltype = length =
SEQUENCE: 253
000

SEQ ID NO: 254 moltype = length =
SEQUENCE: 254
000

SEQ ID NO: 255 moltype = length =
SEQUENCE: 255
000

SEQ ID NO: 256 moltype = length =
SEQUENCE: 256
000

SEQ ID NO: 257 moltype = length =
SEQUENCE: 257
000

SEQ ID NO: 258 moltype = length =
SEQUENCE: 258
000

SEQ ID NO: 259 moltype = length =
SEQUENCE: 259
000

SEQ ID NO: 260 moltype = length =
SEQUENCE: 260
000

SEQ ID NO: 261 moltype = length =
SEQUENCE: 261
000

SEQ ID NO: 262 moltype = length =
SEQUENCE: 262
000

SEQ ID NO: 263 moltype = length =
SEQUENCE: 263
000

SEQ ID NO: 264 moltype = length =
SEQUENCE: 264
000

SEQ ID NO: 265 moltype = length =
SEQUENCE: 265
000

SEQ ID NO: 266 moltype = length =
SEQUENCE: 266
000

SEQ ID NO: 267 moltype = length =
SEQUENCE: 267
000

SEQ ID NO: 268 moltype = length =
SEQUENCE: 268
000

SEQ ID NO: 269 moltype = length =
SEQUENCE: 269
000

SEQ ID NO: 270 moltype = length =
SEQUENCE: 270
000

SEQ ID NO: 271 moltype = length =
SEQUENCE: 271

-continued

000

SEQ ID NO: 272 moltype = length =
SEQUENCE: 272
000

SEQ ID NO: 273 moltype = length =
SEQUENCE: 273
000

SEQ ID NO: 274 moltype = length =
SEQUENCE: 274
000

SEQ ID NO: 275 moltype = length =
SEQUENCE: 275
000

SEQ ID NO: 276 moltype = length =
SEQUENCE: 276
000

SEQ ID NO: 277 moltype = length =
SEQUENCE: 277
000

SEQ ID NO: 278 moltype = length =
SEQUENCE: 278
000

SEQ ID NO: 279 moltype = length =
SEQUENCE: 279
000

SEQ ID NO: 280 moltype = length =
SEQUENCE: 280
000

SEQ ID NO: 281 moltype = length =
SEQUENCE: 281
000

SEQ ID NO: 282 moltype = length =
SEQUENCE: 282
000

SEQ ID NO: 283 moltype = length =
SEQUENCE: 283
000

SEQ ID NO: 284 moltype = length =
SEQUENCE: 284
000

SEQ ID NO: 285 moltype = length =
SEQUENCE: 285
000

SEQ ID NO: 286 moltype = length =
SEQUENCE: 286
000

SEQ ID NO: 287 moltype = length =
SEQUENCE: 287
000

SEQ ID NO: 288 moltype = length =
SEQUENCE: 288
000

SEQ ID NO: 289 moltype = length =
SEQUENCE: 289
000

SEQ ID NO: 290 moltype = length =
SEQUENCE: 290

-continued

```

000
SEQ ID NO: 291      moltype = length =
SEQUENCE: 291
000

SEQ ID NO: 292      moltype = length =
SEQUENCE: 292
000

SEQ ID NO: 293      moltype = length =
SEQUENCE: 293
000

SEQ ID NO: 294      moltype = length =
SEQUENCE: 294
000

SEQ ID NO: 295      moltype = length =
SEQUENCE: 295
000

SEQ ID NO: 296      moltype = length =
SEQUENCE: 296
000

SEQ ID NO: 297      moltype = AA length = 8
FEATURE            Location/Qualifiers
REGION            1..8
note = AAV capsid protein amino acid substitution
source           1..8
mol_type = protein
organism = synthetic construct

SEQUENCE: 297
VVGNGGVV                      8

SEQ ID NO: 298      moltype = AA length = 8
FEATURE            Location/Qualifiers
REGION            1..8
note = AAV capsid protein amino acid substitution
source           1..8
mol_type = protein
organism = synthetic construct

SEQUENCE: 298
NFREMPIG                      8

SEQ ID NO: 299      moltype = AA length = 9
FEATURE            Location/Qualifiers
REGION            1..9
note = AAV capsid protein amino acid substitution
source           1..9
mol_type = protein
organism = synthetic construct

SEQUENCE: 299
RRSEDMGTI                    9

SEQ ID NO: 300      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION            1..738
note = AAV capsid variant
source           1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 300
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTVVGNGGV VNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVVQV NRDVYLQGPV WAKIPHTDGN FHPSPLMGGF GLKHPPPPQIL IKNTVPVADP 660
PTTFNQSKLN SPITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYSK TSVDFAVANTE 720

```

-continued

GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 301 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 301
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQQR VSTNFRMEMP GNFPAWTAGT YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
 QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
 PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNE IQYTSNYYS TSVDFAVNT 720
 GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 302 moltype = AA length = 739
 FEATURE Location/Qualifiers
 REGION 1..739
 note = AAV capsid variant
 source 1..739
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 302
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQQR VSTRRSEDMG TINFAWTAGT KYHLNGRNSL ANPGIAMATHK DDEERFFPSN 540
 NGILIFGKQN AARDNADYSD VMLTSEEEIK TNPVATEEYG IVADNLQQQN TAPQIGTVN 600
 SQGALPGMVWQ NRDVYLQGP IWAKIPHTDG NFHPSPLMGG FGLKHPPPQI LIKNTVPVAD 660
 PPTTFNQSKL NSFITQYSTG QVSVEIEWEL QKENSKRWNE EIQYTSNYYS STSVDPAVNT 720
 EGVYSEPRPI GTRYLTRNL 739

SEQ ID NO: 303 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 303
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVVGNGGVV NFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 ILIFGKQNA ARDNADYSDV MLTSEEEIKT NPVATEEYGI VADNLQQQN APQIGTVNSQ 600
 GALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF LKHPPPQILI KNTVPVADPP 660
 TTFNQSKLNS FITQYSTGQV SVVEIEWELQ KENSKRWNEI QYTSNYYSKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 304 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 304

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNFREMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
PTTFNQSKLN	SFITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					738

SEQ ID NO: 305 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STRSEDMGT	INFAWTAGTK	YHLNGRNSLA	NGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	SVEIEWELQ	KENSKRWNPFI	IQYTSNYKKS	TSVDFAVNTG	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 306 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVVGNGGV	VNFAWTAGTK	YHLNGRNSLA	NGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	SVEIEWELQ	KENSKRWNPFI	IQYTSNYKKS	TSVDFAVNTG	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 307 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVVGNGGV	VNFAWTAGTK	YHLNGRNSLA	NGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600

-continued

QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PITTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNP	IQYTSNYKYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 308 moltype = AA length = 739
 FEATURE Location/Qualifiers
 REGION 1..739
 note = AAV capsid variant
 source 1..739
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 308

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTRSEDMG	TINFAWTAGT	KYHLNGRNSL	ANPGIAMATH	KDDEERFFPS	540
NGILIFGKQN	AARDNADYS	VMLTSEEEK	TNPVATEEY	GIVADNMEP	TRAPQIGTVN	600
SQGALPGMVW	QNRDVYLQGP	IWAKIPHTDG	NFHPSPLMGG	FGLKHPPPQI	LIKNTVPVAD	660
PPTTFNQSKL	NSFITQYSTG	QVSVEIEWEL	QKENSKRWNP	EIQYTSNYK	STSVDFAVNT	720
EGVYSEPRPI	GTRYLTRNL					739

SEQ ID NO: 309 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 309

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTNNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVVGNGGVV	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEKIT	NPVATEEYGI	VADNVMETPR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 310 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 310

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTNNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNFREMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEKIT	NPVATEEYGI	VADNVMETPR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 311 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 311
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEAGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSWLGDREV 240
ITSTRTWAL PTYNHLYKQI ISNGTSGGAT NDNTYFGYST PWGYFDNRFH HCHFSPRDWQ 300
RLINNWGFR PKRSLFKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPFHSSYAHQ QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STRRSEDGMT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMTEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGPV WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 312      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 312
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDREVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVVGNGGVV NFAWTAGTKY HLNNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPV AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP EIQYTSNYYSK SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 738

SEQ ID NO: 313      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 313
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDREVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNFREMPIG NFAWTAGTKY HLNNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPV AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP EIQYTSNYYSK SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 738

SEQ ID NO: 314      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 314
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDREVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STRRSEDMGT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLGQPI WAKIPHTDGN FHPSPLMGGF GLKHPQPQIL IKNTVPVADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 315      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 315
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TVVGNNGVNV FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNP EIQYTSNYYS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 316      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 316
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TNPREMPIGN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNP EIQYTSNYYS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 317      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 317
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TRRSEDMGTI NFAWTAGTKY HLNNGRNSLAN PGIAMATHKDD DEERFFPSNG 540
LIFGKQNAAR RDNADYSVDM L TSEEEIKTTN NPVATEEYGI VADNLQQQNTA APQIGTVNSQ 600
GALPGMVWQNR RDVYLGQPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPVADPPT 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP EIQYTSNYYS VDFAVNTEGV 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 318      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant

```

-continued

```

source                1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 318
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVVGNGGVW NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSVDM LTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 319      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 319
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNPREMPIG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSVDM LTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 320      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 320
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STRRSEDGMT INFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILLIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYGI IVADNVMEPTR RAPQIGTVNS 600
QGALPGMVWQ NRDVYLGPI WAKIPHDTGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPEI IQYTSNYKST TSVDFAVNTG 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 321      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 321
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360

```


-continued

QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
 GPCYRQQRVS TVVNGGCVN FAWTAGTKYH LNDRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGV ADNVMEPTRA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPPQILIK NTPVPADPPT 660
 TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 322 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 322
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
 LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
 GPCYRQQRVS TVVNGGCVN FAWTAGTKYH LNDRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGV ADNVMEPTRA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPPQILIK NTPVPADPPT 660
 TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 323 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 323
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
 LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
 GPCYRQQRVS TRRSEDGMI NFAWTAGTKY HLNDRNSLANP PGIAMATHKDD DEERFFPSNGI 540
 ILIFGKQNAAR RDADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTRA APQIGTVNSQ 600
 GALPGMVWQNR RDVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPPQLI KNTVPADPPT 660
 TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 324 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 324
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKRVLEPLG LVEEAGKATP GKRRPVEPSP QRSPTSSTGI GKKGQPPARK RLNFQGTGDS 180
 ESVPDPQPLG EPPAAPSGVGP PNTMAAGGGA PMADNNEGAD GVGSSGNWHC CDSWLGDRV 240
 ITTSTRTWALP PYYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDNRFH HCHFSPRDWQ 300
 RLINNNWGFPR PKRLSFKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQPTYTFED 420
 VPFHSSYAHS QSLDRLMNPLI IDQYLYLSR TQTTSNDRGVT TLGFSQGGPNT TMANQAKNWL 480
 PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNDRNSLANP PGIAMATHKDD DEERFFPSNGI 540
 ILIFGKQNAAR RDADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQNR RDVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPPQLI KNTVPADPPT 660
 STFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 325 moltype = AA length = 738
 FEATURE Location/Qualifiers

-continued

REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 325

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTNLAENFK	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPIIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 326 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 326

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVLSGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPIIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 327 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 327

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTMSAASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPIIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 328 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 328

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240

-continued

```

ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTGTNLGKE QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 329      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 329
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTSSHSGTN QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 330      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 330
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTVATRDGQ LNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 331      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 331
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDV 240
ITSTRWTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTALNADTG TNSFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

```

-continued

```

SEQ ID NO: 332      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source           1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 332
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTTTGQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGPV WAKIPHTDGN FHPSPLMGGF GLKHPQPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNTE 720
GVSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 333      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 333
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDV MLTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPV AKIPHTDGNF HPSPLMGGFG LKHPQPQILI KNTPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP EIQYTSNYYS SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 334      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 334
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDV MLTSEEEIKT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPV AKIPHTDGNF HPSPLMGGFG LKHPQPQILI KNTPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNP EIQYTSNYYS SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 335      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 335
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120

```

-continued

```

AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVLSGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737
    
```

```

SEQ ID NO: 336          moltype = AA length = 737
FEATURE                Location/Qualifiers
REGION                 1..737
                        note = AAV capsid variant
source                 1..737
                        mol_type = protein
                        organism = synthetic construct
    
```

```

SEQUENCE: 336
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPYGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMSAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737
    
```

```

SEQ ID NO: 337          moltype = AA length = 737
FEATURE                Location/Qualifiers
REGION                 1..737
                        note = AAV capsid variant
source                 1..737
                        mol_type = protein
                        organism = synthetic construct
    
```

```

SEQUENCE: 337
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPYGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STGTNLGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737
    
```

```

SEQ ID NO: 338          moltype = AA length = 737
FEATURE                Location/Qualifiers
REGION                 1..737
                        note = AAV capsid variant
source                 1..737
                        mol_type = protein
                        organism = synthetic construct
    
```

```

SEQUENCE: 338
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPYGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STSHSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RNLFGQTGDS 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
    
```

-continued

VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 339 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 339
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVATRQGL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQV LTVSEEEIKT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMWVQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 340 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 340
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQV LTVSEEEIKT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMWVQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 341 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 341
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPPGCPYRQR VSTNLAENFK YNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA RDNADYSQV LTVSEEEIKT TNPVATEEYGI IVADNVMEPT RAPQIGTVNS 600
 QGALPGMWVQN RDVYLQGPW WAKIPHTDGN HPSPLMGGFG GLKHPPQILI IKNTVPADPR 660
 RSTFNGDKLN SFTQYSTGQV SVEIEWELQ KENSKRWNPEI IQYTSNYYKS TSVDFAVNTE 720
 GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 342 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 342

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTVLSGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 343 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTMSAASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 344 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTGTNLGKE	QNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 345 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTSSHGNTN	QNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600

-continued

QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 346 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 346						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVATRDGQ	LNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 347 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 347						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTVATRDGQ	LNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 348 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 348						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTNNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNLAENFKY	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	SFITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYSKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 349 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 349
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVLSGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQV LNSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQW RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 350      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 350
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMAAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQV LNSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQW RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 351      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 351
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STGTNLGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQV LNSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQW RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 352      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 352
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPPPA DVFMPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STSSHSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 353      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 353
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEAGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSPKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVATRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 354      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 354
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEAGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSPKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 355      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 355
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPFY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDS 180
SVPDPQLG EPPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYDFNRFH CHFSPRDWR 300
LNNNNWGFPR KRLSPKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPPPAD DVFMIPQYGY LTLNNGSQAV RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STTTGQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 356      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant

```

-continued

source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 356
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDS E 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNGRGVT LGFSGGGPNT MANQAKNWLP 480
GPCYRQQRVS TTTQNNNSW FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 357 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 357
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDS E 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTGGTANTQ TLGFSQGGPN TMANQAKNWLP 480
PGPCYRQQRV STNLAENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
LILIFGKQNA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQNR RDVYLGQPIW AKIPHTDGNF HPSPLMGGFGL LKHPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 358 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 358
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDS E 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTGGTANTQ TLGFSQGGPN TMANQAKNWLP 480
PGPCYRQQRV STVLSGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
LILIFGKQNA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQNR RDVYLGQPIW AKIPHTDGNF HPSPLMGGFGL LKHPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 359 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 359
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDS E 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360

-continued

```

QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMSAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 360      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 360
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGPEVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKCR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STMSAASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 361      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 361
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGPEVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKCR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STSHSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 362      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 362
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGPEVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKCR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVATRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 363      moltype = AA length = 737
FEATURE           Location/Qualifiers

```

-continued

```

REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 363
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 364        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 364
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 365        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 365
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSGRGVTV LGFSQGGENT MANQAKNWL 480
GPCYRQQRVS TTTGQNNNSN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGIWA KIPHTDGNF HPSPLMGGFGL KHPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 366        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 366
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240

```

-continued

```

TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TNLAENFKYN  FAWTAGTKYH  LNDRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPRS  660
TFNGDKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 367      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION             1..736
                   note = AAV capsid variant
source             1..736
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 367
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TVLSGDHSAN  FAWTAGTKYH  LNDRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPRS  660
TFNGDKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 368      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION             1..736
                   note = AAV capsid variant
source             1..736
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 368
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TMSAASGSGN  FAWTAGTKYH  LNDRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPRS  660
TFNGDKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

```

SEQ ID NO: 369      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION             1..736
                   note = AAV capsid variant
source             1..736
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 369
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFQ  120
AKKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNCRGVT  LGFSQGGPNT  MANQAKNWLP  480
GPCYRQQRVS  TGTNLGKEQN  FAWTAGTKYH  LNDRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSVVML  TSEEEIKTTN  PVATEEYGIV  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPPIWA  KIPHTDGNFH  PSPLMGGFGL  KHPPPQILIK  NTPVPADPRS  660
TFNGDKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYYKSTS  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```

-continued

```

SEQ ID NO: 370      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 370
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TSSHSGTQNG FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 371      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 371
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TVATRDQQLN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 372      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 372
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TALNADTGTN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 373      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 373
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120

```

-continued

AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNLAENFKY	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 374 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 374

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVLSGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 375 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 375

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STMSAASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 376 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 376

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STGTNLGKEQ	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720

-continued

 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 377 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 377
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STSVHSQGTQV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 378 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 378
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STVATRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 379 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 379
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STALNADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSQVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 380 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 380

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TNLAENFKYN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 381 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TNLAENFKYN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 382 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TMSAASGSGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 383 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TMTNLGKEQN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600

-continued

ALPGMVWQNR	DVYLQGPiWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 384 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 384

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TSSHSGTNQN	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPiWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 385 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 385

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TSSHSGTNQN	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPiWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 386 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 386

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TALNADTGNT	FAWTAGTKYH	LNGRNSLAMP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPiWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 387 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 387
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGRF PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTVVGNNGV VNFPAWTAGT YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 388      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 388
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGRF PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTNPREMPI GNFPAWTAGT YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 389      moltype = AA length = 739
FEATURE           Location/Qualifiers
REGION           1..739
                 note = AAV capsid variant
source          1..739
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 389
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGRF PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTRRSEDMG TINFAWTAGT KYHLNGRNSL ANPGIAMATH KDDEERFFPS 540
NGILIFGKQN AARDNADYS VMLTSEEEIK TNPVATEEY GIVADNLQQQ NTAPQIGTVN 600
SQGALPGMVW QNRDVYLQGP IWAKIPHTDG NPHPSPLMGG FGLKHPPPQI LIKNTVPVAD 660
PRSTFNGDKL NSFITQYSTG QVSVEIEWEL QKENSKRWNP EIQYTSNYYS STSVDFAVNT 720
EGVYSEPRPI GTRYLTRNL 739

SEQ ID NO: 390      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 390
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGRF PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STVVVGGGV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQON RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 391      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 391
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STNPREMPIG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQON RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 392      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 392
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STRSEDMGT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSVDM MLTSEEEIKT TNPVATEEYGI IVADNLQQQNT TAPQIGTVNS 600
QGALPGMVWQON NRDVYLQGPW WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIGT TRYLTRNL 738

```

```

SEQ ID NO: 393      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 393
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYG LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
LPGPCYRQQRV STVVVGGGV NFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSVDM MLTSEEEIKT TNPVATEEYGI IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQON NRDVYLQGPW WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIGT TRYLTRNL 738

```

```

SEQ ID NO: 394      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant

```

-continued

```

source                1..738
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 394
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVELEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTNFRMPPI GNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 395      moltype = AA length = 739
FEATURE            Location/Qualifiers
REGION             1..739
                    note = AAV capsid variant
source             1..739
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 395
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVELEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTRRSEDMG TINFAWTAGT KYHLNGRNSL ANPGIAMATH KDDERFFPS 540
NGILIFGKQN AARDNADYSV VMLTSEEEIK TNPVATEEY GIVADNVMEP TRAPQIGTVN 600
SQGALPGMVW QNRDVYLQGP I WAKIPHTDG NPHPSPLMGG FGLKHPPPQI LIKNTVPAD 660
PRSTFNGDKL NSFITQYSTG QVSVEIEWEL QKENSKRWNP EIQYTSNYYS STSVDFAVNT 720
EGVYSEPRPI GTRYLTRNL 739

SEQ ID NO: 396      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                    note = AAV capsid variant
source             1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 396
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVELEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STVVGNGGVV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP I WAKIPHTDGN FHSPLMGGF LKHPPPQILI KNTVPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYSKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 397      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                    note = AAV capsid variant
source             1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 397
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVELEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360

```

-continued

HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNFREMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 398 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 398

MAADGYLPDW	LEDNLSEGR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNWGF	PKRSLFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNFREMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHDTGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVIEWELQ	KENSKRWNPFI	IQYTSNYYKS	TSVDFAVNTG	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 399 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 399

MAADGYLPDW	LEDNLSEGR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLELEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQLG	PPAAPSGVGP	NMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGF	KRSLFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPPPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STVVGNGGVV	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 400 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 400

MAADGYLPDW	LEDNLSEGR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLELEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQLG	PPAAPSGVGP	NMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGF	KRSLFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPPPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STNFREMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 401 moltype = AA length = 738
 FEATURE Location/Qualifiers

-continued

```

REGION                1..738
                      note = AAV capsid variant
source                1..738
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 401
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STRSEDMGT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYV IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP E IQYTSNYKYS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 736

SEQ ID NO: 402        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 402
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGRVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TVVNGGQVNV FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNFH PSPLMGGFGL KHPPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNP EIQ YTSNYKYSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 403        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 403
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGRVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TNFREMPIGN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNFH PSPLMGGFGL KHPPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNP EIQ YTSNYKYSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 404        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 404
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240

```


-continued

TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTSNNGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TRRSEDMGTI	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 405 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 405

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFPQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTSNNGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRV	TRRSEDMGTI	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 406 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 406

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFPQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTSNNGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRV	TRRSEDMGTI	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 407 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 407

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFPQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTSNNGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRV	TRRSEDMGTI	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYGI	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQN	NRDVYLQGPW	WAKIPHTDGN	HPSPLMGGFG	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLNS	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPEI	IQYTSNYYKS	TSVDFAVNTE	720
GVYSEPRPIGT	TRYLTRNL					738

-continued

```

SEQ ID NO: 408      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 408
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLMNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TVVGNNGVVN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGLV ADNVMPEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 409      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 409
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLMNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TNPREMPIGN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGLV ADNVMPEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 410      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 410
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLMNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TRRSEDMGTI NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAAR RDADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMPEPTRA APQIGTVNSQ 600
GALPGMVWQNR RDVYLQGPPIW AKIPHTDGNPH HPSPLMGGFGL LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITYSTGQV SVIEWELQK ENSKRWNPEI QYTSNYYKST VDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 411      moltype = AA length = 8
FEATURE           Location/Qualifiers
REGION           1..8
                 note = AAV capsid protein amino acid substitution
source           1..8
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 411
YPLQNNNS

```

-continued

SEQ ID NO: 412	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 412		
YPLENFKY		8
SEQ ID NO: 413	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 413		
YPLGDHSA		8
SEQ ID NO: 414	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 414		
YPLASGSG		8
SEQ ID NO: 415	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 415		
YPLLGKEQ		8
SEQ ID NO: 416	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 416		
YPLSGTNQ		8
SEQ ID NO: 417	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 417		
YPLRDGQL		8
SEQ ID NO: 418	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 418		
YPLADTGT		8
SEQ ID NO: 419	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = AAV capsid protein amino acid substitution	
	1..8	
	mol_type = protein	

-continued

organism = synthetic construct

SEQUENCE: 419
YPLNGGVV 8

SEQ ID NO: 420
FEATURE Location/Qualifiers
REGION 1..8
note = AAV capsid protein amino acid substitution
source 1..8
mol_type = protein
organism = synthetic construct

SEQUENCE: 420
YPLEMPIG 8

SEQ ID NO: 421
FEATURE Location/Qualifiers
REGION 1..9
note = AAV capsid protein amino acid substitution
source 1..9
mol_type = protein
organism = synthetic construct

SEQUENCE: 421
YPLEDMGTI 9

SEQ ID NO: 422
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant
source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 422
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTYPLQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGPV WAKIPHTDGN FHPSPLMGGF GLKHPPQIIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVANTE 720
GVSEPRPIG TRYLTRNL 738

SEQ ID NO: 423
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 423
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQORV STYPLQNNNS NFAWTAGTK YHLNGRNSLAN NPGIAMATHK DEERFFPSNG 540
ILIFGKQNAA RDNADYSV MLTSEEEIKT NPVATEEYGI VADNLQQQN APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPV WAKIPHTDGN FHPSPLMGGF LKHPPQIIL KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVVEIEWELQ ENSKRWNP EIQYTSNYYS SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 424
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant
source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 424

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVPQ	120
AKKRVLPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQOR	VSTYPLQNNN	SNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 425 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVPQ	120
AKKRVLPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSGRGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQORV	STYPLQNNNS	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYSKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 426 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQLG	PPAAPSGVGP	NNTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRV	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQORV	STYPLQNNNS	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYSKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 427 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKKR	LNFGQTGDSE	180
SVPDPQLG	PPAAPSGVGP	NNTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRV	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQORVS	TYPLQNNNSN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNLQQQNTA	PQIGTVNSQG	600

-continued

ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 428 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 428

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFP	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLQNNNS	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTVPVADPP	660
TFNQSKLNSF	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 429 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 429

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFP	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYYLSRT	QTTSNRGT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLQNNNSN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSDVML	TSEEEIKTTN	PVATEEYGI	ADNVMEPTR	PQIGTVNSQ	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 430 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 430

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQQKD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRIVLEPLG	LVEEAGKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQOPARK	RLNFGQTDGS	180
ESVPDPQPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDNFRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQPTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLQNNN	SNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILLIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEY	IVADNLQOON	TAPQIGTVNS	600
QGALPGMVWQ	NRDYLQGPPI	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTVPVADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 431 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 431
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGF RRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LTSEEEIKT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 432      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 432
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGF RRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILLIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYI IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGIW WAKIPHTDGN FHPSPMLGGF GLKHPPPQILI IKNTFPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYKTS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 433      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 433
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGF RRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSQV LTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 434      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 434
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF QERLKEDTSF GGNLGRAVFPQ 120
AKKRLLEPLG LVEEAAKTAP GKRRPVEPSP QEPDSSAGIG KSGAQPAPKR LNFQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYDFNRFH CHFSPRDWQR 300
LINNNWGF RRLSFKLFNI QVKEVTQNEGT TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 435      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 435
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLQNNNSN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 436      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 436
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWLP 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 437      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source           1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 437
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLQNNNSN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNVMEPTR PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 438      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant

```


-continued

```

source                1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 438
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSENGRV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA RDNADYSVDM LTSEEEIKT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPII KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 439      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION             1..738
                    note = AAV capsid variant
source             1..738
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 439
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLENFK YNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPII IKNTVPVADP 660
PTTFNQSKLN SFIQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 440      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION             1..738
                    note = AAV capsid variant
source             1..738
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 440
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLGDHS ANFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGPI WAKIPHTDGN FHPSPLMGGF GLKHPPPII IKNTVPVADP 660
PTTFNQSKLN SFIQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 441      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION             1..738
                    note = AAV capsid variant
source             1..738
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 441
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360

```

-continued

HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMWVQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 442 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 442

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMWVQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 443 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 443

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLSGTN	QNFATWAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMWVQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 444 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 444

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLRDGQ	LNFATWAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMWVQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 445 moltype = AA length = 738
 FEATURE Location/Qualifiers

-continued

REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 445

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLADTG	TNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 446 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 446

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLQNNN	TNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 447 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 447

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSGNGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLQNNNS	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	WAKIPHTDGN	HPSPLMGGFG	LKHPPPPQILI	KNTPVPADPP	660
PTTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYSKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 448 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 448

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240

-continued

ITSTRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNGWFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLENFYK	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 449 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 449

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNGWFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLGDHSA	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 450 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 450

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNGWFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 451 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 451

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNGWFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLLGKEQ	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

-continued

SEQ ID NO: 452 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 452
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLRSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 453 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 453
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLRSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 454 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 454
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNGWFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCCLPPPPA DVMFIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VPPHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 455 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 455
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120

-continued

AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGF	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLNFK	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 456 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 456

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGF	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 457 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 457

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGF	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 458 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 458

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGF	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLLLGKE	QNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720

-continued

GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 459 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 459
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQQR VSTYPLSGTN QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
 QGALPGMWVQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPPQIL IKNTPVPADP 660
 PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP I QYTSNYYS TSVDFAVNTE 720
 GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 460 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 460
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQQR VSTYPLRDGQ LNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
 QGALPGMWVQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPPQIL IKNTPVPADP 660
 PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP I QYTSNYYS TSVDFAVNTE 720
 GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 461 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 461
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQQR VSTYPLADTG T NFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
 QGALPGMWVQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPPQIL IKNTPVPADP 660
 PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP I QYTSNYYS TSVDFAVNTE 720
 GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 462 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 462

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLENFKY	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 463 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLGDSH	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 464 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 465 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLGKEQ	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600

-continued

GALPGMVWQN	RDVYLQGIW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 466 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 466

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLSGTNQ	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGIW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 467 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 467

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLRQGL	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGIW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 468 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 468

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLADTGT	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNAA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGIW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 469 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 469
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAV FQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYS DVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP IW AKIPH TDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 470      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 470
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAV FQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTNNGRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLQNNNS FAWTAGTKYH LNNGRNSLAN PGIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYS DVM LTSEEEIKTT NPVATEEYGI VADNLQQQNTA PQIGTVNSQ 600
ALPGMVWQNR DVYLQGP IWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYKSTS VDFAVNTEG 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 471      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 471
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAV FQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYS DVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP IW AKIPH TDGNF HPSPLMGGFG LKHPPPQILI KNTFPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 472      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 472
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAV FQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STYPLGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 473      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 473
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 474      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 474
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLGKQEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 475      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 475
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSDVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 476      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant

```

-continued

```

source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 476
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQTDGSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYS DVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP IW AKIPHTDGNF HPSPLMGFGF LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 477        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION               1..737
                      note = AAV capsid variant
source               1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 477
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQTDGSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYS DVM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP IW AKIPHTDGNF HPSPLMGFGF LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 478        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION               1..737
                      note = AAV capsid variant
source               1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 478
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQTDGSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLQNNNS NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA A RDNADYS DVM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGP IW AKIPHTDGNF HPSPLMGFGF LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 479        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION               1..736
                      note = AAV capsid variant
source               1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 479
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQTDGSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360

```

-continued

QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLQNNNSN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 480 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 480

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFQGTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLENPKYN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNLQQQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 481 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 481

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFQGTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLGDHSAN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNLQQQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 482 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 482

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFQGTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLASGSGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNLQQQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 483 moltype = AA length = 736
 FEATURE Location/Qualifiers

-continued

```

REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 483
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNNGRGT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLLGKEQN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 484        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 484
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNNGRGT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLSGTNQN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 485        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 485
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNNGRGT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLRDGQLN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 486        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION                1..736
                      note = AAV capsid variant
source                1..736
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 486
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240

```

-continued

TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLADTGTN	FAWTAGTKYH	LNGRNLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGI	ADNLQQQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 487 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 487

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
PGPCYRQQRV	STYPLENFYK	NFAWTAGTKY	HLNNGRNLAN	PGIAMATHKD	DEERFFPSNG	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	NPVATEEYGI	VADNVM EPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNSF	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 488 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 488

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
PGPCYRQQRV	STYPLGDHSA	NFAWTAGTKY	HLNNGRNLAN	PGIAMATHKD	DEERFFPSNG	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	NPVATEEYGI	VADNVM EPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNSF	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

SEQ ID NO: 489 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
 note = AAV capsid variant
source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 489

MAADGYLPDW	LEDNLSEIGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTGDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNCRGVT	LGFSQGGPNT	MANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNNGRNLAN	PGIAMATHKD	DEERFFPSNG	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	NPVATEEYGI	VADNVM EPTR	APQIGTVNSQ	600
GALPGMVWQNR	RDVYLQGPPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNSF	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYKST	SVDFAVNTEG	720
YSEPRPIGTR	RYLTRNL					737

-continued

```

SEQ ID NO: 490      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 490
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLLGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 491      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 491
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 492      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 492
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 493      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 493
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120

```


-continued

AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
GPCYRQQRV	STYPLADTGT	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPBI	QYTSNYYKST	SVDFAVNTG	720
YSEPRPIGT	RYLTRNL					737

SEQ ID NO: 494 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 494

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGVTV	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLENFKYN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNF	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPBIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 495 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 495

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGVTV	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLGDHSAN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNF	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPBIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 496 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 496

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQGTGDS	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGVTV	LGFSQGGPNT	MANQAKNWLP	480
GPCYRQQRVS	TYPLASGSGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNF	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPBIQ	YTSNYYKSTS	VDFAVNTEGV	720

-continued

YSEPRPIGTR YLTRNL 736

SEQ ID NO: 497 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 497
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
 GPCYRQQRVS TYPLSGTQNI FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
 TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 498 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 498
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
 GPCYRQQRVS TYPLSGTQNI FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
 TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 499 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 499
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
 GPCYRQQRVS TYPLRQGLN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
 TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 500 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 500

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVPQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVDPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDFNRFH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGPN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRST	QTTSNNGRGT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLADTGTN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLRNL					736

SEQ ID NO: 501 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVPQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSSTGI	GKKGQOPARK	RLNFGQTDGS	180
ESVDPDPQPLG	EPPAAPSGVGP	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFPR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQPTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLNGGV	VNFPAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYKKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRLN					738

SEQ ID NO: 502 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVPQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSSTGI	GKKGQOPARK	RLNFGQTDGS	180
ESVDPDPQPLG	EPPAAPSGVGP	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFPR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQPTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLEMPI	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYKKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRLN					738

SEQ ID NO: 503 moltype = AA length = 739
 FEATURE Location/Qualifiers
 REGION 1..739
 note = AAV capsid variant
 source 1..739
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVPQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSSTGI	GKKGQOPARK	RLNFGQTDGS	180
ESVDPDPQPLG	EPPAAPSGVGP	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFPR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQPTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLDMG	TINFAWTAGT	KYHLNGRNSL	ANPGIAMATH	KDDEERFFPS	540
NGILIFGKQN	AARDNADYS	VMLTSEEEIK	TNPVATEEY	GIVADNLQQQ	NTAPQIGTVN	600

-continued

SQGALPGMVW	QNRDVLQGP	IWAKIPHTDG	NFHPSPLMGG	FGLKHPPII	LIKNTVPAD	660
PPTTFNQSKL	NSFITQYSTG	QVSVEIEWEL	QKENSKRWNP	EIQYTSNYK	STSVDFAVNT	720
EGVYSEPRPI	GTRYLTRNL					739

SEQ ID NO: 504 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 504

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLNGGVV	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQ	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPII	KNTVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP	EIQYTSNYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 505 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 505

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEMPIG	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQ	RDVYLQGPW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPII	KNTVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP	EIQYTSNYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 506 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 506

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEDMGT	INFAWTAGTK	YHLNNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYGI	IVADNLQQQNT	TAPQIGTVNS	600
QGALPGMVWQ	NRDVLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPII	IKNTVPADP	660
PPTTFNQSKL	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNP	EIQYTSNYK	TSVDFAVNTG	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 507 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 507
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLNGGV VNFPAWTAGT YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 508      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 508
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLEMPI GNFPAWTAGT YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 509      moltype = AA length = 739
FEATURE           Location/Qualifiers
REGION           1..739
                 note = AAV capsid variant
source          1..739
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 509
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLEDMG TINFAWTAGT KYHLNGRNSL ANPGIAMATH KDDEERFFPS 540
NGILIFGKQN AARDNADYS VMLTSEEEIK TNPVATEEY GIVADNVMEP TRAPQIGTVN 600
SQGALPGMVW QNRDVYLQGP IWAKIPHTDG NFPSPMLMGG FGLKHPPPQI LIKNTVPVAD 660
PPTTFNQSKL NSFITQYSTG QVSVEIEWEL QKENSKRWNP EIQYTSNYYS STSVDFAVNT 720
EGVYSEPRPI GTRYLTRNL 739

SEQ ID NO: 510      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 510
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTNNGRGV TLGFSQGGPN TMANQAKNWL 480

```

-continued

```

PGPCYRQQRV STYPLNGGVV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 511      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 511
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDNRF HCHFSPRDWQ 300
RLINNWGFR PKRLSPKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLEMPIG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 512      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 512
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDNRF HCHFSPRDWQ 300
RLINNWGFR PKRLSPKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLEDMGT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSVDM MLTSEEEIKT TNPVATEEYGI IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQN NRDVYLQGIW WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 513      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 513
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDS 180
SVPDPQLG EPPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPPPAD DVFMIPQYGY LTLNNGSQAV RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLNGGVV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AALNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 514      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant

```

-continued

```

source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 514
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLEMPIG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTPVPADPP 660
TTFNQSKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 515        moltype = AA length = 738
FEATURE              Location/Qualifiers
REGION              1..738
                    note = AAV capsid variant
source              1..738
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 515
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLEDMGT INFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLGQPI WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPADP 660
PTTFNQSKLN SFIQTQYSTGQ VSVEIEWELQ KENSKRWNP EIQYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 516        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION              1..736
                    note = AAV capsid variant
source              1..736
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 516
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGRVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLNGGVVN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEG 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 517        moltype = AA length = 736
FEATURE              Location/Qualifiers
REGION              1..736
                    note = AAV capsid variant
source              1..736
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 517
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360

```

-continued

```

QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEMPIGN FAWTAGTKYH LNDRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDM TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PPSPLMGGFGL KHPPPQILIK NTPVPADPPT 660
TFNQSKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 518      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 518
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEMPIGN FAWTAGTKY HLNDRNSLANP GIAMATHKDD DEERFFPSNGI 540
LIFGKQNAAR DNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQNR DVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPADPPT 660
TFNQSKLNSF ITQYSTGQVS SVEIEWELQK ENSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 737

```

```

SEQ ID NO: 519      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 519
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEMPIGN FAWTAGTKY HLNDRNSLANP GIAMATHKDD DEERFFPSNGI 540
LIFGKQNAAR DNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQNR DVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPADPPT 660
TFNQSKLNSF ITQYSTGQVS SVEIEWELQK ENSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 737

```

```

SEQ ID NO: 520      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 520
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNDRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEMPIGN FAWTAGTKY HLNDRNSLANP GIAMATHKDD DEERFFPSNGI 540
LIFGKQNAAR DNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQNR DVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPADPPT 660
TFNQSKLNSF ITQYSTGQVS SVEIEWELQK ENSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 737

```

```

SEQ ID NO: 521      moltype = AA length = 738
FEATURE           Location/Qualifiers

```


-continued

REGION 1..738
note = AAV capsid variant

source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 521

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEDMGT	INFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSV	MLTSEEEIKT	TNPVATEEYV	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
PTTFNQSKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYKYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 522 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
note = AAV capsid variant

source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 522

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLNGGVN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGP	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNP	YTSNYKYSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 523 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
note = AAV capsid variant

source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 523

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNFRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRGRVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLEMIGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVML	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGP	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPPT	660
TFNQSKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNP	YTSNYKYSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 524 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 524

MAADGYLPDW	LEDNLSEKIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240

-continued

TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRST	QTTSNNGRGT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLEDMGTI	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDVYLDSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLDGPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
TTFNQSKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 525 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 525

MAADGYLPDW	LEDNLSEIGIR	EWALKKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEP	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNNGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLQNNNS	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDVYLDSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLDGPIW	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPP	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 526 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 526

MAADGYLPDW	LEDNLSEIGIR	EWALKKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEP	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLENFK	ANFAWTAGTK	YHLNNGRNSLA	NGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLDGPI	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPFI	IQYTSNYKKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 527 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 527

MAADGYLPDW	LEDNLSEIGIR	EWALKKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEP	QERLQEDTSF	GGNLGRAVFPQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLGDHS	ANFAWTAGTK	YHLNNGRNSLA	NGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLDGPI	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPFI	IQYTSNYKKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

-continued

SEQ ID NO: 528 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 528
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTYPLASGS GNAFWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 529 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 529
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTYPLGKE QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 530 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 530
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RNLFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQOR VSTYPLSGTN QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP WAKIPHTDGN FHPSPLMGGF GLKHPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVANTE 720
GVYSEPRPIG TRYLTRNL 738

SEQ ID NO: 531 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 531
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120

-continued

AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLRDGQ	LNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYSK	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 532 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 532

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLADTG	TNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYSK	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 533 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 533

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLQNNN	SNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPTR	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYSK	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 534 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 534

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLQAGDNPY	LRYNHADA EF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFDNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VFFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRGRV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLQNNNS	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP	AKIPHTDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPEI	QYTSNYYSKST	SVDFAVNTEG	720

-continued

VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 535 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 535
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFRL PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STYPLENFKY NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQV LNSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 536 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 536
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFRL PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STYPLGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQV LNSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 537 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 537
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
 ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
 RLINNNWGFRL PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRV STYPLASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNAA RDNADYSQV LNSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
 GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 538 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 538

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLLGKEQ	NFAWTAGTKY	HLNRRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 539 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLSGTNQ	NFAWTAGTKY	HLNRRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 540 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLRDGQL	NFAWTAGTKY	HLNRRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 541 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPTSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYFDFNRF	HCHFSPRDWQ	300
RLINNNWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNRRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLADTGT	NFAWTAGTKY	HLNRRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQAV	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600

-continued

GALPGMVWQ	RDVYLQGP	AKIPHTDGN	HPSPLMGGF	LKHPPPQIL	KNTVPVADP	660
STFNGDKLN	FITQYSTGQ	SVEIEWELQ	ENSKRWNPE	QYTSNYKST	SVDFAVNTEG	720
VYSEPRPIG	RYLTRNL					737

SEQ ID NO: 542 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 542						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCPLPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLENFK	YNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTVPVADP	660
RSTFNGDKLN	SFITQYSTGQ	SVEIEWELQ	KENSKRWNPE	IQYTSNYKST	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 543 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 543						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCPLPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLGDHS	ANFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTVPVADP	660
RSTFNGDKLN	SFITQYSTGQ	SVEIEWELQ	KENSKRWNPE	IQYTSNYKST	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 544 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 544						
MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFP	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPPLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITSTRTWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYDFPNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCPLPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLASGS	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTVPVADP	660
RSTFNGDKLN	SFITQYSTGQ	SVEIEWELQ	KENSKRWNPE	IQYTSNYKST	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 545 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein

-continued

```

organism = synthetic construct
SEQUENCE: 545
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLLGKE QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 546      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 546
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLSGTN QNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 547      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 547
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLRDGQ LNFATWAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 548      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 548
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFGNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFPQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNHWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCPLPPFA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480

```


-continued

```

LPGPCYRQQR VSTYPLADTG TNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFPFSN 540
GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNVMEPT RAPQIGTVNS 600
QGALPGMVWQ NRDVYLGQPI WAKIPHTDGN HPSPLMGGF GLKHPPPQIL IKNTPVPADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYS TSVDFAVNT 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 549      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 549
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLENFYK NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFPFSNG 540
ILIFGKQNAA RDNADYSV MLTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYSKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 550      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 550
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFPFSNG 540
ILIFGKQNAA RDNADYSV MLTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYSKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 551      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source           1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 551
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPPDSSTGI GKKGQQPARK RLFNGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFPNRF HCHFSPRDWQ 300
RLINNNWGFPR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPIQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFPFSNG 540
ILIFGKQNAA RDNADYSV MLTSEEEIKT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYSKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 552      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant

```

-continued

```

source                1..737
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 552
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLLLGKIQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 553      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 553
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLSGTNQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 554      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 554
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLRDGQL NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSQAV LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 555      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 555
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360

```

-continued

HQGCLPPPPA	DVFMIPOQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLADTGT	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 556 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 556

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLQNNNS	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 557 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 557

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSGRGT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLQNNNS	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSDVML	TSEEEIKTTN	PVATEEYGI	ADNLQQQNTA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNF	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPFIQ	YTSNYYKSTS	VDFAVNTG	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 558 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 558

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKCR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYFDNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLENFYK	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSDVM	LTSEEEIKTT	NPVATEEYGI	VADNLQQQNT	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 559 moltype = AA length = 737
 FEATURE Location/Qualifiers

-continued

```

REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 559
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLGDHSA NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 560        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 560
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLASGSG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 561        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 561
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLLGKEQ NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNAA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNLQQQNT APQIGTVNSQ 600
GALPGMVWQN RDVYLQGPW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTFPVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

SEQ ID NO: 562        moltype = AA length = 737
FEATURE              Location/Qualifiers
REGION                1..737
                      note = AAV capsid variant
source                1..737
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 562
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240

```

-continued

```

TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLSGTNQ  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSVDM  LTSEEEIKTT  NPVATEEYGI  VADNLQQQNT  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPHTDGNF  HPSPLMGGFG  LKHPPPQILI  KNTPVPADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTG  720
VYSEPRPIGT  RYLTRNL  737

```

```

SEQ ID NO: 563      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 563
MAADGYLPDW  LEDNLSEGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVPQ  120
AKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLRQDQL  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSVDM  LTSEEEIKTT  NPVATEEYGI  VADNLQQQNT  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPHTDGNF  HPSPLMGGFG  LKHPPPQILI  KNTPVPADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTG  720
VYSEPRPIGT  RYLTRNL  737

```

```

SEQ ID NO: 564      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 564
MAADGYLPDW  LEDNLSEGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVPQ  120
AKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLADTGT  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSVDM  LTSEEEIKTT  NPVATEEYGI  VADNLQQQNT  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPHTDGNF  HPSPLMGGFG  LKHPPPQILI  KNTPVPADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTG  720
VYSEPRPIGT  RYLTRNL  737

```

```

SEQ ID NO: 565      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

```

```

SEQUENCE: 565
MAADGYLPDW  LEDNLSEGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVPQ  120
AKRLLLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLQNNNS  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSVDM  LTSEEEIKTT  NPVATEEYGI  VADNVMPEPR  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPHTDGNF  HPSPLMGGFG  LKHPPPQILI  KNTPVPADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTG  720
VYSEPRPIGT  RYLTRNL  737

```

-continued

```

SEQ ID NO: 566      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 566
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLQNNNSN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 567      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 567
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLENFKYN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 568      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 568
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLGDHSAN FAWTAGTKYH LNGRNSLAMP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 569      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 569
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120

```

-continued

```

AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQYGL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLASGSGN FAWTAGTKYH LNCRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 570      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 570
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQYGL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLLGKEQN FAWTAGTKYH LNCRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 571      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 571
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQYGL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLSGTNQN FAWTAGTKYH LNCRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 572      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 572
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFGQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQYGL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLRDGQLN FAWTAGTKYH LNCRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720

```

-continued

YSEPRPIGTR YLTRNL 736

SEQ ID NO: 573 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = AAV capsid variant
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 573
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLSGAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGT LGFSGGGPNT MANQAKNWL 480
 GPCYRQQRVV TYPLADTGTN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
 LIFGKQNAAR DNADYSDVML TSEEEIKTTN PVATEEYGI ADNLQQQNTA PQIGTVNSQG 600
 ALPGMVWQNR DVYLQGP IWA KIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
 TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 736

SEQ ID NO: 574 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 574
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLSGAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRVV STYPLENFYK NFAWTAGTKY HLNGRNSLANP GIAMATHKDD DEERFFPSNG 540
 ILIFGKQNAAR DNADYSDVML TSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQG 600
 GALPGMVWQNR RDVYLQGP IWA AKIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 737

SEQ ID NO: 575 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 575
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
 LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLSGAH 360
 QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
 PGPCYRQQRVV STYPLGDHSA NFAWTAGTKY HLNGRNSLANP GIAMATHKDD DEERFFPSNG 540
 ILIFGKQNAAR DNADYSDVML TSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQG 600
 GALPGMVWQNR RDVYLQGP IWA AKIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST VDFAVNTEGV 720
 YSEPRPIGTR YLTRNL 737

SEQ ID NO: 576 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 576

-continued

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA A	RDNADYS DVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP IW	AKIPH TDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 577 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA A	RDNADYS DVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP IW	AKIPH TDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 578 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA A	RDNADYS DVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGP IW	AKIPH TDGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNP EI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 579 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAV FQ	120
AKKRLLLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAK KR	LNFGQTDGSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLASGSG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA A	RDNADYS DVM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600

-continued

```

GALPGMVWQON RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 580      moltype = AA length = 737
FEATURE           Location/Qualifiers
REGION           1..737
                 note = AAV capsid variant
source          1..737
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 580
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYDFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTGGTANTQ TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLADTGT NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
LIFGKQNAAR RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
GALPGMVWQON RDVYLGQPIW AKIPHTDGNF HPSPLMGGFG LKHPPPQILI KNTVPVADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL 737

```

```

SEQ ID NO: 581      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 581
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYDFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGVTV LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLENFKYN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDMV TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 582      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 582
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYDFDNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNRGVTV LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLGDHNSAN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVDMV TSEEEIKTTN PVATEEYGIV ADNVMETRA PQIGTVNSQG 600
ALPGMVWQNR DVYLGQPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 583      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein

```

-continued

```

organism = synthetic construct
SEQUENCE: 583
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLASGSGN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 584      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 584
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLLGKQON FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 585      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 585
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TYPLSGTNQN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNPH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 586      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 586
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRILLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFPR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOQGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480

```

-continued

```

GPCYRQQRVS TYPLRDGQLN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGVV ADNVMPEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 587      moltype = AA length = 736
FEATURE           Location/Qualifiers
REGION           1..736
                 note = AAV capsid variant
source          1..736
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 587
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPFY KYLGPGNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF QERLKEDTSF GGNLGRAVFQ 120
AKKRLEPLG LVVEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQGTGDS 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDFNRFH CHFSPRDWQR 300
LNNNNWGFPR KRLSFKLFNI IQVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRLMNPFI DQYLYLSRT QTTSNRRGVT LGFSQGGFNT MANQAKNWL 480
GPCYRQQRVS TYPLADTGTN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGVV ADNVMPEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

```

```

SEQ ID NO: 588      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 588
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRLEPLG LVVEGAKTAP GKRRPVEPSP QRSPPSSSTGI GKKGQOPARK RLNFQGTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRI 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLNNNNWGFPR KRLSFKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPFI IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLNGGV VNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYV IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP I QYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 589      moltype = AA length = 738
FEATURE           Location/Qualifiers
REGION           1..738
                 note = AAV capsid variant
source          1..738
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 589
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPFY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRLEPLG LVVEGAKTAP GKRRPVEPSP QRSPPSSSTGI GKKGQOPARK RLNFQGTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRI 240
ITSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
RLNNNNWGFPR KRLSFKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFPFHSSYAHS QSLDRLMNPFI IDQYLYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLEMPI GNFPAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
GILIFGKQNA ARDNADYSDV MLTSEEEIKT TNPVATEEYV IVADNLQQQN TAPQIGTVNS 600
QGALPGMVWQ NRDVYLQGP I WAKIPHTDGN FHPSPLMGGF GLKHPPPQIL IKNTVPVADP 660
RSTFNGDKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNP I QYTSNYYKS TSVDFAVNTE 720
GVYSEPRPIG TRYLTRNL 738

```

```

SEQ ID NO: 590      moltype = AA length = 739
FEATURE           Location/Qualifiers
REGION           1..739
                 note = AAV capsid variant

```

-continued

```

source                1..739
                    mol_type = protein
                    organism = synthetic construct

SEQUENCE: 590
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTGGTANT QTLGFSQGGP NTMANQAKNW 480
LPGPCYRQQR VSTYPLEDMG TINFAWTAGT KYHLNGRNSL ANPGIAMATH KDDEERFFPS 540
NGILIFGKQN AARDNADYSY VMLTSEEEIK TTNPVATEEY GIVADNLQQQ NTAPQIGTVN 600
SQGALPGMVW QNRDVYLQGP IWAKI PHTDG NPHPSPLMGG FGLKHPPII LIKNTVPPAD 660
PRSTFNGDKL NSFITQYSTG QVSVEIEWEL QKENSKRWNP EIQTYSNYYK STSVDFAVNT 720
EGVYSEPRPI GTRYLTRNL                                     739

SEQ ID NO: 591      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 591
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLNGGVV NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AARDNADYSY VMLTSEEEIK TTNPVATEEY GIVADNLQQQ NTAPQIGTVN 600
GALPGMVWQN RDVYLQGP IWAKI PHTDG NPHPSPLMGG FGLKHPPII LIKNTVPPAD 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL                                     737

SEQ ID NO: 592      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 592
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
HQGCLPPPPA DVFMIPOQGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
VFFHSSYAHS QSLDRLMNPL IDQYLYLSR TQTTSNGRGV TLGFSQGGPN TMANQAKNWL 480
PGPCYRQQRV STYPLEMPIG NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
ILIFGKQNA AARDNADYSY VMLTSEEEIK TTNPVATEEY GIVADNLQQQ NTAPQIGTVN 600
GALPGMVWQN RDVYLQGP IWAKI PHTDG NPHPSPLMGG FGLKHPPII LIKNTVPPAD 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
VYSEPRPIGT RYLTRNL                                     737

SEQ ID NO: 593      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

SEQUENCE: 593
MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQKQD DGRGLVLPGY KYLGPFNGLD 60
KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADAEF QERLQEDTSF GGNLGRAVFQ 120
AKKRVLEPLG LVEEGAKTAP GKKRPVEPSP QRSPTSSTGI GKKGQQPARK RLNFGQTGDS 180
ESVDPDPQLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD GVGSSSGNWH CDSTWLGDRV 240
ITTSRTRWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYDFNRF HCHFSPRDWQ 300
RLINNNWGFGR PKRLSFKLFN IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360

```

-continued

HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEDMGT	INFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNLQQQN	TAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 594 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 594

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLNGV	INFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 595 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 595

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLEMPI	GNFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSVD	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHTDGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSVEIEWELQ	KENSKRWNPE	IQYTSNYYS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 596 moltype = AA length = 739
 FEATURE Location/Qualifiers
 REGION 1..739
 note = AAV capsid variant
 source 1..739
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 596

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALEHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNNGWGR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFOFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTGGGTANT	QTLGFSQGGP	NTMANQAKNW	480
LPGPCYRQQR	VSTYPLEDMG	TINFAWTAGT	KYHLNGRNSL	ANPGIAMATH	KDDEERFFPS	540
NGILIFGKQN	AARDNADYSVD	VMLTSEEEIK	TNPVATEEY	GIVADNVMEP	TRAPQIGTVN	600
SQGALPGMVW	QNRDVYLQGP	WAKIPHTDGN	NFHPSPLMGG	FGLKHPPPQIL	LKINTPVPAD	660
PRSTFNGDKL	NSFITQYSTG	QVSVEIEWEL	QKENSKRWNP	EIQYTSNYYS	STSVDFAVNT	720
EGVYSEPRPI	GTRYLTRNL					739

SEQ ID NO: 597 moltype = AA length = 737
 FEATURE Location/Qualifiers

-continued

REGION 1..737
note = AAV capsid variant

source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 597

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLNGGVV	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 598 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 598

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLNGGVV	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
VYSEPRPIGT	RYLTRNL					737

SEQ ID NO: 599 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
note = AAV capsid variant
source 1..738
mol_type = protein
organism = synthetic construct

SEQUENCE: 599

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	KPKANQQKQD	DGRGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLQAGDNPY	LRYNHADAEF	QERLQEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QRSPDSSTGI	GKKGQQPARK	RLNFGQTGDS	180
ESVDPDPQLG	EPPAAPSGVG	PNTMAAGGGA	PMADNNEGAD	GVGSSSGNWH	CDSTWLGDRV	240
ITTSRTRWAL	PTYNNHLYKQ	ISNGTSGGAT	NDNTYFGYST	PWGYPDFNRF	HCHFSPRDWQ	300
RLINNHWGFR	PKRLSFKLFN	IQVKEVTQNE	GTKTIANNLT	STIQVFTDSE	YQLPYVLGSA	360
HQGCLPPPPA	DVFMIPQYGY	LTLNNGSQAV	GRSSFYCLEY	FPSQMLRTGN	NFQFTYTFED	420
VPFHSSYAHS	QSLDRLMNPL	IDQYLYLSR	TQTTSNGRGV	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEDMGT	NFAWTAGTKY	HLNNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
GILIFGKQNA	RDNADYSQV	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
QALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
RSTFNGDKLN	SFITQYSTGQ	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
GVYSEPRPIGT	RYLTRNL					738

SEQ ID NO: 600 moltype = AA length = 737
FEATURE Location/Qualifiers
REGION 1..737
note = AAV capsid variant
source 1..737
mol_type = protein
organism = synthetic construct

SEQUENCE: 600

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQKQD	NARGLVLPGY	KYLGPFNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRVLEPLG	LVEEGAKTAP	GKKRPVEPSP	QEPDSSAGIG	KSGAQPAPKR	LNFGQTGDS	180
SVPDPQLG	EPPAAPSGVG	PNTMAAGGGA	MADNNEGADG	GVGSSSGNWH	DSTWLGDRVI	240

-continued

```

TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLNGGVV  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSDVM  LTSEEEIKTT  NPVATEEYGI  VADNLQQQNT  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPTHGDNF  HPSPLMGGFG  LKHPPPQILI  KNTVPVADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTEG  720
VYSEPRPIGT  RYLTRNL  737

```

```

SEQ ID NO: 601      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION            1..737
                  note = AAV capsid variant
source            1..737
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 601
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFPQ  120
AKKRILLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLEMPIG  NFAWTAGTKY  HLNGRNSLAN  PGIAMATHKD  DEERFFPSNG  540
ILIFGKQNA  RDNADYSDVM  LTSEEEIKTT  NPVATEEYGI  VADNLQQQNT  APQIGTVNSQ  600
GALPGMVWQN  RDVYLQGPW  AKIPTHGDNF  HPSPLMGGFG  LKHPPPQILI  KNTVPVADPR  660
STFNGDKLNS  FITQYSTGQV  SVEIEWELQK  ENSKRWNPEI  QYTSNYKST  SVDFAVNTEG  720
VYSEPRPIGT  RYLTRNL  737

```

```

SEQ ID NO: 602      moltype = AA length = 738
FEATURE            Location/Qualifiers
REGION            1..738
                  note = AAV capsid variant
source            1..738
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 602
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFPQ  120
AKKRILLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTGGTANTQ  TLGFSQGGPN  TMANQAKNWL  480
PGPCYRQQRV  STYPLEDMGT  NFAWTAGTKY  YHLNGRNSLA  NPGIAMATHK  DDEERFFPSN  540
GILIFGKQNA  ARDNADYSDV  MLTSEEEIKT  TNPVATEEYG  IVADNLQQQN  TAPQIGTVNS  600
QGALPGMVWQ  NRDVYLQGP  WAKIPTHGDN  HPSPLMGGFG  GLKHPPPQIL  IKNTVPVADP  660
RSTFNGDKLN  SFITQYSTGQ  VSVEIEWELQ  KENSKRWNPE  IQYTSNYKKS  TSVDFAVNTE  720
GVYSEPRPIG  TRYLTRNL  738

```

```

SEQ ID NO: 603      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION            1..736
                  note = AAV capsid variant
source            1..736
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 603
MAADGYLPDW  LEDNLSEIGIR  EWWALKPGAP  QPKANQQHQD  NARGLVLPGY  KYLGPNGGLD  60
KGEPVNAADA  AALEHDKAYD  QQLKAGDNPY  LKYNHADAEF  QERLKEDTSF  GGNLGRAVFPQ  120
AKKRILLEPLG  LVEEAAKTAP  GKRRPVEQSP  QEPDSSAGIG  KSGAQPAKRR  LNFQQTGDSE  180
SVPDPQPLGE  PPAAPSGVGP  NTMAAGGGAP  MADNNEGADG  VGSSSGNWHC  DSTWLGDRVI  240
TTSTRTWALP  TYNNHLYKQI  SNGTSGGATN  DNTYFGYSTP  WGYPDFNRFH  CHFSPRDWQR  300
LINNNWGFRP  KRLSFKLFNI  QVKEVTQNEG  TKTIANNLTS  TIQVFTDSEY  QLPYVLGSAH  360
QGCLPPFPAD  VFMIPQYGYL  TLMNGSQAVG  RSSFYCLEYF  PSQMLRTGNN  FQPTYTFEDV  420
PFHSSYAHSQ  SLDRLMNPLI  DQYLYLSRT  QTTSNRGT  LGFSQGGFNT  MANQAKNWL  480
GPCYRQQRVS  TYPLNGGVV  FAWTAGTKYH  LNGRNSLANP  GIAMATHKDD  EERFFPSNGI  540
LIFGKQNAAR  DNADYSDVML  TSEEEIKTTN  PVATEEYGI  ADNLQQQNTA  PQIGTVNSQG  600
ALPGMVWQNR  DVYLQGPWA  KIPHTDGNFH  PPSPLMGGFGL  KHPPPQILIK  NTPVPADPRS  660
TFNGDKLNSF  ITQYSTGQVS  VEIEWELQKE  NSKRWNPEIQ  YTSNYKST  VDFAVNTEGV  720
YSEPRPIGTR  YLTRNL  736

```


-continued

```

SEQ ID NO: 604      moltype = AA length = 736
FEATURE            Location/Qualifiers
REGION             1..736
                   note = AAV capsid variant
source             1..736
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 604
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRMLNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEMIGN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNLQQQNTA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNF HPSPLMGGFGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 605      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 605
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRMLNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLEDMGTI NFAWTAGTKY HLNGRNSLANP GIAMATHKD DEERFFPSNG 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN NPVATEEYGI VADNLQQQNTA APQIGTVNSQ 600
GALPGMVWQNR RDVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
YSEPRPIGTR RYLTRNL 737

SEQ ID NO: 606      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 606
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120
AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAKRR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYPDFNRFH CHFSPRDWQR 300
LINNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
PFHSSYAHSQ SLDRMLNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWL 480
GPCYRQQRVS TYPLNGGVV NFAWTAGTKY HLNGRNSLANP GIAMATHKD DEERFFPSNG 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN NPVATEEYGI VADNVMPEPR APQIGTVNSQ 600
GALPGMVWQNR RDVYLQGPPIW AKIPHTDGNF HPSPLMGGFGL LKHPPPQILI KNTVPADPR 660
STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
YSEPRPIGTR RYLTRNL 737

SEQ ID NO: 607      moltype = AA length = 737
FEATURE            Location/Qualifiers
REGION             1..737
                   note = AAV capsid variant
source             1..737
                   mol_type = protein
                   organism = synthetic construct

SEQUENCE: 607
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVFQ 120

```

-continued

AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEMPIG	NFAWTAGTKY	HLNGRNSLAN	PGIAMATHKD	DEERFFPSNG	540
ILIFGKQNA	RDNADYSVDM	LTSEEEIKTT	NPVATEEYGI	VADNVMEPTR	APQIGTVNSQ	600
GALPGMVWQN	RDVYLQGPW	AKIPHDTGNF	HPSPLMGGFG	LKHPPPQILI	KNTPVPADPR	660
STFNGDKLNS	FITQYSTGQV	SVEIEWELQK	ENSKRWNPFI	QYTSNYYKST	SVDFAVNTEG	720
YVSEPRPIGT	RYLTRNL					737

SEQ ID NO: 608 moltype = AA length = 738
FEATURE Location/Qualifiers
REGION 1..738
 note = AAV capsid variant
source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 608

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTGGTANTQ	TLGFSQGGPN	TMANQAKNWL	480
PGPCYRQQRV	STYPLEDMGT	INFAWTAGTK	YHLNGRNSLA	NPGIAMATHK	DDEERFFPSN	540
GILIFGKQNA	ARDNADYSDV	MLTSEEEIKT	TNPVATEEYG	IVADNVMEPT	RAPQIGTVNS	600
QGALPGMVWQ	NRDVYLQGP	WAKIPHDTGN	FHPSPLMGGF	GLKHPPPQIL	IKNTPVPADP	660
RSTFNGDKLN	SFITQYSTGQ	VSV EIEWELQ	KENSKRWNP	IQYTSNYYKS	TSVDFAVNTE	720
GVYSEPRPIG	TRYLTRNL					738

SEQ ID NO: 609 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
 note = AAV capsid variant
source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 609

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTNNGRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLNGGVVN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNPH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPFIQ	YTSNYYKSTS	VDFAVNTEG	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 610 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
 note = AAV capsid variant
source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 610

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPGY	KYLGPGNGLD	60
KGEPVNAADA	AAL EHDKAYD	QQLKAGDNPY	LKYNHADA EF	QERLKEDTSF	GGNLGRAVFQ	120
AKKRILLEPLG	LVEEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPDFNRFH	CHFSPRDWQR	300
LINNNWGFRP	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQFTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTNNGRGVT	LGFSQGGPNT	MANQAKNWL	480
GPCYRQQRVS	TYPLEMPIGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVDM	TSEEEIKTTN	PVATEEYGIV	ADNVMEPTR	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPW	KIPHDTGNPH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPFIQ	YTSNYYKSTS	VDFAVNTEG	720

-continued

YSEPRPIGTR YLTRNL 736

SEQ ID NO: 611 moltype = AA length = 737
 FEATURE Location/Qualifiers
 REGION 1..737
 note = AAV capsid variant
 source 1..737
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 611
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLPGNGLD 60
 KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADADEF QERLKEDTSF GGNLGRAVFQ 120
 AKKRLLLEPLG LVEEAAKTAP GKRRPVEQSP QEPDSSAGIG KSGAQPAAKR LNFQQTGDSE 180
 SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
 TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDFNRFH CHFSPRDWQR 300
 LNNNWGFRP KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLGSAH 360
 QGCLPPFPAD VFMIPQYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQFTYTFEDV 420
 PFHSSYAHSV SLDRLMNP LI DQVLYYLSRT QTTSNRGT LGFSQGGPNT MANQAKNWLP 480
 GPCYRQQRVS TYPLEDMGTI NFAWTAGTKY HLNGRNSLAN PGIAMATHKD DEERFFPSNG 540
 ILIFGKQNA RDNADYSVDM LTSEEEIKTT NPVATEEYGI VADNVMEPTR APQIGTVNSQ 600
 GALPGMWQON RDVYLQGP IW AKIPHDTGNF HPSPLMGGFG LKHPPPQILI KNTPVPADPR 660
 STFNGDKLNS FITQYSTGQV SVEIEWELQK ENSKRWNPEI QYTSNYYKST SVDFAVNTEG 720
 YSEPRPIGT RYLTRNL 737

SEQ ID NO: 612 moltype = AA length = 738
 FEATURE Location/Qualifiers
 REGION 1..738
 note = AAV capsid variant
 source 1..738
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 612
 MAADGYLPDW LEDNLSEGIR EWWALKPGAP KPKANQQQKD DGRGLVLPGY KYLGPFGNLD 60
 KGEPVNAADA AALEHDKAYD QQLQAGDNPY LRYNHADADEF QERLQEDTSF GGNLGRAVFQ 120
 AKKRVLLEPLG LVEEGAKTAP GKRRPVEPSP QRSPDSSTGI GKKGQQPARK RLNFQQTGDS 180
 ESVPDPQPLG EPPAAPSGVG PNTMAAGGGA PMADNNEGAD VGSSSGNWH CDSTWLGDRV 240
 ITTSTRTWAL PTYNNHLYKQ ISNGTSGGAT NDNTYFGYST PWGYFDFNRF HCHFSPRDWQ 300
 RLNNNWGFR PKRLSFKLFNI IQVKEVTQNE GTKTIANNLT STIQVFTDSE YQLPYVLGSA 360
 HQGCLPPPPA DVMIPQYGY LTLNNGSQAV GRSSFYCLEY FPSQMLRTGN NFQFTYTFED 420
 VPFHSSYAHS QSLDRLMNP LI IDQVLYYLSR TQTTGGTANT QTLGFSQGGP NTMANQAKNW 480
 LPGPCYRQOR VSTYPLQNNN SNFAWTAGTK YHLNGRNSLA NPGIAMATHK DDEERFFPSN 540
 GILIFGKQNA ARDNADYSV MLTSEEEIKT TNPVATEEYG IVADNLQQON TAPQIGTVNS 600
 QGALPGMWQO NRDVYLQGP I WAKIPHDTGN FHPSPLMGGF GLKHPPPQIL IKNTVPADP 660
 PTTFNQSKLN SFITQYSTGQ VSVEIEWELQ KENSKRWNPE IQYTSNYYKS TSVDFAVNTE 720
 GYSEPRPIG TRYLTRNL 738

SEQ ID NO: 613 moltype = AA length = 7
 FEATURE Location/Qualifiers
 source 1..7
 mol_type = protein
 note = Parvovirus Adeno-associated virus
 organism = unidentified

SEQUENCE: 613
 SASTGAS 7

SEQ ID NO: 614 moltype = AA length = 10
 FEATURE Location/Qualifiers
 source 1..10
 mol_type = protein
 note = Parvovirus Adeno-associated virus
 organism = unidentified

SEQUENCE: 614
 VFMIPQYGYL 10

SEQ ID NO: 615 moltype = AA length = 9
 FEATURE Location/Qualifiers
 source 1..9
 mol_type = protein
 note = Parvovirus Adeno-associated virus
 organism = unidentified

SEQUENCE: 615
 NQSGSAQNK 9

SEQ ID NO: 616 moltype = length =
 SEQUENCE: 616
 000

-continued

SEQ ID NO: 617	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 617		
KTDNNSN		8
SEQ ID NO: 618	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 618		
KDDEDKF		7
SEQ ID NO: 619	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 619		
SAGASN		6
SEQ ID NO: 620	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 620		
STDPATGDVH		10
SEQ ID NO: 621	moltype = length =	
SEQUENCE: 621		
000		
SEQ ID NO: 622	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 622		
DNNGLYT		7
SEQ ID NO: 623	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 623		
SQSGAS		6
SEQ ID NO: 624	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 624		
VFMVPQYGYL		10
SEQ ID NO: 625	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 625		
TPSGTTQS		9

-continued

SEQ ID NO: 626	moltype = length =	
SEQUENCE: 626		
000		
SEQ ID NO: 627	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 627		8
SADNNNSE		
SEQ ID NO: 628	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 628		7
KDDEEKF		
SEQ ID NO: 629	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 629		6
GSEKTN		
SEQ ID NO: 630	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 630		10
NRQAATADVN		
SEQ ID NO: 631	moltype = length =	
SEQUENCE: 631		
000		
SEQ ID NO: 632	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 632		7
DTINGVYS		
SEQ ID NO: 633	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 633		6
SQSGAS		
SEQ ID NO: 634	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 634		10
VFMVPQYGYL		
SEQ ID NO: 635	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	

-continued

SEQUENCE: 635 TTSGTTNQS	note = Parvovirus Adeno-associated virus organism = unidentified	9
SEQ ID NO: 636 SEQUENCE: 636 000	moltype = length =	
SEQ ID NO: 637 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 637 ANDNNNSN		8
SEQ ID NO: 638 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 638 KDDEEKP		7
SEQ ID NO: 639 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 639 GTTASN		6
SEQ ID NO: 640 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 640 NTAPTGTVM		10
SEQ ID NO: 641 SEQUENCE: 641 000	moltype = length =	
SEQ ID NO: 642 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 642 DTNGVYS		7
SEQ ID NO: 643 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 643 RLGESLQS		8
SEQ ID NO: 644 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 644 VFMVPQYGYC		10

-continued

SEQ ID NO: 645	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 645		
GTTLNAGTA		9
SEQ ID NO: 646	moltype = length =	
SEQUENCE: 646		
000		
SEQ ID NO: 647	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
source	1..12	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 647		
ANQNYKIPAT GS		12
SEQ ID NO: 648	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 648		
GPADSKF		7
SEQ ID NO: 649	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 649		
QNGNTA		6
SEQ ID NO: 650	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 650		
SNLPTVDRLT		10
SEQ ID NO: 651	moltype = length =	
SEQUENCE: 651		
000		
SEQ ID NO: 652	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 652		
DAAGKYT		7
SEQ ID NO: 653	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 653		
EIKSGSVDGS		10
SEQ ID NO: 654	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	

-continued

SEQUENCE: 654 VFVLPQYGYA	organism = unidentified	10
SEQ ID NO: 655 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 655 STNNTGGVQ		9
SEQ ID NO: 656 SEQUENCE: 656 000	moltype = length =	
SEQ ID NO: 657 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 657 SGVNRAS		7
SEQ ID NO: 658 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 658 LQGSNTY		7
SEQ ID NO: 659 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 659 ANPGTTAT		8
SEQ ID NO: 660 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 660 TTAPATGTYN		10
SEQ ID NO: 661 SEQUENCE: 661 000	moltype = length =	
SEQ ID NO: 662 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 662 DSTGEYR		7
SEQ ID NO: 663 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 663 SASTGAS		7
SEQ ID NO: 664	moltype = AA length = 10	

-continued

FEATURE	Location/Qualifiers	
source	1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 664 VFMIPQYGYL		10
SEQ ID NO: 665 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 665 NQGSAQNK		9
SEQ ID NO: 666 SEQUENCE: 666 000	moltype = length =	
SEQ ID NO: 667 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 667 KTDNNNSN		8
SEQ ID NO: 668 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 668 KDDKDKF		7
SEQ ID NO: 669 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 669 SAGASN		6
SEQ ID NO: 670 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 670 STDPATGDVH		10
SEQ ID NO: 671 SEQUENCE: 671 000	moltype = length =	
SEQ ID NO: 672 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 672 DNNGLYT		7
SEQ ID NO: 673 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	

-continued

SEQUENCE: 673 SETAGST		7
SEQ ID NO: 674 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 674 VFMIPQYGYL		10
SEQ ID NO: 675 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 675 NPGGTAGNR		9
SEQ ID NO: 676 SEQUENCE: 676 000	moltype = length =	
SEQ ID NO: 677 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 677 LDQNNNSN		8
SEQ ID NO: 678 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 678 KDDEDRF		7
SEQ ID NO: 679 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 679 GATNKT		6
SEQ ID NO: 680 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 680 NTAAQTQVVN		10
SEQ ID NO: 681 SEQUENCE: 681 000	moltype = length =	
SEQ ID NO: 682 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 682 DSQGVYS		7
SEQ ID NO: 683 FEATURE	moltype = AA length = 8 Location/Qualifiers	

-continued

source	1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 683 NGTSGGAT		8
SEQ ID NO: 684 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 684 VFMIPQYGYL		10
SEQ ID NO: 685 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 685 TTGGTANTQ		9
SEQ ID NO: 686 SEQUENCE: 686 000	moltype = length =	
SEQ ID NO: 687 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 687 TGQNNNSN		8
SEQ ID NO: 688 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 688 KDDEERF		7
SEQ ID NO: 689 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 689 NAARDN		6
SEQ ID NO: 690 FEATURE source	moltype = AA length = 11 Location/Qualifiers 1..11 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 690 NTAPQIGTVN S		11
SEQ ID NO: 691 SEQUENCE: 691 000	moltype = length =	
SEQ ID NO: 692 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 692		

-continued

NTEGVYS		7
SEQ ID NO: 693	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 693		8
NSTSGGSS		
SEQ ID NO: 694	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 694		10
VFMIPOGYL		
SEQ ID NO: 695	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 695		9
INGSGNQQQ		
SEQ ID NO: 696	moltype = length =	
SEQUENCE: 696		
000		
SEQ ID NO: 697	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 697		8
VTQNNNSE		
SEQ ID NO: 698	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 698		7
KEGEDRF		
SEQ ID NO: 699	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 699		6
GTGRDN		
SEQ ID NO: 700	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 700		10
QAQAQTGWVQ		
SEQ ID NO: 701	moltype = length =	
SEQUENCE: 701		
000		
SEQ ID NO: 702	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	

-continued

SEQUENCE: 702 NTEGVYS	mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	7
SEQ ID NO: 703 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 703 NGTSGGST		8
SEQ ID NO: 704 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 704 VFMVPQYGYL		10
SEQ ID NO: 705 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 705 QTTGTGGTQ		9
SEQ ID NO: 706 SEQUENCE: 706 000	moltype = length =	
SEQ ID NO: 707 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 707 TNQNNNSN		8
SEQ ID NO: 708 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 708 KDDDDRF		7
SEQ ID NO: 709 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 709 GAGNDG		6
SEQ ID NO: 710 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 710 NTQAQTGLVH		10
SEQ ID NO: 711 SEQUENCE: 711 000	moltype = length =	

-continued

SEQ ID NO: 712	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 712		7
NTEGVYS		
SEQ ID NO: 713	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 713		8
NGTSGGST		
SEQ ID NO: 714	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 714		10
VFMIPQYGYL		
SEQ ID NO: 715	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 715		9
STGGTAGTQ		
SEQ ID NO: 716	moltype = length =	
SEQUENCE: 716		
000		
SEQ ID NO: 717	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 717		8
LSQNNNSN		
SEQ ID NO: 718	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 718		7
KDDEERF		
SEQ ID NO: 719	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 719		6
GAGKDN		
SEQ ID NO: 720	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 720		10
NAAPIVGAVN		

-continued

SEQ ID NO: 721	moltype = length =	
SEQUENCE: 721		
000		
SEQ ID NO: 722	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 722		7
NTDGTYS		
SEQ ID NO: 723	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 723		8
NGTSGGST		
SEQ ID NO: 724	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 724		10
VFMIPQYGYL		
SEQ ID NO: 725	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 725		9
STGGTQGTQ		
SEQ ID NO: 726	moltype = length =	
SEQUENCE: 726		
000		
SEQ ID NO: 727	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 727		8
LSQNNNSN		
SEQ ID NO: 728	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 728		7
KDDEERF		
SEQ ID NO: 729	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 729		6
GAGRDN		
SEQ ID NO: 730	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	

-continued

SEQUENCE: 730 NTGPIVGNVN	note = Parvovirus Adeno-associated virus organism = unidentified	10
SEQ ID NO: 731 SEQUENCE: 731 000	moltype = length =	
SEQ ID NO: 732 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 732 NTEGTYS		7
SEQ ID NO: 733 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 733 RLGTTSSS		8
SEQ ID NO: 734 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 734 VFMVPQYGYC		10
SEQ ID NO: 735 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 735 GETLNQGNA		9
SEQ ID NO: 736 SEQUENCE: 736 000	moltype = length =	
SEQ ID NO: 737 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 737 ASQNYKIPAS GG		12
SEQ ID NO: 738 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 738 GPSDGDF		7
SEQ ID NO: 739 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 739 VTGNNT		6

-continued

SEQ ID NO: 740 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 740 TTAPITGNVT		10
SEQ ID NO: 741 SEQUENCE: 741 000	moltype = length =	
SEQ ID NO: 742 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 742 DTTGKYT		7
SEQ ID NO: 743 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 743 RIGTTANS		8
SEQ ID NO: 744 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 744 VFMVPQYGYC		10
SEQ ID NO: 745 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 745 GNSLNQGT A		9
SEQ ID NO: 746 SEQUENCE: 746 000	moltype = length =	
SEQ ID NO: 747 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 747 ANQNYKIPAS GG		12
SEQ ID NO: 748 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 748 GAGDSDF		7
SEQ ID NO: 749 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus	

-continued

SEQUENCE: 749 PSGNTT	organism = unidentified	6
SEQ ID NO: 750 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 750 TTAPHIANLD		10
SEQ ID NO: 751 SEQUENCE: 751 000	moltype = length =	
SEQ ID NO: 752 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 752 DNAGNYH		7
SEQ ID NO: 753 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 753 RLGTTSNS		8
SEQ ID NO: 754 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 754 VFMVPQYGYC		10
SEQ ID NO: 755 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 755 GETLNQGNA		9
SEQ ID NO: 756 SEQUENCE: 756 000	moltype = length =	
SEQ ID NO: 757 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 757 ASQNYKIPAS GG		12
SEQ ID NO: 758 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 758 GPSDGDF		7
SEQ ID NO: 759	moltype = AA length = 6	

-continued

FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 759		
VTGNTT		6
SEQ ID NO: 760	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 760		
TTAPITGNVT		10
SEQ ID NO: 761	moltype = length =	
SEQUENCE: 761		
000		
SEQ ID NO: 762	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 762		
DTTGKYT		7
SEQ ID NO: 763	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 763		
RLGSSNAS		8
SEQ ID NO: 764	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 764		
VFMVPQYGYC		10
SEQ ID NO: 765	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
source	1..9	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 765		
GGTLNQGNS		9
SEQ ID NO: 766	moltype = length =	
SEQUENCE: 766		
000		
SEQ ID NO: 767	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
source	1..12	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	
SEQUENCE: 767		
ASQNYKIPQG RN		12
SEQ ID NO: 768	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
source	1..7	
	mol_type = protein	
	note = Parvovirus Adeno-associated virus	
	organism = unidentified	

-continued

SEQUENCE: 768 ANDATDF		7
SEQ ID NO: 769 FEATURE source	moltype = AA length = 6 Location/Qualifiers 1..6 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 769 ITGNTT		6
SEQ ID NO: 770 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 770 TTVPTVDDVD		10
SEQ ID NO: 771 SEQUENCE: 771 000	moltype = length =	
SEQ ID NO: 772 FEATURE source	moltype = AA length = 7 Location/Qualifiers 1..7 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 772 DNAGAYK		7
SEQ ID NO: 773 FEATURE source	moltype = AA length = 8 Location/Qualifiers 1..8 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 773 RIQGPSGG		8
SEQ ID NO: 774 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 774 IYTIPQGYC		10
SEQ ID NO: 775 FEATURE source	moltype = AA length = 9 Location/Qualifiers 1..9 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 775 VSQAGSSGR		9
SEQ ID NO: 776 SEQUENCE: 776 000	moltype = length =	
SEQ ID NO: 777 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein note = Parvovirus Adeno-associated virus organism = unidentified	
SEQUENCE: 777 ASNITKNNVF SV		12
SEQ ID NO: 778 FEATURE	moltype = AA length = 7 Location/Qualifiers	

-continued

source 1..7
mol_type = protein
note = Parvovirus Adeno-associated virus
organism = unidentified

SEQUENCE: 778
FSGEPDR 7

SEQ ID NO: 779 moltype = AA length = 8
FEATURE Location/Qualifiers
source 1..8
mol_type = protein
note = Parvovirus Adeno-associated virus
organism = unidentified

SEQUENCE: 779
VYDQTTAT 8

SEQ ID NO: 780 moltype = AA length = 10
FEATURE Location/Qualifiers
source 1..10
mol_type = protein
note = Parvovirus Adeno-associated virus
organism = unidentified

SEQUENCE: 780
VTPGTRAAVN 10

SEQ ID NO: 781 moltype = length =
SEQUENCE: 781
000

SEQ ID NO: 782 moltype = AA length = 7
FEATURE Location/Qualifiers
source 1..7
mol_type = protein
note = Parvovirus Adeno-associated virus
organism = unidentified

SEQUENCE: 782
SDTGSYS 7

SEQ ID NO: 783 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
note = Recombinant AAV capsid protein
source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 783
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRLLLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLSGAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480
GPCYRQQRVS TGTNLGKEQN FAWTAGTKYH LNGRNSLANP GIAMATHKDD EERFFPSNGI 540
LIFGKQNAAR DNADYSVVML TSEEEIKTTN PVATEEYGIV ADNVMEPTRA PQIGTVNSQG 600
ALPGMVWQNR DVYLQGPPIWA KIPHTDGNFH PSPLMGGPGL KHPPPQILIK NTPVPADPRS 660
TFNGDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ YTSNYYKSTS VDFAVNTEGV 720
YSEPRPIGTR YLTRNL 736

SEQ ID NO: 784 moltype = AA length = 736
FEATURE Location/Qualifiers
REGION 1..736
note = Recombinant AAV capsid protein
source 1..736
mol_type = protein
organism = synthetic construct

SEQUENCE: 784
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY KYLGPNGLD 60
KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADA EF QERLKEDTSF GGNLGRAVPQ 120
AKKRLLLEPLG LVEEAAKTAP GKRPVEQSP QEPDSSAGIG KSGAQPAKKR LNFQQTGDSE 180
SVPDPQPLGE PPAAPSGVGP NTMAAGGGAP MADNNEGADG VGSSSGNWHC DSTWLGDRVI 240
TTSTRTWALP TYNNHLYKQI SNGTSGGATN DNTYFGYSTP WGYFDNFRFH CHFSPRDWQR 300
LINNNWGFRR KRLSFKLFNI QVKEVTQNEG TKTIANNLTS TIQVFTDSEY QLPYVLSGAH 360
QGCLPPFPAD VFMIPOYGYL TLNNGSQAVG RSSFYCLEYF PSQMLRTGNN FQPTYTFEDV 420
PFHSSYAHSQ SLDRLMNPLI DQYLYLSRT QTTSNCRGVT LGFSQGGPNT MANQAKNWLP 480

-continued

GPCYRQQRVS	TMSAASGSGN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

SEQ ID NO: 785 moltype = AA length = 736
 FEATURE Location/Qualifiers
 REGION 1..736
 note = Recombinant AAV capsid protein
 source 1..736
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 785

MAADGYLPDW	LEDNLSEGIR	EWWALKPGAP	QPKANQQHQD	NARGLVLPFY	KYLGPGNGLD	60
KGEPVNAADA	AALSHDKAYD	QQLKAGDNPY	LKYNHADAEF	QERLKEDTSF	GGNLGRAVQ	120
AKKRLLLEPLG	LVVEAAKTAP	GKKRPVEQSP	QEPDSSAGIG	KSGAQPAKRR	LNFGQTDSE	180
SVPDPQPLGE	PPAAPSGVGP	NTMAAGGGAP	MADNNEGADG	VGSSSGNWHC	DSTWLGDRVI	240
TTSTRTWALP	TYNNHLYKQI	SNGTSGGATN	DNTYFGYSTP	WGYPFDNRFH	CHFSPRDWQR	300
LINNNWGFPR	KRLSFKLFNI	QVKEVTQNEG	TKTIANNLTS	TIQVFTDSEY	QLPYVLGSAH	360
QGCLPPFPAD	VFMIPQYGYL	TLNNGSQAVG	RSSFYCLEYF	PSQMLRTGNN	FQPTYTFEDV	420
PFHSSYAHSQ	SLDRLMNPLI	DQYLYLSRT	QTTSNRRGVT	LGFSQGGFNT	MANQAKNWL	480
GPCYRQQRVS	TVATRDRQLN	FAWTAGTKYH	LNGRNSLANP	GIAMATHKDD	EERFFPSNGI	540
LIFGKQNAAR	DNADYSVVML	TSEEEIKTTN	PVATEEYGIV	ADNVMETRA	PQIGTVNSQG	600
ALPGMVWQNR	DVYLQGPPIWA	KIPHTDGNFH	PSPLMGGFGL	KHPPPQILIK	NTPVPADPRS	660
TFNGDKLNSF	ITQYSTGQVS	VEIEWELQKE	NSKRWNPEIQ	YTSNYYKSTS	VDFAVNTEGV	720
YSEPRPIGTR	YLTRNL					736

1.-53. (canceled)

54. An adeno-associated virus (AAV) vector comprising an AAV capsid protein, wherein the AAV capsid protein comprises an amino acid sequence of SEQ ID NO: 380.

55. The AAV vector of claim **54**, wherein the AAV vector comprises an encapsidated nucleic acid, wherein the encapsidated nucleic acid is encapsidated by the AAV capsid protein.

56. The AAV vector of claim **55**, wherein the encapsidated nucleic acid comprises at least one terminal repeat sequence.

57. The AAV vector of claim **56**, wherein the encapsidated nucleic acid further comprises a heterologous nucleic acid sequence.

58. The AAV vector of claim **57**, wherein the encapsidated nucleic acid comprises inverted terminal repeat (ITR) sequences located 3' and 5' of the heterologous nucleic acid sequence.

59. The AAV vector of claim **57**, wherein the heterologous nucleic acid sequence encodes a polypeptide.

60. The AAV vector of claim **59**, wherein the polypeptide is a therapeutic polypeptide.

61. The AAV vector of claim **59**, wherein the polypeptide is an immunogenic polypeptide.

62. The AAV vector of claim **59**, wherein the polypeptide is nuclease.

63. The AAV vector of claim **62**, wherein the nuclease is a Cas9 nuclease or a Cpf1 nuclease.

64. The AAV vector of claim **57**, wherein the heterologous nucleic acid sequence encodes an untranslated RNA.

65. The AAV vector of claim **64**, wherein the untranslated RNA is a guide RNA.

66. The AAV vector of claim **64**, wherein the untranslated RNA is an antisense RNA, a ribozyme, or an interfering RNA.

67. A pharmaceutical composition comprising the AAV vector of claim **55** and a pharmaceutically acceptable carrier.

68. A method of introducing a nucleic acid into a cell, comprising contacting the cell with the AAV vector of claim **55**.

69. An adeno-associated virus (AAV) capsid protein comprising an amino acid sequence of SEQ ID NO: 380.

70. A nucleic acid comprising a nucleic acid sequence encoding the AAV capsid protein of claim **69**.

71. An expression vector comprising a nucleic acid sequence encoding the AAV capsid protein of claim **70**.

72. A cell comprising the nucleic acid of claim **70**.

73. A method of producing an adeno-associated virus (AAV) vector, the method comprising:

- culturing a cell that comprises (i) the nucleic acid of claim **70**, (ii) a nucleic acid comprising 5' inverted terminal repeat (ITR), a heterologous nucleic acid sequence, and a 3' ITR, and (iii) AAV sequences sufficient for replication and encapsidation of nucleic acid, wherein the cell is cultured under conditions such that it produces the AAV vector; and
- collecting the AAV vector from the cell.

* * * * *